<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Equivalent schedules of intradermal fractional dose versus intramuscular full dose of inactivated polio vaccine for prevention of poliomyelitis - Jaiswal, N - 2019 | Cochrane Library</title> <meta content="Equivalent schedules of intradermal fractional dose versus intramuscular full dose of inactivated polio vaccine for prevention of poliomyelitis - Jaiswal, N - 2019 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011780.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Equivalent schedules of intradermal fractional dose versus intramuscular full dose of inactivated polio vaccine for prevention of poliomyelitis - Jaiswal, N - 2019 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011780.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD011780.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Equivalent schedules of intradermal fractional dose versus intramuscular full dose of inactivated polio vaccine for prevention of poliomyelitis" name="citation_title"/> <meta content="Nishant Jaiswal" name="citation_author"/> <meta content="Postgraduate Institute of Medical Education and Research" name="citation_author_institution"/> <meta content="Shreya Singh" name="citation_author"/> <meta content="Postgraduate Institute of Medical Education and Research" name="citation_author_institution"/> <meta content="Amit Agarwal" name="citation_author"/> <meta content="Postgraduate Institute of Medical Education and Research" name="citation_author_institution"/> <meta content="Anil Chauhan" name="citation_author"/> <meta content="Postgraduate Institute of Medical Education and Research" name="citation_author_institution"/> <meta content="Kiran K Thumburu" name="citation_author"/> <meta content="Postgraduate Institute of Medical Education and Research" name="citation_author_institution"/> <meta content="Harpreet Kaur" name="citation_author"/> <meta content="Panjab University" name="citation_author_institution"/> <meta content="Meenu Singh" name="citation_author"/> <meta content="Postgraduate Institute of Medical Education and Research" name="citation_author_institution"/> <meta content="meenusingh4@gmail.com" name="citation_author_email"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="12" name="citation_issue"/> <meta content="10.1002/14651858.CD011780.pub2" name="citation_doi"/> <meta content="2019" name="citation_date"/> <meta content="2019/12/19" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011780.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011780.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011780.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Immunization Schedule; Injections, Intradermal; Injections, Intramuscular; Poliomyelitis [*prevention &amp; control]; Poliovirus [*immunology]; Poliovirus Vaccine, Inactivated [administration &amp; dosage, immunology]; Poliovirus Vaccine, Oral [*administration &amp; dosage, immunology]; Randomized Controlled Trials as Topic; Vaccination [methods]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011780.pub2&amp;doi=10.1002/14651858.CD011780.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011780.pub2&amp;doi=10.1002/14651858.CD011780.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011780.pub2&amp;doi=10.1002/14651858.CD011780.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011780.pub2&amp;doi=10.1002/14651858.CD011780.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011780.pub2&amp;doi=10.1002/14651858.CD011780.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011780.pub2&amp;doi=10.1002/14651858.CD011780.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011780.pub2&amp;doi=10.1002/14651858.CD011780.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011780.pub2&amp;doi=10.1002/14651858.CD011780.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011780.pub2&amp;doi=10.1002/14651858.CD011780.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011780.pub2&amp;doi=10.1002/14651858.CD011780.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011780.pub2&amp;doi=10.1002/14651858.CD011780.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011780.pub2&amp;doi=10.1002/14651858.CD011780.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011780.pub2&amp;doi=10.1002/14651858.CD011780.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011780.pub2&amp;doi=10.1002/14651858.CD011780.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011780.pub2&amp;doi=10.1002/14651858.CD011780.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011780.pub2&amp;doi=10.1002/14651858.CD011780.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011780.pub2&amp;doi=10.1002/14651858.CD011780.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011780.pub2&amp;doi=10.1002/14651858.CD011780.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011780.pub2&amp;doi=10.1002/14651858.CD011780.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011780.pub2&amp;doi=10.1002/14651858.CD011780.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011780.pub2&amp;doi=10.1002/14651858.CD011780.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011780.pub2&amp;doi=10.1002/14651858.CD011780.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011780.pub2&amp;doi=10.1002/14651858.CD011780.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774054000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774081000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000"}};Liferay.authToken="zCmos3jT";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD011780\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD011780\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011780\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011780\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1559916434000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","fa","pl","zh_HANS","ms"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD011780.pub2",title:"Equivalent schedules of intradermal fractional dose versus intramuscular full dose of inactivated polio vaccine for prevention of poliomyelitis",firstPublishedDate:"Dec 19, 2019 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Developmental, Psychosocial and Learning Problems Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738735355000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=zCmos3jT&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD011780.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD011780.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD011780.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD011780.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD011780.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD011780.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD011780.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD011780.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD011780.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD011780.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;pl&quot;,&quot;title&quot;:&quot;Streszczenie prostym językiem&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD011780.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD011780.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD011780.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD011780.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>1876 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD011780.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011780.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011780.pub2/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011780.pub2/full#CD011780-abs-0004"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011780.pub2/full#CD011780-sec-0112"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011780.pub2/full#CD011780-sec-0022"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011780.pub2/full#CD011780-sec-0023"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011780.pub2/full#CD011780-sec-0028"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011780.pub2/full#CD011780-sec-0029"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011780.pub2/full#CD011780-sec-0058"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011780.pub2/full#CD011780-sec-0106"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD011780.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011780.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011780.pub2/appendices#CD011780-sec-0117"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011780.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011780.pub2/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD011780.pub2/media/CDSR/CD011780/table_n/CD011780StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD011780.pub2/media/CDSR/CD011780/table_n/CD011780StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011780.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011780.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011780.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD011780.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD011780.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD011780.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2019 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD011780.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Equivalent schedules of intradermal fractional dose versus intramuscular full dose of inactivated polio vaccine for prevention of poliomyelitis </h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011780.pub2/information#CD011780-cr-0002">Nishant Jaiswal</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011780.pub2/information#CD011780-cr-0003">Shreya Singh</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011780.pub2/information#CD011780-cr-0004">Amit Agarwal</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011780.pub2/information#CD011780-cr-0005">Anil Chauhan</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011780.pub2/information#CD011780-cr-0006">Kiran K Thumburu</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011780.pub2/information#CD011780-cr-0007">Harpreet Kaur</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011780.pub2/information#CD011780-cr-0008"><i class="icon corresponding-author fa fa-envelope"></i>Meenu Singh</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD011780.pub2/information/en#CD011780-sec-0136">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 19 December 2019 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD011780.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD011780.pub2">https://doi.org/10.1002/14651858.CD011780.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD011780-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD011780-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD011780-abs-0003">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD011780-abs-0002">فارسی</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD011780-abs-0008">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD011780-abs-0001" lang="en"> <section id="CD011780-sec-0001"> <h3 class="title" id="CD011780-sec-0001">Background</h3> <p>Poliomyelitis is a debilitating and deadly infection. Despite exponential growth in medical science, there is still no cure for the disease, which is caused by three types of wild polioviruses: types 1, 2, and 3. According to the Global Polio Eradication Initiative (GPEI), wild poliovirus is still in circulation in three countries, and fresh cases have been reported even in the year 2018. </p> <p>Due to the administration of live vaccines, the risk for vaccine‐derived poliovirus (VDPV) is high in areas that are free from wild polioviruses. This is evident based on the fact that VDPV caused 20 outbreaks between 2000 and 2011. </p> <p>Recent recommendations from the World Health Organization favoured the inclusion of inactivated poliovirus vaccine (IPV) in the global immunisation schedule. IPV can be delivered in two ways: intramuscularly and intradermally. IPV was previously administered intramuscularly, but shortages in vaccine supplies, coupled with the higher costs of the vaccines, led to the innovation of delivering a fractional dose (one‐fifth) of IPV intradermally. However, there is uncertainty regarding the efficacy, immunogenicity, and safety of an intradermal, fractional dose of IPV compared to an intramuscular, full dose of IPV. </p> </section> <section id="CD011780-sec-0002"> <h3 class="title" id="CD011780-sec-0002">Objectives</h3> <p>To compare the immunogenicity and efficacy of an inactivated poliovirus vaccine (IPV) in equivalent immunisation schedules using fractional‐dose IPV given via the intradermal route versus full‐dose IPV given via the intramuscular route. </p> </section> <section id="CD011780-sec-0003"> <h3 class="title" id="CD011780-sec-0003">Search methods</h3> <p>We searched CENTRAL, MEDLINE, Embase, 10 other databases, and two trial registers up to February 2019. We also searched the GPEI website and scanned the bibliographies of key studies and reviews in order to identify any additional published and unpublished trials in this area not captured by our electronic searches. </p> </section> <section id="CD011780-sec-0004"> <h3 class="title" id="CD011780-sec-0004">Selection criteria</h3> <p>Randomised controlled trials (RCTs) and quasi‐RCTs of healthy individuals of any age who are eligible for immunisation with IPV, comparing intradermal fractional‐dose (one‐fifth) IPV to intramuscular full‐dose IPV. </p> </section> <section id="CD011780-sec-0005"> <h3 class="title" id="CD011780-sec-0005">Data collection and analysis</h3> <p> We used standard methodological procedures expected by Cochrane.</p> </section> <section id="CD011780-sec-0006"> <h3 class="title" id="CD011780-sec-0006">Main results</h3> <p>We included 13 RCTs involving a total of 7292 participants, both children (n = 6402) and adults (n = 890). Nine studies were conducted in middle‐income countries, three studies in high‐income countries, and only one study in a low‐income country. Five studies did not report methods of randomisation, and one study failed to conceal the allocations. Eleven studies did not blind participants, and six studies did not blind outcome assessments. Two studies had high attrition rates, and one study selectively reported the results. Three studies were funded by pharmaceutical companies. </p> <p><b>Paralytic poliomyelitis.</b> No study reported data on this outcome. </p> <p><b>Seroconversion rates.</b> These were significantly higher for all three types of wild poliovirus for children given intramuscular full‐dose IPV after a single primary dose and two primary doses, but only significantly higher for type two wild poliovirus given intramuscularly after three primary doses:<br/> • dose one (six studies): poliovirus type 1 (odds ratio (OR) 0.30, 95% confidence interval (CI) 0.22 to 0.41; 2570 children); poliovirus type 2 (OR 0.43, 95% CI 0.31 to 0.60; 2567 children); poliovirus type 3 (OR 0.19, 95% CI 0.12 to 0.30; 2571 children);<br/> • dose two (three studies): poliovirus type 1 (OR 0.23, 95% CI 0.16 to 0.33; 981 children); poliovirus type 2 (OR 0.41, 95% CI 0.28 to 0.60; 853 children); and poliovirus type 3 (OR 0.12, 95% CI 0.07 to 0.22; 855 children); and<br/> • dose three (three studies): poliovirus type 1 (OR 0.45, 95% CI 0.07 to 3.15; 973 children); poliovirus type 2 (OR 0.34, 95% CI 0.19 to 0.63; 973 children); and poliovirus type 3 (OR 0.18, 95% CI 0.01 to 2.58; 973 children). </p> <p>Using the GRADE approach, we rated the certainty of the evidence as low or very low for seroconversion rate (after a single, two, or three primary doses) for all three poliovirus types due to significant risk of bias, heterogeneity, and indirectness in applicability/generalisability. </p> <p><b>Geometric mean titres.</b> No study reported mean antibody titres. Median antibody titres were higher for intramuscular full‐dose IPV (7 studies with 4887 children); although these studies also reported a rise in antibody titres in the intradermal group, none reported the duration for which the titres remained high. </p> <p><b>Any vaccine‐related adverse event.</b> Five studies (2217 children) reported more adverse events, such as fever and redness, in the intradermal group, whilst two studies (1904 children) reported more adverse events in the intramuscular group. </p> </section> <section id="CD011780-sec-0007"> <h3 class="title" id="CD011780-sec-0007">Authors' conclusions</h3> <p>There is low‐ and very low‐certainty evidence that intramuscular full‐dose IPV may result in a slight increase in seroconversion rates for all three types of wild poliovirus, compared with intradermal fractional‐dose IPV. We are uncertain whether intradermal fractional‐dose (one‐fifth) IPV has better protective effects and causes fewer adverse events in children than intramuscular full‐dose IPV. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD011780-abs-0004" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD011780-abs-0004">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD011780-abs-0007">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD011780-abs-0005">فارسی</a> </li> <li class="section-language"> <a class="" href="full/ms#CD011780-abs-0010">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/pl#CD011780-abs-0006">Polski</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD011780-abs-0009">简体中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD011780-abs-0004" lang="en"> <h3>Effectiveness of equivalent schedules of full‐dose inactivated poliovirus vaccine injected into muscle compared to a smaller dose injected into skin </h3> <p><b>Background</b> </p> <p>Polio is a disabling disease that is only preventable via vaccination. There are two types of polio vaccines: live poliovirus vaccine delivered orally (by mouth – so‐called OPV) and inactivated (killed) poliovirus vaccine (IPV). OPV is the mainstay of polio eradication but carries a risk of causing vaccine‐associated polio. This is not the case for IPV, which also has fewer side effects and can be given to people with low immunity, making it vital for the complete elimination of poliovirus. Killed vaccines can be given via injection either into the muscles (intramuscular) or into the skin (intradermal). </p> <p><b>Review question</b> </p> <p>How effective is a small dose of IPV injected into the skin compared to a full dose of IPV injected into muscle in similar schedules? </p> <p><b>Study characteristics</b> </p> <p>The database searches, up‐to‐date to February 2019, found 13 randomised controlled trials (a type of experiment in which participants are randomly assigned to one of two or more treatment groups). Three studies comprised 890 adult participants; a further 10 studies comprised 6402 infants and children. </p> <p>Nine studies were conducted in middle‐income countries; three studies in high‐income countries; and one study in a low‐income country. The studies had a duration of 2 to 19 months. Three studies were supported financially by drug companies, and three studies received the vaccines from the pharmaceutical company. There is overall limited confidence in the quality of the included studies since, for example, in most trials the recipient or assessor (or both) were aware of the vaccine being given. </p> <p><b>Key results</b> </p> <p>The review included 13 studies with a total of 7292 participants (6402 children and 890 adults). Where possible, we combined the results of similar studies in a meta‐analysis (a statistical method of combining the results of multiple single studies to calculate an overall effect). </p> <p>There are three types of wild poliovirus: types 1, 2, and 3. We found that the number of antibody responses to the vaccine (measured using something called seroconversion rates) in children was higher in the group that received the vaccine by intramuscular injection compared to the group that had a similar number of injections given intradermally, after one single dose (6 studies, 2571 children) and two doses (3 studies, 981 children) for all three types of poliovirus, and after three doses for type 2 poliovirus (3 studies, 973 children). </p> <p>The vaccines produce antibodies against all three types of poliovirus. The quantity of antibodies produced by the vaccines (measured as geometric median titres) was higher in children receiving a full dose of IPV via intramuscular route for all three types of poliovirus (7 studies, 4887 children). </p> <p>Five studies (2217 children) reported more adverse events, such as fever and redness, in the intradermal group, whilst two studies (1904 children) reported more adverse events in the intramuscular group. </p> <p>None of the included studies reported data on the occurrence of paralytic poliomyelitis.</p> <p><b>Certainty of the evidence</b> </p> <p>Based on the evidence, intramuscular full‐dose IPV may result in a slight increase in seroconversion rates for all three types of wild poliovirus when compared with intradermal fractional‐dose IPV. We are uncertain if a fractional dose of IPV given intradermally is better than a full dose of IPV given intramuscularly at producing antibodies for all three types of poliovirus or reducing adverse effects. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD011780-sec-0112" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD011780-sec-0112"></div> <h3 class="title" id="CD011780-sec-0113">Implications for practice</h3> <section id="CD011780-sec-0113"> <p>There is low‐ and very low‐certainty evidence suggesting better seroconversion rates with full‐dose inactivated poliovirus vaccine (IPV) delivered intramuscularly compared to fractional‐dose IPV delivered intradermally. However, antibody titres show protective levels with a fractional (one‐fifth) dose of IPV delivered intradermally, albeit in fewer participants. The current evidence does not address immunocompromised or low‐birthweight babies. The available evidence for adults is scarce. The current systematic review does not describe the costs involved in training people in the technical skills required to administer vaccines intradermally. </p> <p>The current systematic review found that the complete immunisation schedules with intramuscular and intradermal IPV are both effective for producing protective antibodies, but per‐dose efficacy of fractional‐dose IPV is lower. Fractional‐dose IPV can be an alternative in places where easy access to vaccination services is available but IPV supply is scarce. </p> </section> <h3 class="title" id="CD011780-sec-0114">Implications for research</h3> <section id="CD011780-sec-0114"> <p>Based on the currently available evidence, there is a need for studies that compare both routes of IPV administration (i.e. intradermal and intramuscular) in real‐world settings, and that take into account the uncertainties surrounding the role of the vaccinator's technical skills in fractional‐dose IPV administration. Unanswered questions include the impact on mucosal immunity, number of doses, impact on low‐birthweight or immunocompromised babies, and the effect on oral polio vaccine‐primed participants. A study designed to assess the mucosal immunity generated via both routes is ongoing, but it is important that more studies of this kind are conducted. Future research should also describe the costs involved in training people in the technical skills required for intradermal versus intramuscular administration, along with the cost of the vaccine. This will better enable consumers to draw a comprehensive overview of the route and dose of the vaccines. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD011780-sec-0022" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD011780-sec-0022"></div> <div class="table" id="CD011780-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Equivalent schedules of intradermal fractional‐dose inactivated poliovirus vaccine compared to intramuscular inactivated poliovirus vaccine for the prevention of poliomyelitis in children</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Equivalent schedules of intradermal fractional‐dose inactivated poliovirus vaccine compared to intramuscular inactivated poliovirus vaccine for the prevention of poliomyelitis in children</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> children<br/> <b>Setting:</b> community<br/> <b>Intervention:</b> intradermal fractional‐dose inactivated poliovirus vaccine<br/> <b>Comparison:</b> intramuscular inactivated poliovirus vaccine </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments </b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with intramuscular IPV</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with intradermal fractional‐dose IPV</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Paralytic poliomyelitis</b> (not measured) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>This outcome was not reported by any of the included studies.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p><b>Seroconversion rate</b> (after a single primary dose) </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Type 1 poliovirus</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>OR 0.30</b> <br/> <b>(0.22 to 0.41)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2570</p> <p>(6 RCTs)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low<sup>a,b</sup> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>721 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>437 per 1000</b><br/> (363 to 515) </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Type 2 poliovirus</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>OR 0.43</b> <br/> <b>(0.31 to 0.60)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2567</p> <p>(6 RCTs)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low<sup>b,d</sup> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>773 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>595 per 1000</b><br/> (514 to 672) </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Type 3 poliovirus</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>OR 0.19</b> <br/> <b>(0.12 to 0.30)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2571</p> <p>(6 RCTs)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low<sup>a,b,d</sup> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>753 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>366 per 1000</b><br/> (268 to 477) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p><b>Seroconversion rate</b> (after 2 primary doses) </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Type 1 poliovirus</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>OR 0.23</b> <br/> <b>(0.16 to 0.33)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>981</p> <p>(3 RCTs)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low<sup>b,e</sup> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>826 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>522 per 1000</b><br/> (432 to 611) </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Type 2 poliovirus</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>OR 0.41</b> <br/> <b>(0.28 to 0.60)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>853</p> <p>(3 RCTs)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low<sup>b,f</sup> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>846 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>693 per 1000</b><br/> (606 to 767) </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Type 3 poliovirus</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>OR 0.12</b> <br/> <b>(0.07 to 0.22)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>855</p> <p>(3 RCTs)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low<sup>b,e</sup> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>941 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>657 per 1000</b><br/> (528 to 778) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p><b>Seroconversion rate</b> (after 3 primary doses) </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Type 1 poliovirus</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>OR 0.45</b> <br/> <b>(0.07 to 3.15)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>973</p> <p>(3 RCTs)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low<sup>b,d,e</sup> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>913 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>825 per 1000</b><br/> (423 to 970) </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Type 2 poliovirus</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>OR 0.34</b> <br/> <b>(0.19 to 0.63)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>973</p> <p>(3 RCTs)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low<sup>a,b</sup> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>969 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>914 per 1000</b><br/> (855 to 951) </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Type 3 poliovirus</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>OR 0.18</b> <br/> <b>(0.01 to 2.58)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>973</p> <p>(3 RCTs)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low<sup>b,c,d,f</sup> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>979 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>894 per 1000</b><br/> (320 to 991) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Geometric mean titres</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>7 studies reported median titres rather than mean titres. In all 7 studies, antibody titres showed better protective effects with intradermal fractional‐dose (1/5) IPV, albeit in fewer numbers of participants. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4887</p> <p>(7 RCTs)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low<sup>b,d,e</sup> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Vaccine‐related adverse events</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>5 studies reported more adverse events in the intradermal group, whilst 2 studies reported more adverse events in the intramuscular group. The most common adverse events were redness, tenderness, erythema, and fever. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4121</p> <p>(7 RCTs)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low<sup>b,c,d</sup> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See <a href="./full#CD011780-tbl-0002">Table 1</a> for full results. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> confidence interval; <b>IPV:</b> inactivated poliovirus vaccine; <b>OR:</b> odds ratio; <b>RCT:</b> randomised controlled trial </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate certainty:</b> We are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low certainty:</b> Our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/> <b>Very low certainty:</b> We have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded one level for risk of bias: one study had high attrition; one study did not report all of the prespecified outcomes; and all studies included in this analysis were open‐label.<br/> <sup>b</sup>Downgraded one level due to indirectness: there were different schedules of the intervention and comparisons.<br/> <sup>c</sup>Downgraded one level due to limitations in the design: there was the potential for high risk of bias due to high attrition in one study and unclear methods of randomisation, and all of the studies included in this analysis were open‐label.<br/> <sup>d</sup>Downgraded one level due to heterogeneity: there was significant heterogeneity in the studies included in this analysis.<br/> <sup>e</sup>Downgraded one level due to limitations in the design: there was the potential for bias due to attrition and selective reporting, and the studies included in this analysis were not blinded.<br/> <sup>f</sup>Downgraded one level due to imprecision: the effect estimate had wide CI. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD011780-tbl-0002"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">1.</span> <span class="table-title">Adverse events: children</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study ID (location)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Doses</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Intradermal (number of individuals with events/total number of individuals)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Intramuscular (number of individuals with events/total number of individuals)</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="11" valign="top"> <p><a href="./references#CD011780-bbs2-0002" title="Cadorna‐CarlosJ , VidorE , BonnetMC . Randomized controlled study of fractional doses of inactivated poliovirus vaccine administered intradermally with a needle in the Philippines. International Journal of Infectious Diseases2012;16(2):e110‐6. [DOI: 10.1016/j.ijid.2011.10.002; PUBMED: 22153001] ">Cadorna‐Carlos 2012</a> (the Philippines) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="11" valign="top"> <p>3 primary doses of intramuscular IPV or fractional dose of intradermal IPV</p> </td> <td align="left" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>Solicited injection site reactions</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tenderness</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>71/109</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>59/114</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Erythema</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>82/109</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34/114</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Swelling</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25/109</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11/114</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>Solicited systemic reactions</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fever</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7/109</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12/114</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Vomiting</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18/109</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25/114</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Crying abnormal</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40/109</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>36/114</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Drowsiness</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>44/109</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>41/114</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Appetite lost</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19/109</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23/114</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Irritability</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>58/109</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>51/114</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011780-bbs2-0003" title="ClarkeE , SaiduY , AdetifaJU , AdigwemeI , HydaraMB , BashorunAO , et al. Safety and immunogenicity of inactivated poliovirus vaccine when given with measles–rubella combined vaccine and yellow fever vaccine and when given via different administration routes: a phase 4, randomised, non‐inferiority trial in The Gambia. Lancet. Global Health2016;4(8):e534‐47. [DOI: 10.1016/S2214‐109X(16)30075‐4; PUBMED: 27364568] NCT01847872 . IPV clinical trial ‐ The Gambia (IPV) [A phase 4, randomized trial to assess the safety and immunogenicity of inactivated poliovirus vaccine when given concomitantly with measles and rubella combined vaccine and yellow fever vaccine at nine months and when administered via different vaccination routes]. clinicaltrials.gov/ct2/show/NCT01847872 (first received 19 April 2013). ">Clarke 2016</a> (The Gambia) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Single primary dose of intramuscular IPV or fractional dose of intradermal IPV</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Redness and swelling on tenderness</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 (needle syringe)</p> <p>2 (jet injector)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 (needle syringe)</p> <p>5 (jet injector)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011780-bbs2-0006" title="MohammedAJ , AlAwaidyS , BawikarS , KurupPJ , ElamirE , ShabanMMA , et al. Fractional doses of inactivated poliovirus vaccine in Oman. New England Journal of Medicine2010;362(25):2351‐9. [DOI: 10.1056/NEJMoa0909383; PUBMED: 20573923] ">Mohammed 2010</a> (Oman) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 primary doses of intramuscular IPV or fractional dose of intradermal IPV</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>42 serious events (39 = infectious disease, 2 = anaemia, 1 = fall)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18 events</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24 events</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="15" valign="top"> <p><a href="./references#CD011780-bbs2-0007" title="ResikS , TejedaA , LagoPM , DiazM , CarmenatesA , SarmientoL , et al. Randomized controlled clinical trial of fractional doses of inactivated poliovirus vaccine administered intradermally by needle‐free device in Cuba. Journal of Infectious Diseases2010;201(9):1344‐52. [DOI: 10.1086/651611; PUBMED: 20350164] ">Resik 2010</a> (Cuba) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="5" valign="top"> <p>Dose 1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Temperature</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>39/187</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34/177</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Redness</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25/187</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8/177</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Induration</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4/187</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2/177</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pain</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/187</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/177</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Combination</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26/187</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9/177</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="5" valign="top"> <p>Dose 2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Temperature</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21/187</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>41/177</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Redness</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8/187</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3/177</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Induration</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3/187</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/177</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pain</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/187</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/177</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Combination</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/187</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/177</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="5" valign="top"> <p>Dose 3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Temperature</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11/187</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28/177</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Redness</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19/187</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/177</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Induration</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5/187</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/177</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pain</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/187</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/177</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Combination</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/187</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/177</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="8" valign="top"> <p><a href="./references#CD011780-bbs2-0008" title='ResikS , TejedaA , SutterRW , DiazM , SarmientoL , AlemañiN , et al. Priming after a fractional dose of inactivated poliovirus vaccine. New England Journal of Medicine2013;368(5):416‐24. [DOI: 10.1056/NEJMoa1202541; PUBMED: 23363495] SutterRW . Regarding your published paper about "Priming after a Fractional Dose of Inactivated Poliovirus Vaccine" published in NEJM 2013 [personal communication]. Email to: KK Thumburu 04 February 2016. '>Resik 2013</a> (Cuba) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Dose 1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Temp ≥ 38 °C</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/157</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2/153</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Redness</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>47/157</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3/153</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Induration</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11/157</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2/153</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Other</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/157</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/153</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Dose 2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Temp ≥ 38 °C</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2/157</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/153</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Redness</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>37/157</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2/153</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Induration</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14/157</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/153</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Other</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/157</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/153</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><a href="./references#CD011780-bbs2-0009" title="ResikS , TejedaA , MachO , FonsecaM , DiazM , AlemanyN , et al. Immune responses after fractional doses of inactivated poliovirus vaccine using newly developed intradermal jet injectors: a randomized controlled trial in Cuba. Vaccine2015;33(2):307‐13. [DOI: 10.1016/j.vaccine.2014.11.025; PUBMED: 25448109] ">Resik 2015</a> (Cuba) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Single primary dose of intramuscular IPV or fractional dose of intradermal IPV</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fever</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13/583</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8/146</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Redness</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9/583</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2/146</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Induration</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15/583</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/146</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Infiltration</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14/583</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/146</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="21" valign="top"> <p><a href="./references#CD011780-bbs2-0012" title="Tejeda FuentesA , DeArmas LópezJ , Silva SosaM , Alemañy BuenoN , Carmenate GarcíaA , García GonzálezG , et al. Reactogenicity associated to the intradermally administered inactivated poliovirus vaccine with a needle‐free injector [Reactogenicidad asociada a la vacuna de poliovirus inactivada administrada por vía intradérmica con un inyector sin aguja]. Revista Cubana de Medicina Tropical2011;63(1):38‐43. [PUBMED: 23437535] ">Tejeda Fuentes 2011</a> (Cuba) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="7" valign="top"> <p>Dose 1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>General adverse events (temperature 37 to 37.9 °C)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>38</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>General adverse events (temperature above 37.9 °C)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>General adverse events (crying &lt; 1 hour)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Local adverse events (redness)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Local adverse events (induration)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Local adverse events (pain)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Combination of all local adverse events</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="7" valign="top"> <p>Dose 2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>General adverse events (temperature 37 to 37.9 °C)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>41</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>General adverse events (temperature above 37.9 °C)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>General adverse events (crying &lt; 1 hour)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Local adverse events (redness)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Local adverse events (induration)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Local adverse events (pain)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Combination of all local adverse events</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="7" valign="top"> <p>Dose 3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>General adverse events (temperature 37 to 37.9 °C)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>General adverse events (temperature above 37.9 °C)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>General adverse events (crying &lt; 1 hour)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Local adverse events (redness)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Local adverse events (induration)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Local adverse events (pain)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Combination of all local adverse events</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="5"> <div class="table-footnote"> <p>ID: identifier<br/> IPV: inactivated poliovirus vaccine </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD011780-sec-0023" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD011780-sec-0023"></div> <section id="CD011780-sec-0024"> <h3 class="title" id="CD011780-sec-0024">Description of the condition</h3> <p>Poliomyelitis (polio) is a debilitating and deadly contagious disease caused by three different types of wild poliovirus, each of which has slightly different capsid proteins (<a href="./references#CD011780-bbs2-0032" title="Centers for Disease Control and Prevention. Progress toward global eradication of poliomyelitis, 2001. Morbidity and Mortality Weekly Report2002;51(12):253‐6. [PUBMED: 11939704] ">CDC 2002</a>; <a href="./references#CD011780-bbs2-0042" title="GrasslyNC . The final stages of the global eradication of poliomyelitis. Philosophical Transitions of the Royal Society of London. Series B, Biological Sciences2013;368(1623):20120140. [DOI: 10.1098/rstb.2012.0140; PMC3720038; PUBMED: 23798688] ">Grassly 2013</a>; <a href="./references#CD011780-bbs2-0051" title="MinorP . The polio endgame. Human Vaccines &amp; Immunotherapeutics2014; Vol. 10, issue 7:2106‐8. [DOI: 10.4161/21645515.2014.981115; PMC4370356; PUBMED: 25608050] ">Minor 2014</a>). Though wild type 2 has been eradicated, and no case due to wild type 3 has been reported since 2012, wild type 1 is still prevalent (<a href="./references#CD011780-bbs2-0038" title="Global Polio EradicationInitiative . Polio + prevention. bit.ly/19VK8ok (accessed 2 May 2014). ">GPEI 2010</a>). The poliovirus is a small <b>r</b> ibo<b>n</b> ucleic <b>a</b>cid (RNA) that measures a mere 30 nm in diameter, with a viral genome of 7500 nucleotides. It spreads through person‐to‐person contact: the virus enters through the mouth and nose, multiplies in the intestine, and is then shed in enormous quantities through faeces into the environment (a gram of stool can contain several million virus particles) (<a href="./references#CD011780-bbs2-0037" title="DowdleWR , GaryHE , SandersR , VanLoonAM . Can post‐eradication laboratory containment of wild polioviruses be achieved?. Bulletin of the World Health Organization2002;80(4):311‐6. [PMC2567771; PUBMED: 12075368] ">Dowdle 2002</a>). Lack of sanitation and poor hygiene that results in the faecal contamination of food and drink facilitate its transmission (<a href="./references#CD011780-bbs2-0037" title="DowdleWR , GaryHE , SandersR , VanLoonAM . Can post‐eradication laboratory containment of wild polioviruses be achieved?. Bulletin of the World Health Organization2002;80(4):311‐6. [PMC2567771; PUBMED: 12075368] ">Dowdle 2002</a>). It can affect people of any age, but primarily occurs in children under five years old (<a href="./references#CD011780-bbs2-0037" title="DowdleWR , GaryHE , SandersR , VanLoonAM . Can post‐eradication laboratory containment of wild polioviruses be achieved?. Bulletin of the World Health Organization2002;80(4):311‐6. [PMC2567771; PUBMED: 12075368] ">Dowdle 2002</a>). </p> <p>The Global Polio Eradication Initiative has succeeded in reducing the incidence of polio, from 350,000 reported cases across 125 endemic countries in 1988, to 33 cases in 2018 (<a href="./references#CD011780-bbs2-0063" title="World Health Organization. Poliomyelitis. www.who.int/mediacentre/factsheets/fs114/en/(accessed June 2018). ">WHO 2018</a>). Despite these efforts, wild poliovirus remains uninterrupted in three regions: Afghanistan, Nigeria, and Pakistan (<a href="./references#CD011780-bbs2-0063" title="World Health Organization. Poliomyelitis. www.who.int/mediacentre/factsheets/fs114/en/(accessed June 2018). ">WHO 2018</a>); in 2016, polio cases were again detected in Nigeria after a period of two years, and although significant progress has been made in Pakistan (99% of poliovirus has been eradicated since 2014), surveillances still reveal the circulation of poliovirus (<a href="./references#CD011780-bbs2-0040" title="Global Polio EradicationInitiative . Vaccine‐derived polioviruses. www.polioeradication.org/polio‐today/polio‐prevention/the‐virus/vaccine‐derived‐polio‐viruses/ (assessed 15 June 2018). ">GPEI 2018</a>). </p> <p>Paralytic polio may be suspected in cases where a child under 15 years of age presents with acute flaccid paralysis (AFP) ‐ sudden onset of limp or droopy muscles in the absence of another cause ‐ or in a person of any age presenting with polio‐like symptoms (<a href="./references#CD011780-bbs2-0038" title="Global Polio EradicationInitiative . Polio + prevention. bit.ly/19VK8ok (accessed 2 May 2014). ">GPEI 2010</a>). Each case presenting with AFP must be reported and tested for poliovirus within 48 hours of onset, even if polio is not suspected, due to difficulties in differentiating polio from other diseases at early stages of infection (<a href="./references#CD011780-bbs2-0038" title="Global Polio EradicationInitiative . Polio + prevention. bit.ly/19VK8ok (accessed 2 May 2014). ">GPEI 2010</a>). Diagnosis is confirmed by a subsequent laboratory analysis of two stool specimens, taken 24 to 48 hours apart, within 14 days of onset of paralysis, as virus excretion decreases after two weeks. Where polio is suspected and it is not possible to obtain samples within the desired time frame, additional stool specimens are collected from up to five healthy individuals in close contact with the individual presenting with symptoms of polio, to improve the sensitivity and specificity of poliovirus detection (<a href="./references#CD011780-bbs2-0060" title="World Health Organization. Case definitions for the four diseases requiring notification to WHO in all circumstances under the International Health Regulations (2005). Weekly Epidemiological Record2009;84(7):52‐6. [www.who.int/wer/2009/wer8407/en/] ">WHO 2009</a>). Although the majority of people infected with wild poliovirus are asymptomatic (approximately 99.5%) (<a href="./references#CD011780-bbs2-0038" title="Global Polio EradicationInitiative . Polio + prevention. bit.ly/19VK8ok (accessed 2 May 2014). ">GPEI 2010</a>), the disease has the potential to cause irreparable paralysis by damaging the nervous system. It is reported that one in every 200 infections leads to paralysis, which most commonly affects the lower limbs, but in severe cases can involve the muscles of the torso and result in quadriplegia (<a href="./references#CD011780-bbs2-0038" title="Global Polio EradicationInitiative . Polio + prevention. bit.ly/19VK8ok (accessed 2 May 2014). ">GPEI 2010</a>). In individuals with bulbar polio, the brainstem is affected, which leads to reduced breathing capacity and difficulty in swallowing and speaking. At least 5% to 10% of affected patients die once their breathing muscles become paralysed (<a href="./references#CD011780-bbs2-0038" title="Global Polio EradicationInitiative . Polio + prevention. bit.ly/19VK8ok (accessed 2 May 2014). ">GPEI 2010</a>). </p> <p>Despite exponential growth in medical sciences, there is still no cure for poliomyelitis, as it is a permanent, lower motor neuron paralysis. Available treatments, such as antispasmodics or physical therapies, provide only symptomatic relief. However, polio can be prevented through immunisation, which can either be live attenuated or inactivated/killed. The attenuated virus in the vaccine replicates in the intestine and stimulates the immune system to produce antibodies against all three types of wild poliovirus. During the process of replication, however, the vaccine viruses mutate, and, after many replications become neuro‐virulent, that is able to cause paralysis in the recipient or his/her contacts; this is known as vaccine‐derived poliovirus (VDPV) (<a href="./references#CD011780-bbs2-0040" title="Global Polio EradicationInitiative . Vaccine‐derived polioviruses. www.polioeradication.org/polio‐today/polio‐prevention/the‐virus/vaccine‐derived‐polio‐viruses/ (assessed 15 June 2018). ">GPEI 2018</a>). VDPV are rare strains of poliovirus that have mutated from the vaccine strains of oral polio vaccine (OPV), and are known to cause two to four cases of vaccine‐associated poliomyelitis per cohort of one million children. VDPV are further classified as cVDPV (i.e. circulating VDPV) and iVDPV (i.e. immunodeficiency‐related vaccine‐derived poliovirus). cVDPV becomes a threat when the population is under‐immunised and the excreted virus becomes virulent and starts circulating. There were approximately 20 outbreaks of cVDPV leading to 580 cases between 2000 and 2011 (<a href="./references#CD011780-bbs2-0040" title="Global Polio EradicationInitiative . Vaccine‐derived polioviruses. www.polioeradication.org/polio‐today/polio‐prevention/the‐virus/vaccine‐derived‐polio‐viruses/ (assessed 15 June 2018). ">GPEI 2018</a>). Prolonged replication of the vaccine virus in people with immunodeficiency and with an inability to clear intestinal vaccine‐virus infection leads to prolonged excretion of iVDPV, and over 100 cases have been reported (<a href="./references#CD011780-bbs2-0040" title="Global Polio EradicationInitiative . Vaccine‐derived polioviruses. www.polioeradication.org/polio‐today/polio‐prevention/the‐virus/vaccine‐derived‐polio‐viruses/ (assessed 15 June 2018). ">GPEI 2018</a>). In the event of an outbreak due to VDPV, antiviral polio drugs are now available for use in combination with OPV (<a href="./references#CD011780-bbs2-0050" title="McKinlayMA , CollettMS , HincksJR , ObersteMS , PallanschMA , OkayasuH , et al. Progress in the development of poliovirus antiviral agents and their essential role in reducing risks that threaten eradication. Journal of Infectious Diseases2014;210 Suppl 1:S447‐53. [DOI: 10.1093/infdis/jiu043; PUBMED: 25316866] ">McKinlay 2014</a>). Due to the risk of vaccine‐associated poliomyelitis, an inactivated poliovirus vaccine (IPV) is required for complete elimination of polio (<a href="./references#CD011780-bbs2-0032" title="Centers for Disease Control and Prevention. Progress toward global eradication of poliomyelitis, 2001. Morbidity and Mortality Weekly Report2002;51(12):253‐6. [PUBMED: 11939704] ">CDC 2002</a>; <a href="./references#CD011780-bbs2-0042" title="GrasslyNC . The final stages of the global eradication of poliomyelitis. Philosophical Transitions of the Royal Society of London. Series B, Biological Sciences2013;368(1623):20120140. [DOI: 10.1098/rstb.2012.0140; PMC3720038; PUBMED: 23798688] ">Grassly 2013</a>). </p> </section> <section id="CD011780-sec-0025"> <h3 class="title" id="CD011780-sec-0025">Description of the intervention</h3> <p>On 25 January 2013, the World Health Organization (WHO) approved an action plan for the eradication and containment of all wild polioviruses in order that no child would suffer paralytic poliomyelitis (<a href="./references#CD011780-bbs2-0033" title="Centers for Disease Control and Prevention. Assessing the risks for poliovirus outbreaks in polio‐free countries ‐ Africa, 2012‐2013. Morbidity and Mortality Weekly Report2013;62(37):768‐72. [PMC4585360; PUBMED: 24048153] ">CDC 2013</a>; <a href="./references#CD011780-bbs2-0061" title="World Health Organization. Polio Eradication &amp; Endgame Strategic Plan 2013‐2018. Geneva: WHO, 2013. [polioeradication.org/wp‐content/uploads/2016/07/PEESP_EN_A4.pdf] ">WHO 2013</a>). IPV may be a prudent choice in the fight against polio. It is a killed vaccine and cannot mutate into neuro‐virulent forms. Furthermore, it has been reported to provide adequate immunogenicity against wild poliovirus (<a href="./references#CD011780-bbs2-0053" title="NelsonKS , JanssenJM , TroySB , MaldonadoY . Intradermal fractional dose inactivated polio vaccine: a review of the literature. Vaccine2012;30(2):121‐5. [DOI: 10.1016/j.vaccine.2011.11.018; PUBMED: 22100886] ">Nelson 2012</a>). IPV can be delivered either intramuscularly or intradermally. Intramuscular IPV is the most widely used IPV. </p> <p>Given that immune responses are more effective when vaccines are delivered directly into the skin (intradermal) than into muscles (intramuscular), it is possible that a lower vaccine dose (one‐fifth) of IPV injected intradermally may be equally or even more immunogenic than a vaccine given intramuscularly. With the development of different delivery methods, intradermal administration of vaccines has become easier. The fractional‐IPV innovation was developed in response to programmatic developments (<a href="./references#CD011780-bbs2-0054" title="OkayasuH , SeinC , Chang BlancD , GonzalezAR , ZehrungD , JarrahianC , et al. Intradermal administration of fractional doses of inactivated poliovirus vaccine: a dose‐sparing option for polio immunization. Journal of Infectious Diseases2017;216(Suppl 1):S161‐7. [DOI: 10.1093/infdis/jix038; PMC5853966; PUBMED: 28838185] ">Okayasu 2017</a>), including: </p> <p> <ol id="CD011780-list-0001"> <li> <p>global shortage of IPV;</p> </li> <li> <p>removal of type 2‐containing component of the oral polio vaccine in April 2016, in response to declaring the eradication of type 2 wild poliovirus in 2015 and the need to provide baseline/boosting of type 2 polio immunity; and </p> </li> <li> <p>cost‐savings for immunisation programmes in routine immunisation or supplementary activities, particularly in large countries. </p> </li> </ol> </p> <p>Intradermal administration of vaccines also requires a different skill set in healthcare professionals, since improper administration of the vaccine can affect its immunogenicity (<a href="./references#CD011780-bbs2-0054" title="OkayasuH , SeinC , Chang BlancD , GonzalezAR , ZehrungD , JarrahianC , et al. Intradermal administration of fractional doses of inactivated poliovirus vaccine: a dose‐sparing option for polio immunization. Journal of Infectious Diseases2017;216(Suppl 1):S161‐7. [DOI: 10.1093/infdis/jix038; PMC5853966; PUBMED: 28838185] ">Okayasu 2017</a>). </p> </section> <section id="CD011780-sec-0026"> <h3 class="title" id="CD011780-sec-0026">How the intervention might work</h3> <p>Intradermal fractionated IPV could be an immensely efficient method of antipoliovirus immunisation. Dendritic cells, including Langerhans cells, are concentrated in the dermis and serve as mediators between innate and adaptive immune responses (<a href="./references#CD011780-bbs2-0048" title="LambertPH , LaurentPE . Intradermal vaccine delivery: will new delivery systems transform vaccine administration?. Vaccine2008;26(26):3197‐208. [DOI: 10.1016/j.vaccine.2008.03.095; PUBMED: 18486285] ">Lambert 2008</a>). After recognising antigens, these cells release cytokines and activate the cell‐mediated, innate immune response. They also act as antigen‐presenting cells with a peptide/major histocompatibility complex (MHC) and generate B‐cell response (<a href="./references#CD011780-bbs2-0048" title="LambertPH , LaurentPE . Intradermal vaccine delivery: will new delivery systems transform vaccine administration?. Vaccine2008;26(26):3197‐208. [DOI: 10.1016/j.vaccine.2008.03.095; PUBMED: 18486285] ">Lambert 2008</a>; <a href="./references#CD011780-bbs2-0055" title="PaluckaK , BanchereauJ , MellmanI . Designing vaccines based on biology of human dendritic cell subsets. Immunity2010;33(4):464‐78. [DOI: 10.1016/j.immuni.2010.10.007; PMC2975953; PUBMED: 21029958] ">Palucka 2010</a>). As dendritic cells induce migration of T cells, the generated immune response (i.e. immunogenicity) is more effective and may be further enhanced by the use of specific adjuvants (<a href="./references#CD011780-bbs2-0055" title="PaluckaK , BanchereauJ , MellmanI . Designing vaccines based on biology of human dendritic cell subsets. Immunity2010;33(4):464‐78. [DOI: 10.1016/j.immuni.2010.10.007; PMC2975953; PUBMED: 21029958] ">Palucka 2010</a>). </p> </section> <section id="CD011780-sec-0027"> <h3 class="title" id="CD011780-sec-0027">Why it is important to do this review</h3> <p>As the global eradication of wild poliovirus progresses, vaccine viruses will become the main source of polioviruses and could conceivably prompt new outbreaks of polio across the world. Affordable IPV choices need to be available for any nation wishing to proceed with polio immunisation. As part of its strategic approach, the Global Polio Eradication Initiative is pursuing a dose‐reduction strategy of intradermal inoculation of fractional IPV (20% or 0.1 mL). Though trials have established the efficacy of full‐dose intramuscular IPV, intradermal IPV, if proved to be as efficacious and immunogenic, may be an alternative that low‐ and middle‐income countries could exploit. This review aimed to find out whether fractionated IPV administered through the intradermal route is as efficacious and immunogenic as full‐dose IPV administrated through the intramuscular route for preventing poliomyelitis in infants, children, and adults. It might help policymakers to weigh the advantages and disadvantages of this treatment. </p> <p>The WHO Strategic Advisory Group of Experts (SAGE) on Immunization currently recommends the use of two doses of fractional IPV over one full dose of intramuscular IPV (<a href="./references#CD011780-bbs2-0062" title="World Health Organization. Polio vaccines: WHO position paper ‐ March, 2016. Weekly Epidemiological Record2016;91(12):145‐68. [www.who.int/wer/2016/wer9112/en/] ">WHO 2016</a>). This recommendation was made during the development of this review and highlights the need to provide further information to inform future policies. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD011780-sec-0028" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD011780-sec-0028"></div> <p>To compare the immunogenicity and efficacy of an inactivated poliovirus vaccine (IPV) in equivalent immunisation schedules using fractional‐dose IPV given via the intradermal route versus full‐dose IPV given via the intramuscular route. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD011780-sec-0029" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD011780-sec-0029"></div> <section id="CD011780-sec-0030"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD011780-sec-0031"> <h4 class="title">Types of studies</h4> <p>All randomised controlled trials (RCTs) and quasi‐RCTs, with the exception of cross‐over trials, which are extremely rare in this area. </p> </section> <section id="CD011780-sec-0032"> <h4 class="title">Types of participants</h4> <p>Healthy individuals of any age group who qualify for immunisation with IPV, irrespective of HIV status, feeding habits, and birth weight (for infants); who may or may not have been exposed to OPV at birth; and who may also have received other vaccines for their age (e.g. diphtheria and tetanus toxoids and pertussis vaccine (DPT), bacille Calmette‐Guérin vaccine (BCG), etc.), provided there was a gap of at least two weeks prior to or after receiving IPV. </p> </section> <section id="CD011780-sec-0033"> <h4 class="title">Types of interventions</h4> <section id="CD011780-sec-0034"> <h5 class="title">Intervention</h5> <p>Fractional‐dose IPV given via the intradermal route.</p> </section> <section id="CD011780-sec-0035"> <h5 class="title">Comparison/control</h5> <p>Full‐dose IPV given via the intramuscular route.</p> </section> </section> <section id="CD011780-sec-0036"> <h4 class="title">Types of outcome measures</h4> <section id="CD011780-sec-0037"> <h5 class="title">Primary outcomes</h5> <p> <ol id="CD011780-list-0002"> <li> <p>Paralytic poliomyelitis</p> </li> <li> <p>Seroconversion rate</p> </li> <li> <p>Geometric mean titres of antibodies for wild poliovirus types 1, 2, and 3</p> </li> <li> <p>Any vaccine‐related adverse event after each dose (early or late events; e.g. injection site reactions, pyrexia, haematomas, or gastroenteritis, etc.), measured by the number of participants in an arm having an adverse event/total number of participants in that arm </p> </li> </ol> </p> </section> <section id="CD011780-sec-0038"> <h5 class="title">Secondary outcomes</h5> <p> <ol id="CD011780-list-0003"> <li> <p>Reciprocal antibody titres (as calculated by the Kärber method and expressed as 1/dilution) seven days after the first dose, second dose, third dose, and one month after the receiving the third primary dose </p> </li> <li> <p>Serum immunoglobulin A (IgA) levels (measured by the enzyme‐linked immunosorbent assay (ELISA), expressed by the number of children with detectable IgA levels in that arm/total number of participants in that arm) seven days after the first dose, second dose, third dose, and one month after receiving the third primary dose </p> </li> <li> <p>Poliovirus shedding in stool after seven days and after the first month of each dose (we analysed both qualitative and quantitative measures separately; we provided a narrative description of values given as interquartile ranges, medians, etc.; when mentioned, we pooled the number of participants in each arm with virus shedding as proportions in each arm) </p> </li> <li> <p>Vaccine‐associated paralytic polio (VAPP), measured by the number of participants in each arm with VAPP/total number of participants in that arm (<a href="./references#CD011780-bbs2-0034" title="CiapponiA , BardachA , Rey AresL , GlujovskyD , CafferataML , RomanoM , et al. Sequential inactivated (IPV) and live oral (OPV) poliovirus vaccines for preventing poliomyelitis. Cochrane Database of Systematic Reviews2014, Issue 8. [DOI: 10.1002/14651858.CD011260] ">Ciapponi 2014</a>) </p> </li> </ol> </p> </section> </section> </section> <section id="CD011780-sec-0039"> <h3 class="title">Search methods for identification of studies</h3> <p>We ran the first searches for this review in October 2015 and updated them in April 2017, March 2018, and February 2019. </p> <section id="CD011780-sec-0040"> <h4 class="title">Electronic searches</h4> <p>We searched the following electronic sources up to February 2019.</p> <p> <ol id="CD011780-list-0004"> <li> <p>Cochrane Central Register of Controlled Trials (CENTRAL; 2019, Issue 2) in the Cochrane Library, which includes the Cochrane Psychosocial, Developmental and Learning Problems Group Specialized Register (searched 13 February 2019). </p> </li> <li> <p>MEDLINE Ovid (1946 to January Week 5 2019).</p> </li> <li> <p>MEDLINE In‐Process and Other Non‐indexed Citations Ovid (searched 13 February 2019).</p> </li> <li> <p>MEDLINE Epub Ahead of Print Ovid (searched 13 February 2019).</p> </li> <li> <p>Embase Ovid (1974 to 12 February 2019).</p> </li> <li> <p>Science Citation Index Web of Science (SCI; 1970 to 14 February 2019).</p> </li> <li> <p>Conference Proceedings Citation Index ‐ Science Web of Science (CPCI‐S; 1990 to 14 February 2019). </p> </li> <li> <p>IndMED (<a href="http://indmed.nic.in/" target="_blank">indmed.nic.in</a>; searched 14 February 2019). </p> </li> <li> <p>Cochrane Database of Systematic Reviews (CDSR; 2019, Issue 2), part of the Cochrane Library (searched 13 February 2019). </p> </li> <li> <p>Database of Abstracts of Reviews of Effects (DARE; 2015, Issue 2), part of the Cochrane Library (final issue of DARE searched 27 April 2017). </p> </li> <li> <p>LILACS (Latin American and Caribbean Health Science Information Database; <a href="http://lilacs.bvsalud.org/en/" target="_blank">lilacs.bvsalud.org/en</a>; searched 14 February 2019). </p> </li> <li> <p>Trip database (<a href="https://www.tripdatabase.com" target="_blank">www.tripdatabase.com</a>; searched 14 February 2019). </p> </li> <li> <p>WHOLIS (World Health Organization Library Database; <a href="http://kohahq.searo.who.int/" target="_blank">kohahq.searo.who.int</a>; searched 14 February 2019). </p> </li> <li> <p>US National Institutes of Health Ongoing Trials Register ClinicalTrials.gov (<a href="http://clinicaltrials.gov" target="_blank">clinicaltrials.gov</a>; searched 14 February 2019). </p> </li> <li> <p>World Health Organization International Clinical Trials Registry Platform (WHO ICTRP; <a href="http://who.int/ictrp/en/" target="_blank">who.int/ictrp/en</a>; searched 14 February 2019). </p> </li> </ol> </p> <p>The search strategies and exact search dates for each database are shown in <a href="./appendices#CD011780-sec-0118">Appendix 1</a>. We did not limit our searches by date, language, or publication status, and where necessary we sought translation and data extraction of studies written in languages other than English (<a href="#CD011780-sec-0030">Criteria for considering studies for this review</a>). </p> </section> <section id="CD011780-sec-0041"> <h4 class="title">Searching other resources</h4> <p>We scanned the bibliographies of key studies and reviews to identify any additional published and unpublished trials that our electronic searches failed to capture. We also searched the websites of relevant organisations, including the Global Polio Eradication Initiative (<a href="http://polioeradication.org" target="_blank">polioeradication.org</a>), to identify any ongoing or unpublished studies. </p> </section> </section> <section id="CD011780-sec-0042"> <h3 class="title" id="CD011780-sec-0042">Data collection and analysis</h3> <section id="CD011780-sec-0043"> <h4 class="title">Selection of studies</h4> <p>After removal of duplicates, two review authors (AA and NJ) screened the titles and abstracts yielded by the searches and separated them into two groups: 'excluded' and 'not excluded'. Next, they retrieved the full texts of those records deemed 'not excluded', and independently assessed them for relevance against the selection criteria (<a href="#CD011780-sec-0030">Criteria for considering studies for this review</a>). Any discrepancies were resolved by discussion and in consultation with a third review author (MS) who acted as an arbiter. The selection process is described in a PRISMA flow diagram, per the PRISMA guidelines (<a href="./references#CD011780-bbs2-0052" title="MoherD , LiberatiA , TetzlaffJ , AltmanDG , PRISMA Group. Preferred reporting items for systematic reviews and meta‐analyses: the PRISMA statement. PLoS Medicine2009;6(7):e1000097. [DOI: 10.1371/journal.pmed.1000097; PMC2707599; PUBMED: 19621072] ">Moher 2009</a>). </p> </section> <section id="CD011780-sec-0044"> <h4 class="title">Data extraction and management</h4> <p>Two review authors (AA and NJ) independently extracted and recorded data on each of the following criteria onto separate, pre‐piloted study report forms. </p> <p> <ol id="CD011780-list-0005"> <li> <p>General information (study identifier, date of extraction, title, authors, and source of study if not published) </p> </li> <li> <p>Study characteristics (study design, participants, and inclusion or exclusion criteria used in the study) </p> </li> <li> <p>Details of the interventions (including vaccine schedule and dosage, comparison details, duration of follow‐up) </p> </li> <li> <p>Outcomes, as described in the <a href="#CD011780-sec-0036">Types of outcome measures</a> section </p> </li> <li> <p>Details for the 'Risk of bias' assessment</p> </li> </ol> </p> <p>Any disagreements were resolved through discussion with a third review author (MS).</p> <p>Three review authors (AC, NJ, and SS) entered the extracted data into Review Manager 5 (RevMan 5) for analysis (<a href="./references#CD011780-bbs2-0057" title="Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">Review Manager 2014</a>). </p> </section> <section id="CD011780-sec-0045"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>We assessed the risk of bias in each included study using Cochrane's 'Risk of bias' tool (<a href="./references#CD011780-bbs2-0045" title="HigginsJPT , AltmanDG , SterneJAC , editor(s) , on behalf of the Cochrane Statistical Methods Group and the Cochrane Bias Methods Group. Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011a</a>). For each domain listed below, three review authors (KKT, AC, and SS) independently judged the risk of bias as low, high, or unclear as per our protocol (<a href="./references#CD011780-bbs2-0065" title="JaiswalN , SinghM , ThumburuKK , AgarwalA , KaurH . Intradermal fractional dose vs intramuscular full dose of inactivated polio vaccine for prevention of poliomyelitis. Cochrane Database of Systematic Reviews2015, Issue 6. [DOI: 10.1002/14651858.CD011780] ">Jaiswal 2015</a>), using the criteria set out in <a href="#CD011780-tbl-0003">Table 2</a>. One review author (MS) acted as the arbiter in case of disagreements. </p> <div class="table" id="CD011780-tbl-0003"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Criteria for assigning 'Risk of bias' judgements</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Domain</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Rating</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Criteria</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b>Random sequence generation</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low risk of bias</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Study used a random method, such as a computer‐generated system or random number table, to generate the allocation sequence and described the approach in sufficient detail. Drawing of lots, tossing of coin, shuffling of cards, or throwing dice was considered adequate if a person who was not otherwise involved in the recruitment of participants performed the procedure. </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear risk of bias</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Method used to generate the allocation sequence was not described.</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High risk of bias</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Study used a non‐random method, such as dates, names, or admittance numbers, to generate the allocation sequence of participants. </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b>Allocation concealment</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low risk of bias</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Allocation of participants to study groups was concealed from participants and investigators using a central independent unit, on‐site locked computer, identical syringes or schedules (used by an independent pharmacist or investigator), or opaque, sealed envelopes. </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear risk of bias</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Method for allocation concealment was not described or was not described in sufficient detail to permit a judgement of low or high risk of bias. </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High risk of bias</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Allocations were not concealed and were known to both participants and investigators.</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b>Blinding of participants and personnel</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low risk of bias</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Parents/guardians or recipients (in cases of older children/adults) were blinded; blinding was described in sufficient detail; and it was unlikely that the blinding could have been broken. </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear risk of bias</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Blinding was not described or was not described in sufficient detail to permit a judgement of low or high risk of bias. </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High risk of bias</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Parents or recipients were not blinded; blinding was broken; or it was likely that the outcome could have been affected by the lack of blinding. </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b>Blinding of outcome assessment</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low risk of bias</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Outcome assessment was blinded; details of blinding were described in sufficient detail; and it was unlikely that the blinding could have been broken, or there was no blinding but the outcome assessment was unlikely to have been affected by the lack of blinding. </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear risk of bias</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Blinding was not described or was not described in sufficient detail to permit a judgement of low or high risk of bias. </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High risk of bias</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Outcome assessment was not blinded; blinding was broken; or it was likely that the outcome assessment could have been influenced by the lack of blinding. </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b>Incomplete outcome data</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low risk of bias</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No missing data; the reasons for the missing data were unrelated to the true outcome; or the study used appropriate methods to impute the data </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear risk of bias</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient information to permit a judgement of low or high risk of bias</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High risk of bias</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Reasons for missing data were related to the true outcome, or the study used inappropriate methods to impute the data. </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b>Selective outcome reporting</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low risk of bias</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Study protocol was available, and all prespecified outcomes were reported and in the manner specified; or study protocol was not available, but it was clear that all prespecified outcomes had been reported. </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear risk of bias</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient information to permit a judgement of low or high risk of bias</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High risk of bias</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Study protocol was available, but not all of the study’s prespecified outcomes were reported, or not all were reported in prespecified way, or one or more were reported incorrectly; or outcomes were reported that were not prespecified; or study did not have a protocol, and not all expected outcomes were reported. </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b>Other bias</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low risk of bias</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No other sources of bias</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear risk of bias</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient information to judge that an important risk of bias exists</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High risk of bias</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Other important potential sources of bias (e.g. studies were privately funded) exist.</p> </td> </tr> </tbody> </table> </div> <p> <ol id="CD011780-list-0006"> <li> <p>Random sequence generation</p> </li> <li> <p>Allocation concealment</p> </li> <li> <p>Blinding of participants and study personnel</p> </li> <li> <p>Blinding of outcome assessments</p> </li> <li> <p>Reporting of incomplete outcome data</p> </li> <li> <p>Selective reporting</p> </li> <li> <p>Other potential sources of bias (we used data pertaining to the study's funding source(s) to populate the column in the 'Risk of bias' table) </p> </li> </ol> </p> <p>We used these judgements to draw a 'Risk of bias' graph, expressed as percentages, and a 'Risk of bias' summary graph employing RevMan 5 (<a href="./references#CD011780-bbs2-0057" title="Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">Review Manager 2014</a>). </p> </section> <section id="CD011780-sec-0046"> <h4 class="title">Measures of treatment effect</h4> <section id="CD011780-sec-0047"> <h5 class="title">Dichotomous data</h5> <p>We used odds ratios (OR) and presented these with 95% confidence intervals (CIs). See <a href="./appendices#CD011780-sec-0134">Appendix 2</a> for additional methods we had planned to use but did not (<a href="./references#CD011780-bbs2-0065" title="JaiswalN , SinghM , ThumburuKK , AgarwalA , KaurH . Intradermal fractional dose vs intramuscular full dose of inactivated polio vaccine for prevention of poliomyelitis. Cochrane Database of Systematic Reviews2015, Issue 6. [DOI: 10.1002/14651858.CD011780] ">Jaiswal 2015</a>). </p> </section> </section> <section id="CD011780-sec-0048"> <h4 class="title">Unit of analysis issues</h4> <p>We analysed trials on adults (aged 18 years and above) separately from trials on children (under 18 years of age). </p> <section id="CD011780-sec-0049"> <h5 class="title">Cluster‐randomised controlled trials</h5> <p>We stated in our protocol that we would combine the adjusted measures of effects of cluster‐randomised trials (<a href="./references#CD011780-bbs2-0065" title="JaiswalN , SinghM , ThumburuKK , AgarwalA , KaurH . Intradermal fractional dose vs intramuscular full dose of inactivated polio vaccine for prevention of poliomyelitis. Cochrane Database of Systematic Reviews2015, Issue 6. [DOI: 10.1002/14651858.CD011780] ">Jaiswal 2015</a>); however, we did not encounter any such trials. Our methods for managing cluster‐randomised trials are summarised in <a href="./appendices#CD011780-sec-0134">Appendix 2</a>. </p> </section> <section id="CD011780-sec-0050"> <h5 class="title">Studies with multiple intervention arms</h5> <p>We combined the data from all eligible intervention arms, and compared them with the combined data from all eligible control groups, making single pair‐wise comparisons; we did not use data from arms including interventions not relevant to this review. For dichotomous outcomes we summed the number of participants with events and the total number of participants across the groups (<a href="./references#CD011780-bbs2-0046" title="HigginsJPT , DeeksJJ , AltmanDG , editor(s) , on behalf of the Cochrane Statistical Methods Group. Chapter 16: Special topics in statistics. In: Higgins JPT, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011b</a>). In the case of continuous outcomes, we combined the mean and standard deviations using the formulae described in Chapter 7 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD011780-bbs2-0047" title="HigginsJPT , DeeksJJ , editor(s) . Chapter 7: Selecting studies and collecting data. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011c</a>). </p> </section> </section> <section id="CD011780-sec-0051"> <h4 class="title">Dealing with missing data</h4> <p>We investigated and reported the reasons, numbers, and characteristics of dropouts in the <a href="./references#CD011780-sec-0142" title="">Characteristics of included studies</a> tables. Where possible, we compared the protocols of the included studies to their respective published reports, and contacted the corresponding authors of included studies to seek clarification or missing data (or both) when necessary. The methods we will use if possible in future updates of this review are shown in <a href="./appendices#CD011780-sec-0134">Appendix 2</a>. </p> </section> <section id="CD011780-sec-0052"> <h4 class="title">Assessment of heterogeneity</h4> <p>We assessed clinical and methodological variation across studies by comparing differences in settings and important participant characteristics (such as age of study participants, exposure to OPV, age of first dose, etc.), as well as trial characteristics (study design, interventions, outcomes, and risk of bias) to identify the source of any observed heterogeneity. We evaluated statistical heterogeneity in the included studies using the Chi<sup>2</sup> test (significance set at P value &lt; 0.10) and the I<sup>2</sup> statistic (<a href="./references#CD011780-bbs2-0044" title="HigginsJPT , ThompsonSG , DeeksJJ , AltmanDG . Measuring inconsistency in meta‐analyses. BMJ2003;327(7414):557‐60. [DOI: 10.1136/bmj.327.7414.557; PMC192859; PUBMED: 12958120] ">Higgins 2003</a>). We based our interpretations of I<sup>2</sup> on the thresholds listed below (<a href="./references#CD011780-bbs2-0036" title="DeeksJJ , HigginsJPT , AltmanDG , editor(s) , on behalf of the Cochrane Statistical Methods Group. Chapter 9: Analysing data and undertaking meta‐analysis. In: Higgins JPT, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Deeks 2011</a>). </p> <p> <ol id="CD011780-list-0007"> <li> <p>0% to 40% as probably not important</p> </li> <li> <p>30% to 60% as moderate heterogeneity</p> </li> <li> <p>50% to 90% as substantial heterogeneity</p> </li> <li> <p>75% to 100% as considerable heterogeneity</p> </li> </ol> </p> </section> <section id="CD011780-sec-0053"> <h4 class="title">Assessment of reporting biases</h4> <p>We were not able to construct funnel plots (plotting trial effects against inverse standard errors of effects) to assess for reporting biases as planned (<a href="./references#CD011780-bbs2-0065" title="JaiswalN , SinghM , ThumburuKK , AgarwalA , KaurH . Intradermal fractional dose vs intramuscular full dose of inactivated polio vaccine for prevention of poliomyelitis. Cochrane Database of Systematic Reviews2015, Issue 6. [DOI: 10.1002/14651858.CD011780] ">Jaiswal 2015</a>), as there were fewer than 10 studies for all outcomes included in the meta‐analysis. The methods we will use if possible in future updates of this review are shown in <a href="./appendices#CD011780-sec-0134">Appendix 2</a>. </p> </section> <section id="CD011780-sec-0054"> <h4 class="title">Data synthesis</h4> <p>Where possible, we pooled data using the random‐effects model with Mantel‐Haenszel weighting, as there was heterogeneity in the included studies with regard to the schedule and number of doses of polio vaccines administered intradermally and intramuscularly. We conducted a sensitivity analysis using the fixed‐effect model to test the robustness of this decision (see <a href="#CD011780-sec-0057">Sensitivity analysis</a>). </p> <p>Where a meta‐analysis was not possible, we provided a narrative synthesis of the results.</p> <section id="CD011780-sec-0055"> <h5 class="title">'Summary of findings' table</h5> <p>Having imported the data from RevMan 5 (<a href="./references#CD011780-bbs2-0057" title="Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">Review Manager 2014</a>), we used GRADEpro GDT to create a 'Summary of findings' table for the comparison 'Equivalent schedules of intradermal fractional‐dose inactivated poliovirus vaccine compared to intramuscular inactivated poliovirus vaccine for the prevention of poliomyelitis in children' (<a href="./references#CD011780-bbs2-0041" title="McMaster University (developed by Evidence Prime). GRADEpro GDT. Version accessed 20 June 2017. Hamilton (ON): McMaster University (developed by Evidence Prime). ">GRADEpro GDT</a>). The table reports the absolute and relative effects for each primary outcome, as well as a rating of the certainty of the evidence, and the number of participants and studies contributing data. </p> <p>Two review authors (AC and NJ) used the GRADE approach to assess the overall certainty of the body of evidence for each primary outcome (<a href="./references#CD011780-bbs2-0043" title="GuyattG , OxmanAD , AklEA , KunzR , VistG , BrozekJ , et al. GRADE guidelines: 1. Introduction ‐ GRADE evidence profiles and summary of findings tables. Journal of Clinical Epidemiology2011;64(4):383‐94. [DOI: 10.1016/j.jclinepi.2010.04.026; PUBMED: 21195583] ">Guyatt 2011</a>); another review author (MS) arbitrated in the case of disagreement. The evidence was downgraded by one level from high to moderate certainty (or by two levels to low or very low certainty, depending on the extent of the violation) for the following criteria: study limitations (risk of bias); indirectness of evidence; inconsistency; imprecision of effect estimates; and publication bias. </p> </section> </section> <section id="CD011780-sec-0056"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>Where possible, we performed subgroup analysis based on the low‐, middle‐, and high‐income country classification of the World Bank, to assess the efficacy and immunogenicity of intradermal IPV against intramuscular IPV (<a href="./references#CD011780-bbs2-0064" title="WorldBank . Data: World Bank country and lending groups. bit.ly/1pUHKTk (assessed 17 September 2014). ">World Bank 2014</a>). We were unable to conduct our other preplanned subgroup analyses (<a href="./references#CD011780-bbs2-0065" title="JaiswalN , SinghM , ThumburuKK , AgarwalA , KaurH . Intradermal fractional dose vs intramuscular full dose of inactivated polio vaccine for prevention of poliomyelitis. Cochrane Database of Systematic Reviews2015, Issue 6. [DOI: 10.1002/14651858.CD011780] ">Jaiswal 2015</a>), which we have archived for use in future updates of this review (<a href="./appendices#CD011780-sec-0134">Appendix 2</a>). </p> </section> <section id="CD011780-sec-0057"> <h4 class="title">Sensitivity analysis</h4> <p>We performed a sensitivity analysis using a fixed‐effect model to test the robustness of our decision to pool results using a random‐effects model. We were unable to conduct any of our other preplanned sensitivity analyses (<a href="./references#CD011780-bbs2-0065" title="JaiswalN , SinghM , ThumburuKK , AgarwalA , KaurH . Intradermal fractional dose vs intramuscular full dose of inactivated polio vaccine for prevention of poliomyelitis. Cochrane Database of Systematic Reviews2015, Issue 6. [DOI: 10.1002/14651858.CD011780] ">Jaiswal 2015</a>), which we have archived for use in future updates of this review (<a href="./appendices#CD011780-sec-0134">Appendix 2</a>). </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD011780-sec-0058" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD011780-sec-0058"></div> <section id="CD011780-sec-0059"> <h3 class="title">Description of studies</h3> <section id="CD011780-sec-0060"> <h4 class="title">Results of the search</h4> <p>Our literature search retrieved a total of 7438 records, of which 2457 were discarded as duplicates. We screened the titles and abstracts of the remaining 4981 records, excluded 4948 irrelevant records and retrieved 33 full‐text reports, which we assessed against our inclusion criteria (<a href="#CD011780-sec-0030">Criteria for considering studies for this review</a>). We included 13 studies (from 15 reports) and excluded 14 studies (from 15 reports), as shown in <a href="#CD011780-fig-0001">Figure 1</a>. One study is awaiting classification (<a href="./references#CD011780-bbs2-0028" title="NCT02347423 . 3 adjuvated reduced dose IPV‐Al SSI and non‐adjuvated full dose IPV SSI given as primary vaccinations to infants [Immunogenicity and safety of 3 adjuvated reduced dose inactivated polio vaccines (IPV‐Al SSI) and non‐adjuvated full dose IPV SSI, given as primary vaccinations to infants at 6, 10 and 14 weeks of age]. clinicaltrials.gov/ct2/show/record/NCT02347423 (first received 15 January 2015). ">NCT02347423</a>), as it was not clear from the available report whether relevant interventions were used, and two studies are ongoing (<a href="./references#CD011780-bbs2-0029" title="NCT02847026 . Fractional inactivated poliovirus vaccine booster and rotavirus study (fIPV) [Immunogenicity of a booster dose of fractional inactivated poliovirus vaccine (fIPV) delivered intradermally concomitantly with rotavirus vaccines]. clinicaltrials.gov/ct2/show/NCT02847026 (first received 25 July 2016). ">NCT02847026</a>; <a href="./references#CD011780-bbs2-0030" title="NCT03016949 . A study to evaluate immunogenicity of various schedules of inactivated polio vaccine [A phase 3, open‐label, randomized trial to evaluate humoral immunogenicity of various schedules of intramuscular full dose and intradermal fractional dose of inactivated polio vaccine in infants]. clinicaltrials.gov/ct2/show/NCT03016949 (first received 5 January 2017). ">NCT03016949</a>). </p> <div class="figure" id="CD011780-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow (PRISMA) diagram." data-id="CD011780-fig-0001" src="/cdsr/doi/10.1002/14651858.CD011780.pub2/media/CDSR/CD011780/image_n/nCD011780-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow (PRISMA) diagram.</p> </div> </div> </div> <p>We contacted the corresponding authors of all included studies for clarification regarding allocation concealment and for data regarding virus shedding in stools. We received replies from four authors (<a href="./references#CD011780-bbs2-0001" title="AnandA . Regarding your published trial on IPV in the Vaccine journal [personal communication]. Email to: N Jaiswal 04 May 2016. AnandA , ZamanK , EstívarizCF , YunusM , GaryHE , WeldonWC , et al. Early priming with inactivated poliovirus vaccine (IPV) and intradermal fractional dose IPV administered by a microneedle device: a randomized controlled trial. Vaccine2015;33(48):6816‐22. [DOI: 10.1016/j.vaccine.2015.09.039; PUBMED: 26476367] ">Anand 2015</a>; <a href="./references#CD011780-bbs2-0004" title='EstívarezCF . Details regarding your published paper about "Immunogenicity of supplemental doses of poliovirus vaccine for children aged 6‐9 months in Moradabad, India: a community‐based, randomised controlled trial. Lancet 2012 [personal communication]. Email to: KK Thumburu 11 March 2016. EstívarizCF , JafariH , SutterRW , JohnTJ , JainV , AgarwalA , et al. Immunogenicity of supplemental doses of poliovirus vaccine for children aged 6‐9 months in Moradabad, India: a community‐based, randomised controlled trial. Lancet. Infectious Diseases2012;12(2):128‐35. [DOI: 10.1016/S1473‐3099(11)70190‐6; PUBMED: 22071249] '>Estívariz 2012</a>; <a href="./references#CD011780-bbs2-0008" title='ResikS , TejedaA , SutterRW , DiazM , SarmientoL , AlemañiN , et al. Priming after a fractional dose of inactivated poliovirus vaccine. New England Journal of Medicine2013;368(5):416‐24. [DOI: 10.1056/NEJMoa1202541; PUBMED: 23363495] SutterRW . Regarding your published paper about "Priming after a Fractional Dose of Inactivated Poliovirus Vaccine" published in NEJM 2013 [personal communication]. Email to: KK Thumburu 04 February 2016. '>Resik 2013</a>; <a href="./references#CD011780-bbs2-0013" title='TroyS . Regarding your paper "Comparison of the Immunogenicity of Various Booster Doses of Inactivated Polio Vaccine Delivered Intradermally Versus Intramuscularly to HIV‐Infected Adults" [personal communication]. Email to: A Agarwal 06 May 2016. TroySB , KouiavskaiaD , SiikJ , KochbaE , BeydounH , MirochnitchenkoO , et al. Comparison of the immunogenicity of various booster doses of inactivated polio vaccine delivered intradermally versus intramuscularly to HIV‐infected adults. Journal of Infectious Diseases2015;211(12):1969‐76. [DOI: 10.1093/infdis/jiu841; PMC4539908; PUBMED: 25567841] '>Troy 2015</a>), who provided clarification regarding allocation concealment. We were unable to obtain any unpublished data. </p> </section> <section id="CD011780-sec-0061"> <h4 class="title">Included studies</h4> <p>We included 13 RCTs in this review (<a href="./references#CD011780-bbs2-0001" title="AnandA . Regarding your published trial on IPV in the Vaccine journal [personal communication]. Email to: N Jaiswal 04 May 2016. AnandA , ZamanK , EstívarizCF , YunusM , GaryHE , WeldonWC , et al. Early priming with inactivated poliovirus vaccine (IPV) and intradermal fractional dose IPV administered by a microneedle device: a randomized controlled trial. Vaccine2015;33(48):6816‐22. [DOI: 10.1016/j.vaccine.2015.09.039; PUBMED: 26476367] ">Anand 2015</a>; <a href="./references#CD011780-bbs2-0002" title="Cadorna‐CarlosJ , VidorE , BonnetMC . Randomized controlled study of fractional doses of inactivated poliovirus vaccine administered intradermally with a needle in the Philippines. International Journal of Infectious Diseases2012;16(2):e110‐6. [DOI: 10.1016/j.ijid.2011.10.002; PUBMED: 22153001] ">Cadorna‐Carlos 2012</a>; <a href="./references#CD011780-bbs2-0003" title="ClarkeE , SaiduY , AdetifaJU , AdigwemeI , HydaraMB , BashorunAO , et al. Safety and immunogenicity of inactivated poliovirus vaccine when given with measles–rubella combined vaccine and yellow fever vaccine and when given via different administration routes: a phase 4, randomised, non‐inferiority trial in The Gambia. Lancet. Global Health2016;4(8):e534‐47. [DOI: 10.1016/S2214‐109X(16)30075‐4; PUBMED: 27364568] NCT01847872 . IPV clinical trial ‐ The Gambia (IPV) [A phase 4, randomized trial to assess the safety and immunogenicity of inactivated poliovirus vaccine when given concomitantly with measles and rubella combined vaccine and yellow fever vaccine at nine months and when administered via different vaccination routes]. clinicaltrials.gov/ct2/show/NCT01847872 (first received 19 April 2013). ">Clarke 2016</a>; <a href="./references#CD011780-bbs2-0004" title='EstívarezCF . Details regarding your published paper about "Immunogenicity of supplemental doses of poliovirus vaccine for children aged 6‐9 months in Moradabad, India: a community‐based, randomised controlled trial. Lancet 2012 [personal communication]. Email to: KK Thumburu 11 March 2016. EstívarizCF , JafariH , SutterRW , JohnTJ , JainV , AgarwalA , et al. Immunogenicity of supplemental doses of poliovirus vaccine for children aged 6‐9 months in Moradabad, India: a community‐based, randomised controlled trial. Lancet. Infectious Diseases2012;12(2):128‐35. [DOI: 10.1016/S1473‐3099(11)70190‐6; PUBMED: 22071249] '>Estívariz 2012</a>; <a href="./references#CD011780-bbs2-0005" title="ACTRN12616000124437p . Comparison of boosting of mucosal immunity after full and fractional dose of inactivated poliovirus vaccine, clinical trial in children in Sri Lanka, 2016 [Comparison of boosting of mucosal immunity after full and fractional dose of inactivated poliovirus vaccine, a randomized clinical trial in 300 children aged 10‐12 years of age living in Kalutara district of Sri Lanka, 2016]. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=369725 (first received 3 December 2015). GamageD , MachO , PalihawadanaP , ZhangY , WeldonWC , ObersteMS , et al. Boosting of mucosal immunity after fractional‐dose inactivated poliovirus vaccine. Journal of Infectious Diseases2018;218(12):1876‐82. [DOI: 10.1093/infdis/jiy389; PUBMED: 29982532] ">Gamage 2018</a>; <a href="./references#CD011780-bbs2-0006" title="MohammedAJ , AlAwaidyS , BawikarS , KurupPJ , ElamirE , ShabanMMA , et al. Fractional doses of inactivated poliovirus vaccine in Oman. New England Journal of Medicine2010;362(25):2351‐9. [DOI: 10.1056/NEJMoa0909383; PUBMED: 20573923] ">Mohammed 2010</a>; <a href="./references#CD011780-bbs2-0007" title="ResikS , TejedaA , LagoPM , DiazM , CarmenatesA , SarmientoL , et al. Randomized controlled clinical trial of fractional doses of inactivated poliovirus vaccine administered intradermally by needle‐free device in Cuba. Journal of Infectious Diseases2010;201(9):1344‐52. [DOI: 10.1086/651611; PUBMED: 20350164] ">Resik 2010</a>; <a href="./references#CD011780-bbs2-0008" title='ResikS , TejedaA , SutterRW , DiazM , SarmientoL , AlemañiN , et al. Priming after a fractional dose of inactivated poliovirus vaccine. New England Journal of Medicine2013;368(5):416‐24. [DOI: 10.1056/NEJMoa1202541; PUBMED: 23363495] SutterRW . Regarding your published paper about "Priming after a Fractional Dose of Inactivated Poliovirus Vaccine" published in NEJM 2013 [personal communication]. Email to: KK Thumburu 04 February 2016. '>Resik 2013</a>; <a href="./references#CD011780-bbs2-0009" title="ResikS , TejedaA , MachO , FonsecaM , DiazM , AlemanyN , et al. Immune responses after fractional doses of inactivated poliovirus vaccine using newly developed intradermal jet injectors: a randomized controlled trial in Cuba. Vaccine2015;33(2):307‐13. [DOI: 10.1016/j.vaccine.2014.11.025; PUBMED: 25448109] ">Resik 2015</a>; <a href="./references#CD011780-bbs2-0010" title="ResikS , TejedaA , DiazM , OkayasuH , SeinC , MolodeckyNA , et al. Boosting immune responses following fractional‐dose inactivated poliovirus vaccine: a randomized, controlled trial. Journal of Infectious Diseases2017;215(2):175‐82. [DOI: 10.1093/infdis/jiw492; PUBMED: 28073858] ">Resik 2017</a>; <a href="./references#CD011780-bbs2-0011" title="SoonawalaD , VerdijkP , Wijmenga‐MonsuurAJ , BoogCJ , KoedamP , VisserLG , et al. Intradermal fractional booster dose of inactivated poliomyelitis vaccine with a jet injector in healthy adults. Vaccine2013;31(36):3688‐94. [DOI: 10.1016/j.vaccine.2013.05.104; PUBMED: 23770332] ">Soonawala 2013</a>; <a href="./references#CD011780-bbs2-0012" title="Tejeda FuentesA , DeArmas LópezJ , Silva SosaM , Alemañy BuenoN , Carmenate GarcíaA , García GonzálezG , et al. Reactogenicity associated to the intradermally administered inactivated poliovirus vaccine with a needle‐free injector [Reactogenicidad asociada a la vacuna de poliovirus inactivada administrada por vía intradérmica con un inyector sin aguja]. Revista Cubana de Medicina Tropical2011;63(1):38‐43. [PUBMED: 23437535] ">Tejeda Fuentes 2011</a>; <a href="./references#CD011780-bbs2-0013" title='TroyS . Regarding your paper "Comparison of the Immunogenicity of Various Booster Doses of Inactivated Polio Vaccine Delivered Intradermally Versus Intramuscularly to HIV‐Infected Adults" [personal communication]. Email to: A Agarwal 06 May 2016. TroySB , KouiavskaiaD , SiikJ , KochbaE , BeydounH , MirochnitchenkoO , et al. Comparison of the immunogenicity of various booster doses of inactivated polio vaccine delivered intradermally versus intramuscularly to HIV‐infected adults. Journal of Infectious Diseases2015;211(12):1969‐76. [DOI: 10.1093/infdis/jiu841; PMC4539908; PUBMED: 25567841] '>Troy 2015</a>). Of these, three studies included 890 adult participants (<a href="./references#CD011780-bbs2-0010" title="ResikS , TejedaA , DiazM , OkayasuH , SeinC , MolodeckyNA , et al. Boosting immune responses following fractional‐dose inactivated poliovirus vaccine: a randomized, controlled trial. Journal of Infectious Diseases2017;215(2):175‐82. [DOI: 10.1093/infdis/jiw492; PUBMED: 28073858] ">Resik 2017</a>; <a href="./references#CD011780-bbs2-0011" title="SoonawalaD , VerdijkP , Wijmenga‐MonsuurAJ , BoogCJ , KoedamP , VisserLG , et al. Intradermal fractional booster dose of inactivated poliomyelitis vaccine with a jet injector in healthy adults. Vaccine2013;31(36):3688‐94. [DOI: 10.1016/j.vaccine.2013.05.104; PUBMED: 23770332] ">Soonawala 2013</a>; <a href="./references#CD011780-bbs2-0013" title='TroyS . Regarding your paper "Comparison of the Immunogenicity of Various Booster Doses of Inactivated Polio Vaccine Delivered Intradermally Versus Intramuscularly to HIV‐Infected Adults" [personal communication]. Email to: A Agarwal 06 May 2016. TroySB , KouiavskaiaD , SiikJ , KochbaE , BeydounH , MirochnitchenkoO , et al. Comparison of the immunogenicity of various booster doses of inactivated polio vaccine delivered intradermally versus intramuscularly to HIV‐infected adults. Journal of Infectious Diseases2015;211(12):1969‐76. [DOI: 10.1093/infdis/jiu841; PMC4539908; PUBMED: 25567841] '>Troy 2015</a>), and 10 studies included 6402 infants and children (<a href="./references#CD011780-bbs2-0001" title="AnandA . Regarding your published trial on IPV in the Vaccine journal [personal communication]. Email to: N Jaiswal 04 May 2016. AnandA , ZamanK , EstívarizCF , YunusM , GaryHE , WeldonWC , et al. Early priming with inactivated poliovirus vaccine (IPV) and intradermal fractional dose IPV administered by a microneedle device: a randomized controlled trial. Vaccine2015;33(48):6816‐22. [DOI: 10.1016/j.vaccine.2015.09.039; PUBMED: 26476367] ">Anand 2015</a>; <a href="./references#CD011780-bbs2-0002" title="Cadorna‐CarlosJ , VidorE , BonnetMC . Randomized controlled study of fractional doses of inactivated poliovirus vaccine administered intradermally with a needle in the Philippines. International Journal of Infectious Diseases2012;16(2):e110‐6. [DOI: 10.1016/j.ijid.2011.10.002; PUBMED: 22153001] ">Cadorna‐Carlos 2012</a>; <a href="./references#CD011780-bbs2-0003" title="ClarkeE , SaiduY , AdetifaJU , AdigwemeI , HydaraMB , BashorunAO , et al. Safety and immunogenicity of inactivated poliovirus vaccine when given with measles–rubella combined vaccine and yellow fever vaccine and when given via different administration routes: a phase 4, randomised, non‐inferiority trial in The Gambia. Lancet. Global Health2016;4(8):e534‐47. [DOI: 10.1016/S2214‐109X(16)30075‐4; PUBMED: 27364568] NCT01847872 . IPV clinical trial ‐ The Gambia (IPV) [A phase 4, randomized trial to assess the safety and immunogenicity of inactivated poliovirus vaccine when given concomitantly with measles and rubella combined vaccine and yellow fever vaccine at nine months and when administered via different vaccination routes]. clinicaltrials.gov/ct2/show/NCT01847872 (first received 19 April 2013). ">Clarke 2016</a>; <a href="./references#CD011780-bbs2-0004" title='EstívarezCF . Details regarding your published paper about "Immunogenicity of supplemental doses of poliovirus vaccine for children aged 6‐9 months in Moradabad, India: a community‐based, randomised controlled trial. Lancet 2012 [personal communication]. Email to: KK Thumburu 11 March 2016. EstívarizCF , JafariH , SutterRW , JohnTJ , JainV , AgarwalA , et al. Immunogenicity of supplemental doses of poliovirus vaccine for children aged 6‐9 months in Moradabad, India: a community‐based, randomised controlled trial. Lancet. Infectious Diseases2012;12(2):128‐35. [DOI: 10.1016/S1473‐3099(11)70190‐6; PUBMED: 22071249] '>Estívariz 2012</a>; <a href="./references#CD011780-bbs2-0005" title="ACTRN12616000124437p . Comparison of boosting of mucosal immunity after full and fractional dose of inactivated poliovirus vaccine, clinical trial in children in Sri Lanka, 2016 [Comparison of boosting of mucosal immunity after full and fractional dose of inactivated poliovirus vaccine, a randomized clinical trial in 300 children aged 10‐12 years of age living in Kalutara district of Sri Lanka, 2016]. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=369725 (first received 3 December 2015). GamageD , MachO , PalihawadanaP , ZhangY , WeldonWC , ObersteMS , et al. Boosting of mucosal immunity after fractional‐dose inactivated poliovirus vaccine. Journal of Infectious Diseases2018;218(12):1876‐82. [DOI: 10.1093/infdis/jiy389; PUBMED: 29982532] ">Gamage 2018</a>; <a href="./references#CD011780-bbs2-0006" title="MohammedAJ , AlAwaidyS , BawikarS , KurupPJ , ElamirE , ShabanMMA , et al. Fractional doses of inactivated poliovirus vaccine in Oman. New England Journal of Medicine2010;362(25):2351‐9. [DOI: 10.1056/NEJMoa0909383; PUBMED: 20573923] ">Mohammed 2010</a>; <a href="./references#CD011780-bbs2-0007" title="ResikS , TejedaA , LagoPM , DiazM , CarmenatesA , SarmientoL , et al. Randomized controlled clinical trial of fractional doses of inactivated poliovirus vaccine administered intradermally by needle‐free device in Cuba. Journal of Infectious Diseases2010;201(9):1344‐52. [DOI: 10.1086/651611; PUBMED: 20350164] ">Resik 2010</a>; <a href="./references#CD011780-bbs2-0008" title='ResikS , TejedaA , SutterRW , DiazM , SarmientoL , AlemañiN , et al. Priming after a fractional dose of inactivated poliovirus vaccine. New England Journal of Medicine2013;368(5):416‐24. [DOI: 10.1056/NEJMoa1202541; PUBMED: 23363495] SutterRW . Regarding your published paper about "Priming after a Fractional Dose of Inactivated Poliovirus Vaccine" published in NEJM 2013 [personal communication]. Email to: KK Thumburu 04 February 2016. '>Resik 2013</a>; <a href="./references#CD011780-bbs2-0009" title="ResikS , TejedaA , MachO , FonsecaM , DiazM , AlemanyN , et al. Immune responses after fractional doses of inactivated poliovirus vaccine using newly developed intradermal jet injectors: a randomized controlled trial in Cuba. Vaccine2015;33(2):307‐13. [DOI: 10.1016/j.vaccine.2014.11.025; PUBMED: 25448109] ">Resik 2015</a>; <a href="./references#CD011780-bbs2-0012" title="Tejeda FuentesA , DeArmas LópezJ , Silva SosaM , Alemañy BuenoN , Carmenate GarcíaA , García GonzálezG , et al. Reactogenicity associated to the intradermally administered inactivated poliovirus vaccine with a needle‐free injector [Reactogenicidad asociada a la vacuna de poliovirus inactivada administrada por vía intradérmica con un inyector sin aguja]. Revista Cubana de Medicina Tropical2011;63(1):38‐43. [PUBMED: 23437535] ">Tejeda Fuentes 2011</a>). We contacted the corresponding authors of all included studies for clarification regarding allocation concealment and for missing data regarding virus shedding in stools. </p> <p>See the <a href="./references#CD011780-sec-0142" title="">Characteristics of included studies</a> tables for a detailed description of the studies. </p> <section id="CD011780-sec-0062"> <h5 class="title">Study design</h5> <p>All included studies were RCTs of fractional doses (one‐fifth) of IPV delivered intradermally compared with full doses of IPV delivered intramuscularly. </p> <p>Seven trials had more than two arms (<a href="./references#CD011780-bbs2-0001" title="AnandA . Regarding your published trial on IPV in the Vaccine journal [personal communication]. Email to: N Jaiswal 04 May 2016. AnandA , ZamanK , EstívarizCF , YunusM , GaryHE , WeldonWC , et al. Early priming with inactivated poliovirus vaccine (IPV) and intradermal fractional dose IPV administered by a microneedle device: a randomized controlled trial. Vaccine2015;33(48):6816‐22. [DOI: 10.1016/j.vaccine.2015.09.039; PUBMED: 26476367] ">Anand 2015</a>; <a href="./references#CD011780-bbs2-0003" title="ClarkeE , SaiduY , AdetifaJU , AdigwemeI , HydaraMB , BashorunAO , et al. Safety and immunogenicity of inactivated poliovirus vaccine when given with measles–rubella combined vaccine and yellow fever vaccine and when given via different administration routes: a phase 4, randomised, non‐inferiority trial in The Gambia. Lancet. Global Health2016;4(8):e534‐47. [DOI: 10.1016/S2214‐109X(16)30075‐4; PUBMED: 27364568] NCT01847872 . IPV clinical trial ‐ The Gambia (IPV) [A phase 4, randomized trial to assess the safety and immunogenicity of inactivated poliovirus vaccine when given concomitantly with measles and rubella combined vaccine and yellow fever vaccine at nine months and when administered via different vaccination routes]. clinicaltrials.gov/ct2/show/NCT01847872 (first received 19 April 2013). ">Clarke 2016</a>; <a href="./references#CD011780-bbs2-0004" title='EstívarezCF . Details regarding your published paper about "Immunogenicity of supplemental doses of poliovirus vaccine for children aged 6‐9 months in Moradabad, India: a community‐based, randomised controlled trial. Lancet 2012 [personal communication]. Email to: KK Thumburu 11 March 2016. EstívarizCF , JafariH , SutterRW , JohnTJ , JainV , AgarwalA , et al. Immunogenicity of supplemental doses of poliovirus vaccine for children aged 6‐9 months in Moradabad, India: a community‐based, randomised controlled trial. Lancet. Infectious Diseases2012;12(2):128‐35. [DOI: 10.1016/S1473‐3099(11)70190‐6; PUBMED: 22071249] '>Estívariz 2012</a>; <a href="./references#CD011780-bbs2-0005" title="ACTRN12616000124437p . Comparison of boosting of mucosal immunity after full and fractional dose of inactivated poliovirus vaccine, clinical trial in children in Sri Lanka, 2016 [Comparison of boosting of mucosal immunity after full and fractional dose of inactivated poliovirus vaccine, a randomized clinical trial in 300 children aged 10‐12 years of age living in Kalutara district of Sri Lanka, 2016]. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=369725 (first received 3 December 2015). GamageD , MachO , PalihawadanaP , ZhangY , WeldonWC , ObersteMS , et al. Boosting of mucosal immunity after fractional‐dose inactivated poliovirus vaccine. Journal of Infectious Diseases2018;218(12):1876‐82. [DOI: 10.1093/infdis/jiy389; PUBMED: 29982532] ">Gamage 2018</a>; <a href="./references#CD011780-bbs2-0009" title="ResikS , TejedaA , MachO , FonsecaM , DiazM , AlemanyN , et al. Immune responses after fractional doses of inactivated poliovirus vaccine using newly developed intradermal jet injectors: a randomized controlled trial in Cuba. Vaccine2015;33(2):307‐13. [DOI: 10.1016/j.vaccine.2014.11.025; PUBMED: 25448109] ">Resik 2015</a>; <a href="./references#CD011780-bbs2-0011" title="SoonawalaD , VerdijkP , Wijmenga‐MonsuurAJ , BoogCJ , KoedamP , VisserLG , et al. Intradermal fractional booster dose of inactivated poliomyelitis vaccine with a jet injector in healthy adults. Vaccine2013;31(36):3688‐94. [DOI: 10.1016/j.vaccine.2013.05.104; PUBMED: 23770332] ">Soonawala 2013</a>; <a href="./references#CD011780-bbs2-0013" title='TroyS . Regarding your paper "Comparison of the Immunogenicity of Various Booster Doses of Inactivated Polio Vaccine Delivered Intradermally Versus Intramuscularly to HIV‐Infected Adults" [personal communication]. Email to: A Agarwal 06 May 2016. TroySB , KouiavskaiaD , SiikJ , KochbaE , BeydounH , MirochnitchenkoO , et al. Comparison of the immunogenicity of various booster doses of inactivated polio vaccine delivered intradermally versus intramuscularly to HIV‐infected adults. Journal of Infectious Diseases2015;211(12):1969‐76. [DOI: 10.1093/infdis/jiu841; PMC4539908; PUBMED: 25567841] '>Troy 2015</a>). <a href="./references#CD011780-bbs2-0011" title="SoonawalaD , VerdijkP , Wijmenga‐MonsuurAJ , BoogCJ , KoedamP , VisserLG , et al. Intradermal fractional booster dose of inactivated poliomyelitis vaccine with a jet injector in healthy adults. Vaccine2013;31(36):3688‐94. [DOI: 10.1016/j.vaccine.2013.05.104; PUBMED: 23770332] ">Soonawala 2013</a> had four study arms, one of which was an intramuscular, fractional‐dose IPV arm. We did not consider the data from the other arms of this study in this review as they did not involve the interventions in question. Three studies had five arms (<a href="./references#CD011780-bbs2-0001" title="AnandA . Regarding your published trial on IPV in the Vaccine journal [personal communication]. Email to: N Jaiswal 04 May 2016. AnandA , ZamanK , EstívarizCF , YunusM , GaryHE , WeldonWC , et al. Early priming with inactivated poliovirus vaccine (IPV) and intradermal fractional dose IPV administered by a microneedle device: a randomized controlled trial. Vaccine2015;33(48):6816‐22. [DOI: 10.1016/j.vaccine.2015.09.039; PUBMED: 26476367] ">Anand 2015</a>; <a href="./references#CD011780-bbs2-0004" title='EstívarezCF . Details regarding your published paper about "Immunogenicity of supplemental doses of poliovirus vaccine for children aged 6‐9 months in Moradabad, India: a community‐based, randomised controlled trial. Lancet 2012 [personal communication]. Email to: KK Thumburu 11 March 2016. EstívarizCF , JafariH , SutterRW , JohnTJ , JainV , AgarwalA , et al. Immunogenicity of supplemental doses of poliovirus vaccine for children aged 6‐9 months in Moradabad, India: a community‐based, randomised controlled trial. Lancet. Infectious Diseases2012;12(2):128‐35. [DOI: 10.1016/S1473‐3099(11)70190‐6; PUBMED: 22071249] '>Estívariz 2012</a>; <a href="./references#CD011780-bbs2-0009" title="ResikS , TejedaA , MachO , FonsecaM , DiazM , AlemanyN , et al. Immune responses after fractional doses of inactivated poliovirus vaccine using newly developed intradermal jet injectors: a randomized controlled trial in Cuba. Vaccine2015;33(2):307‐13. [DOI: 10.1016/j.vaccine.2014.11.025; PUBMED: 25448109] ">Resik 2015</a>). <a href="./references#CD011780-bbs2-0004" title='EstívarezCF . Details regarding your published paper about "Immunogenicity of supplemental doses of poliovirus vaccine for children aged 6‐9 months in Moradabad, India: a community‐based, randomised controlled trial. Lancet 2012 [personal communication]. Email to: KK Thumburu 11 March 2016. EstívarizCF , JafariH , SutterRW , JohnTJ , JainV , AgarwalA , et al. Immunogenicity of supplemental doses of poliovirus vaccine for children aged 6‐9 months in Moradabad, India: a community‐based, randomised controlled trial. Lancet. Infectious Diseases2012;12(2):128‐35. [DOI: 10.1016/S1473‐3099(11)70190‐6; PUBMED: 22071249] '>Estívariz 2012</a>, compared bivalent with trivalent OPV and, in addition to the two arms relevant to this review (i.e. fractional‐dose IPV delivered intradermally and full‐dose IPV delivered intramuscularly), had an arm combining intradermal fractional‐dose IPV and bivalent OPV (bOPV). <a href="./references#CD011780-bbs2-0001" title="AnandA . Regarding your published trial on IPV in the Vaccine journal [personal communication]. Email to: N Jaiswal 04 May 2016. AnandA , ZamanK , EstívarizCF , YunusM , GaryHE , WeldonWC , et al. Early priming with inactivated poliovirus vaccine (IPV) and intradermal fractional dose IPV administered by a microneedle device: a randomized controlled trial. Vaccine2015;33(48):6816‐22. [DOI: 10.1016/j.vaccine.2015.09.039; PUBMED: 26476367] ">Anand 2015</a> also had five study arms, and compared OPV preparations by different manufacturers along with intradermal fractional‐dose IPV and intramuscular full‐dose IPV, whereas <a href="./references#CD011780-bbs2-0009" title="ResikS , TejedaA , MachO , FonsecaM , DiazM , AlemanyN , et al. Immune responses after fractional doses of inactivated poliovirus vaccine using newly developed intradermal jet injectors: a randomized controlled trial in Cuba. Vaccine2015;33(2):307‐13. [DOI: 10.1016/j.vaccine.2014.11.025; PUBMED: 25448109] ">Resik 2015</a> compared the administration of intradermal fractional‐dose IPV using different devices and IPV vaccine. The Gambian study by <a href="./references#CD011780-bbs2-0003" title="ClarkeE , SaiduY , AdetifaJU , AdigwemeI , HydaraMB , BashorunAO , et al. Safety and immunogenicity of inactivated poliovirus vaccine when given with measles–rubella combined vaccine and yellow fever vaccine and when given via different administration routes: a phase 4, randomised, non‐inferiority trial in The Gambia. Lancet. Global Health2016;4(8):e534‐47. [DOI: 10.1016/S2214‐109X(16)30075‐4; PUBMED: 27364568] NCT01847872 . IPV clinical trial ‐ The Gambia (IPV) [A phase 4, randomized trial to assess the safety and immunogenicity of inactivated poliovirus vaccine when given concomitantly with measles and rubella combined vaccine and yellow fever vaccine at nine months and when administered via different vaccination routes]. clinicaltrials.gov/ct2/show/NCT01847872 (first received 19 April 2013). ">Clarke 2016</a> had eight study arms, comparing intramuscular full‐dose IPV and intradermal fractional‐dose IPV alone or in combination with measles and yellow fever vaccines. <a href="./references#CD011780-bbs2-0013" title='TroyS . Regarding your paper "Comparison of the Immunogenicity of Various Booster Doses of Inactivated Polio Vaccine Delivered Intradermally Versus Intramuscularly to HIV‐Infected Adults" [personal communication]. Email to: A Agarwal 06 May 2016. TroySB , KouiavskaiaD , SiikJ , KochbaE , BeydounH , MirochnitchenkoO , et al. Comparison of the immunogenicity of various booster doses of inactivated polio vaccine delivered intradermally versus intramuscularly to HIV‐infected adults. Journal of Infectious Diseases2015;211(12):1969‐76. [DOI: 10.1093/infdis/jiu841; PMC4539908; PUBMED: 25567841] '>Troy 2015</a> had four arms, of which two administered two‐fifths of IPV given intradermally and intramuscularly. These were not relevant to this review, and hence the data were not considered. We included the other two arms, involving fractional‐dose intradermal IPV and full‐dose intramuscular IPV, in the current review. The Sri Lankan study had three arms: intramuscular full‐dose IPV, intradermal fractional‐dose IPV, and no IPV vaccine (<a href="./references#CD011780-bbs2-0005" title="ACTRN12616000124437p . Comparison of boosting of mucosal immunity after full and fractional dose of inactivated poliovirus vaccine, clinical trial in children in Sri Lanka, 2016 [Comparison of boosting of mucosal immunity after full and fractional dose of inactivated poliovirus vaccine, a randomized clinical trial in 300 children aged 10‐12 years of age living in Kalutara district of Sri Lanka, 2016]. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=369725 (first received 3 December 2015). GamageD , MachO , PalihawadanaP , ZhangY , WeldonWC , ObersteMS , et al. Boosting of mucosal immunity after fractional‐dose inactivated poliovirus vaccine. Journal of Infectious Diseases2018;218(12):1876‐82. [DOI: 10.1093/infdis/jiy389; PUBMED: 29982532] ">Gamage 2018</a>); we excluded the no‐IPV arm from this review as it was not relevant. </p> </section> <section id="CD011780-sec-0063"> <h5 class="title">Participants</h5> <p>Three studies recruited adult participants only (<a href="./references#CD011780-bbs2-0010" title="ResikS , TejedaA , DiazM , OkayasuH , SeinC , MolodeckyNA , et al. Boosting immune responses following fractional‐dose inactivated poliovirus vaccine: a randomized, controlled trial. Journal of Infectious Diseases2017;215(2):175‐82. [DOI: 10.1093/infdis/jiw492; PUBMED: 28073858] ">Resik 2017</a>; <a href="./references#CD011780-bbs2-0011" title="SoonawalaD , VerdijkP , Wijmenga‐MonsuurAJ , BoogCJ , KoedamP , VisserLG , et al. Intradermal fractional booster dose of inactivated poliomyelitis vaccine with a jet injector in healthy adults. Vaccine2013;31(36):3688‐94. [DOI: 10.1016/j.vaccine.2013.05.104; PUBMED: 23770332] ">Soonawala 2013</a>; <a href="./references#CD011780-bbs2-0013" title='TroyS . Regarding your paper "Comparison of the Immunogenicity of Various Booster Doses of Inactivated Polio Vaccine Delivered Intradermally Versus Intramuscularly to HIV‐Infected Adults" [personal communication]. Email to: A Agarwal 06 May 2016. TroySB , KouiavskaiaD , SiikJ , KochbaE , BeydounH , MirochnitchenkoO , et al. Comparison of the immunogenicity of various booster doses of inactivated polio vaccine delivered intradermally versus intramuscularly to HIV‐infected adults. Journal of Infectious Diseases2015;211(12):1969‐76. [DOI: 10.1093/infdis/jiu841; PMC4539908; PUBMED: 25567841] '>Troy 2015</a>). <a href="./references#CD011780-bbs2-0013" title='TroyS . Regarding your paper "Comparison of the Immunogenicity of Various Booster Doses of Inactivated Polio Vaccine Delivered Intradermally Versus Intramuscularly to HIV‐Infected Adults" [personal communication]. Email to: A Agarwal 06 May 2016. TroySB , KouiavskaiaD , SiikJ , KochbaE , BeydounH , MirochnitchenkoO , et al. Comparison of the immunogenicity of various booster doses of inactivated polio vaccine delivered intradermally versus intramuscularly to HIV‐infected adults. Journal of Infectious Diseases2015;211(12):1969‐76. [DOI: 10.1093/infdis/jiu841; PMC4539908; PUBMED: 25567841] '>Troy 2015</a> recruited only adults who were HIV positive, and <a href="./references#CD011780-bbs2-0010" title="ResikS , TejedaA , DiazM , OkayasuH , SeinC , MolodeckyNA , et al. Boosting immune responses following fractional‐dose inactivated poliovirus vaccine: a randomized, controlled trial. Journal of Infectious Diseases2017;215(2):175‐82. [DOI: 10.1093/infdis/jiw492; PUBMED: 28073858] ">Resik 2017</a> recruited only male participants, whereas <a href="./references#CD011780-bbs2-0011" title="SoonawalaD , VerdijkP , Wijmenga‐MonsuurAJ , BoogCJ , KoedamP , VisserLG , et al. Intradermal fractional booster dose of inactivated poliomyelitis vaccine with a jet injector in healthy adults. Vaccine2013;31(36):3688‐94. [DOI: 10.1016/j.vaccine.2013.05.104; PUBMED: 23770332] ">Soonawala 2013</a> included both men and women irrespective of any comorbidities. </p> <p>Nine studies included children younger than two years of age (<a href="./references#CD011780-bbs2-0001" title="AnandA . Regarding your published trial on IPV in the Vaccine journal [personal communication]. Email to: N Jaiswal 04 May 2016. AnandA , ZamanK , EstívarizCF , YunusM , GaryHE , WeldonWC , et al. Early priming with inactivated poliovirus vaccine (IPV) and intradermal fractional dose IPV administered by a microneedle device: a randomized controlled trial. Vaccine2015;33(48):6816‐22. [DOI: 10.1016/j.vaccine.2015.09.039; PUBMED: 26476367] ">Anand 2015</a>; <a href="./references#CD011780-bbs2-0002" title="Cadorna‐CarlosJ , VidorE , BonnetMC . Randomized controlled study of fractional doses of inactivated poliovirus vaccine administered intradermally with a needle in the Philippines. International Journal of Infectious Diseases2012;16(2):e110‐6. [DOI: 10.1016/j.ijid.2011.10.002; PUBMED: 22153001] ">Cadorna‐Carlos 2012</a>; <a href="./references#CD011780-bbs2-0003" title="ClarkeE , SaiduY , AdetifaJU , AdigwemeI , HydaraMB , BashorunAO , et al. Safety and immunogenicity of inactivated poliovirus vaccine when given with measles–rubella combined vaccine and yellow fever vaccine and when given via different administration routes: a phase 4, randomised, non‐inferiority trial in The Gambia. Lancet. Global Health2016;4(8):e534‐47. [DOI: 10.1016/S2214‐109X(16)30075‐4; PUBMED: 27364568] NCT01847872 . IPV clinical trial ‐ The Gambia (IPV) [A phase 4, randomized trial to assess the safety and immunogenicity of inactivated poliovirus vaccine when given concomitantly with measles and rubella combined vaccine and yellow fever vaccine at nine months and when administered via different vaccination routes]. clinicaltrials.gov/ct2/show/NCT01847872 (first received 19 April 2013). ">Clarke 2016</a>; <a href="./references#CD011780-bbs2-0004" title='EstívarezCF . Details regarding your published paper about "Immunogenicity of supplemental doses of poliovirus vaccine for children aged 6‐9 months in Moradabad, India: a community‐based, randomised controlled trial. Lancet 2012 [personal communication]. Email to: KK Thumburu 11 March 2016. EstívarizCF , JafariH , SutterRW , JohnTJ , JainV , AgarwalA , et al. Immunogenicity of supplemental doses of poliovirus vaccine for children aged 6‐9 months in Moradabad, India: a community‐based, randomised controlled trial. Lancet. Infectious Diseases2012;12(2):128‐35. [DOI: 10.1016/S1473‐3099(11)70190‐6; PUBMED: 22071249] '>Estívariz 2012</a>; <a href="./references#CD011780-bbs2-0006" title="MohammedAJ , AlAwaidyS , BawikarS , KurupPJ , ElamirE , ShabanMMA , et al. Fractional doses of inactivated poliovirus vaccine in Oman. New England Journal of Medicine2010;362(25):2351‐9. [DOI: 10.1056/NEJMoa0909383; PUBMED: 20573923] ">Mohammed 2010</a>; <a href="./references#CD011780-bbs2-0007" title="ResikS , TejedaA , LagoPM , DiazM , CarmenatesA , SarmientoL , et al. Randomized controlled clinical trial of fractional doses of inactivated poliovirus vaccine administered intradermally by needle‐free device in Cuba. Journal of Infectious Diseases2010;201(9):1344‐52. [DOI: 10.1086/651611; PUBMED: 20350164] ">Resik 2010</a>; <a href="./references#CD011780-bbs2-0008" title='ResikS , TejedaA , SutterRW , DiazM , SarmientoL , AlemañiN , et al. Priming after a fractional dose of inactivated poliovirus vaccine. New England Journal of Medicine2013;368(5):416‐24. [DOI: 10.1056/NEJMoa1202541; PUBMED: 23363495] SutterRW . Regarding your published paper about "Priming after a Fractional Dose of Inactivated Poliovirus Vaccine" published in NEJM 2013 [personal communication]. Email to: KK Thumburu 04 February 2016. '>Resik 2013</a>; <a href="./references#CD011780-bbs2-0009" title="ResikS , TejedaA , MachO , FonsecaM , DiazM , AlemanyN , et al. Immune responses after fractional doses of inactivated poliovirus vaccine using newly developed intradermal jet injectors: a randomized controlled trial in Cuba. Vaccine2015;33(2):307‐13. [DOI: 10.1016/j.vaccine.2014.11.025; PUBMED: 25448109] ">Resik 2015</a>; <a href="./references#CD011780-bbs2-0012" title="Tejeda FuentesA , DeArmas LópezJ , Silva SosaM , Alemañy BuenoN , Carmenate GarcíaA , García GonzálezG , et al. Reactogenicity associated to the intradermally administered inactivated poliovirus vaccine with a needle‐free injector [Reactogenicidad asociada a la vacuna de poliovirus inactivada administrada por vía intradérmica con un inyector sin aguja]. Revista Cubana de Medicina Tropical2011;63(1):38‐43. [PUBMED: 23437535] ">Tejeda Fuentes 2011</a>). Only one study, <a href="./references#CD011780-bbs2-0009" title="ResikS , TejedaA , MachO , FonsecaM , DiazM , AlemanyN , et al. Immune responses after fractional doses of inactivated poliovirus vaccine using newly developed intradermal jet injectors: a randomized controlled trial in Cuba. Vaccine2015;33(2):307‐13. [DOI: 10.1016/j.vaccine.2014.11.025; PUBMED: 25448109] ">Resik 2015</a>, recruited children older than 12 months of age and up to 20 months of age, whereas three studies recruited newborns (<a href="./references#CD011780-bbs2-0006" title="MohammedAJ , AlAwaidyS , BawikarS , KurupPJ , ElamirE , ShabanMMA , et al. Fractional doses of inactivated poliovirus vaccine in Oman. New England Journal of Medicine2010;362(25):2351‐9. [DOI: 10.1056/NEJMoa0909383; PUBMED: 20573923] ">Mohammed 2010</a>; <a href="./references#CD011780-bbs2-0007" title="ResikS , TejedaA , LagoPM , DiazM , CarmenatesA , SarmientoL , et al. Randomized controlled clinical trial of fractional doses of inactivated poliovirus vaccine administered intradermally by needle‐free device in Cuba. Journal of Infectious Diseases2010;201(9):1344‐52. [DOI: 10.1086/651611; PUBMED: 20350164] ">Resik 2010</a>; <a href="./references#CD011780-bbs2-0008" title='ResikS , TejedaA , SutterRW , DiazM , SarmientoL , AlemañiN , et al. Priming after a fractional dose of inactivated poliovirus vaccine. New England Journal of Medicine2013;368(5):416‐24. [DOI: 10.1056/NEJMoa1202541; PUBMED: 23363495] SutterRW . Regarding your published paper about "Priming after a Fractional Dose of Inactivated Poliovirus Vaccine" published in NEJM 2013 [personal communication]. Email to: KK Thumburu 04 February 2016. '>Resik 2013</a>), and five studies recruited infants up to nine months of age (<a href="./references#CD011780-bbs2-0001" title="AnandA . Regarding your published trial on IPV in the Vaccine journal [personal communication]. Email to: N Jaiswal 04 May 2016. AnandA , ZamanK , EstívarizCF , YunusM , GaryHE , WeldonWC , et al. Early priming with inactivated poliovirus vaccine (IPV) and intradermal fractional dose IPV administered by a microneedle device: a randomized controlled trial. Vaccine2015;33(48):6816‐22. [DOI: 10.1016/j.vaccine.2015.09.039; PUBMED: 26476367] ">Anand 2015</a>; <a href="./references#CD011780-bbs2-0002" title="Cadorna‐CarlosJ , VidorE , BonnetMC . Randomized controlled study of fractional doses of inactivated poliovirus vaccine administered intradermally with a needle in the Philippines. International Journal of Infectious Diseases2012;16(2):e110‐6. [DOI: 10.1016/j.ijid.2011.10.002; PUBMED: 22153001] ">Cadorna‐Carlos 2012</a>; <a href="./references#CD011780-bbs2-0003" title="ClarkeE , SaiduY , AdetifaJU , AdigwemeI , HydaraMB , BashorunAO , et al. Safety and immunogenicity of inactivated poliovirus vaccine when given with measles–rubella combined vaccine and yellow fever vaccine and when given via different administration routes: a phase 4, randomised, non‐inferiority trial in The Gambia. Lancet. Global Health2016;4(8):e534‐47. [DOI: 10.1016/S2214‐109X(16)30075‐4; PUBMED: 27364568] NCT01847872 . IPV clinical trial ‐ The Gambia (IPV) [A phase 4, randomized trial to assess the safety and immunogenicity of inactivated poliovirus vaccine when given concomitantly with measles and rubella combined vaccine and yellow fever vaccine at nine months and when administered via different vaccination routes]. clinicaltrials.gov/ct2/show/NCT01847872 (first received 19 April 2013). ">Clarke 2016</a>; <a href="./references#CD011780-bbs2-0004" title='EstívarezCF . Details regarding your published paper about "Immunogenicity of supplemental doses of poliovirus vaccine for children aged 6‐9 months in Moradabad, India: a community‐based, randomised controlled trial. Lancet 2012 [personal communication]. Email to: KK Thumburu 11 March 2016. EstívarizCF , JafariH , SutterRW , JohnTJ , JainV , AgarwalA , et al. Immunogenicity of supplemental doses of poliovirus vaccine for children aged 6‐9 months in Moradabad, India: a community‐based, randomised controlled trial. Lancet. Infectious Diseases2012;12(2):128‐35. [DOI: 10.1016/S1473‐3099(11)70190‐6; PUBMED: 22071249] '>Estívariz 2012</a>; <a href="./references#CD011780-bbs2-0012" title="Tejeda FuentesA , DeArmas LópezJ , Silva SosaM , Alemañy BuenoN , Carmenate GarcíaA , García GonzálezG , et al. Reactogenicity associated to the intradermally administered inactivated poliovirus vaccine with a needle‐free injector [Reactogenicidad asociada a la vacuna de poliovirus inactivada administrada por vía intradérmica con un inyector sin aguja]. Revista Cubana de Medicina Tropical2011;63(1):38‐43. [PUBMED: 23437535] ">Tejeda Fuentes 2011</a>). </p> <p>The male‐to‐female ratio was equally distributed in 12 of the 13 included trials (<a href="./references#CD011780-bbs2-0001" title="AnandA . Regarding your published trial on IPV in the Vaccine journal [personal communication]. Email to: N Jaiswal 04 May 2016. AnandA , ZamanK , EstívarizCF , YunusM , GaryHE , WeldonWC , et al. Early priming with inactivated poliovirus vaccine (IPV) and intradermal fractional dose IPV administered by a microneedle device: a randomized controlled trial. Vaccine2015;33(48):6816‐22. [DOI: 10.1016/j.vaccine.2015.09.039; PUBMED: 26476367] ">Anand 2015</a>; <a href="./references#CD011780-bbs2-0002" title="Cadorna‐CarlosJ , VidorE , BonnetMC . Randomized controlled study of fractional doses of inactivated poliovirus vaccine administered intradermally with a needle in the Philippines. International Journal of Infectious Diseases2012;16(2):e110‐6. [DOI: 10.1016/j.ijid.2011.10.002; PUBMED: 22153001] ">Cadorna‐Carlos 2012</a>; <a href="./references#CD011780-bbs2-0003" title="ClarkeE , SaiduY , AdetifaJU , AdigwemeI , HydaraMB , BashorunAO , et al. Safety and immunogenicity of inactivated poliovirus vaccine when given with measles–rubella combined vaccine and yellow fever vaccine and when given via different administration routes: a phase 4, randomised, non‐inferiority trial in The Gambia. Lancet. Global Health2016;4(8):e534‐47. [DOI: 10.1016/S2214‐109X(16)30075‐4; PUBMED: 27364568] NCT01847872 . IPV clinical trial ‐ The Gambia (IPV) [A phase 4, randomized trial to assess the safety and immunogenicity of inactivated poliovirus vaccine when given concomitantly with measles and rubella combined vaccine and yellow fever vaccine at nine months and when administered via different vaccination routes]. clinicaltrials.gov/ct2/show/NCT01847872 (first received 19 April 2013). ">Clarke 2016</a>; <a href="./references#CD011780-bbs2-0004" title='EstívarezCF . Details regarding your published paper about "Immunogenicity of supplemental doses of poliovirus vaccine for children aged 6‐9 months in Moradabad, India: a community‐based, randomised controlled trial. Lancet 2012 [personal communication]. Email to: KK Thumburu 11 March 2016. EstívarizCF , JafariH , SutterRW , JohnTJ , JainV , AgarwalA , et al. Immunogenicity of supplemental doses of poliovirus vaccine for children aged 6‐9 months in Moradabad, India: a community‐based, randomised controlled trial. Lancet. Infectious Diseases2012;12(2):128‐35. [DOI: 10.1016/S1473‐3099(11)70190‐6; PUBMED: 22071249] '>Estívariz 2012</a>; <a href="./references#CD011780-bbs2-0005" title="ACTRN12616000124437p . Comparison of boosting of mucosal immunity after full and fractional dose of inactivated poliovirus vaccine, clinical trial in children in Sri Lanka, 2016 [Comparison of boosting of mucosal immunity after full and fractional dose of inactivated poliovirus vaccine, a randomized clinical trial in 300 children aged 10‐12 years of age living in Kalutara district of Sri Lanka, 2016]. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=369725 (first received 3 December 2015). GamageD , MachO , PalihawadanaP , ZhangY , WeldonWC , ObersteMS , et al. Boosting of mucosal immunity after fractional‐dose inactivated poliovirus vaccine. Journal of Infectious Diseases2018;218(12):1876‐82. [DOI: 10.1093/infdis/jiy389; PUBMED: 29982532] ">Gamage 2018</a>; <a href="./references#CD011780-bbs2-0006" title="MohammedAJ , AlAwaidyS , BawikarS , KurupPJ , ElamirE , ShabanMMA , et al. Fractional doses of inactivated poliovirus vaccine in Oman. New England Journal of Medicine2010;362(25):2351‐9. [DOI: 10.1056/NEJMoa0909383; PUBMED: 20573923] ">Mohammed 2010</a>; <a href="./references#CD011780-bbs2-0007" title="ResikS , TejedaA , LagoPM , DiazM , CarmenatesA , SarmientoL , et al. Randomized controlled clinical trial of fractional doses of inactivated poliovirus vaccine administered intradermally by needle‐free device in Cuba. Journal of Infectious Diseases2010;201(9):1344‐52. [DOI: 10.1086/651611; PUBMED: 20350164] ">Resik 2010</a>; <a href="./references#CD011780-bbs2-0008" title='ResikS , TejedaA , SutterRW , DiazM , SarmientoL , AlemañiN , et al. Priming after a fractional dose of inactivated poliovirus vaccine. New England Journal of Medicine2013;368(5):416‐24. [DOI: 10.1056/NEJMoa1202541; PUBMED: 23363495] SutterRW . Regarding your published paper about "Priming after a Fractional Dose of Inactivated Poliovirus Vaccine" published in NEJM 2013 [personal communication]. Email to: KK Thumburu 04 February 2016. '>Resik 2013</a>; <a href="./references#CD011780-bbs2-0009" title="ResikS , TejedaA , MachO , FonsecaM , DiazM , AlemanyN , et al. Immune responses after fractional doses of inactivated poliovirus vaccine using newly developed intradermal jet injectors: a randomized controlled trial in Cuba. Vaccine2015;33(2):307‐13. [DOI: 10.1016/j.vaccine.2014.11.025; PUBMED: 25448109] ">Resik 2015</a>; <a href="./references#CD011780-bbs2-0011" title="SoonawalaD , VerdijkP , Wijmenga‐MonsuurAJ , BoogCJ , KoedamP , VisserLG , et al. Intradermal fractional booster dose of inactivated poliomyelitis vaccine with a jet injector in healthy adults. Vaccine2013;31(36):3688‐94. [DOI: 10.1016/j.vaccine.2013.05.104; PUBMED: 23770332] ">Soonawala 2013</a>; <a href="./references#CD011780-bbs2-0012" title="Tejeda FuentesA , DeArmas LópezJ , Silva SosaM , Alemañy BuenoN , Carmenate GarcíaA , García GonzálezG , et al. Reactogenicity associated to the intradermally administered inactivated poliovirus vaccine with a needle‐free injector [Reactogenicidad asociada a la vacuna de poliovirus inactivada administrada por vía intradérmica con un inyector sin aguja]. Revista Cubana de Medicina Tropical2011;63(1):38‐43. [PUBMED: 23437535] ">Tejeda Fuentes 2011</a>; <a href="./references#CD011780-bbs2-0013" title='TroyS . Regarding your paper "Comparison of the Immunogenicity of Various Booster Doses of Inactivated Polio Vaccine Delivered Intradermally Versus Intramuscularly to HIV‐Infected Adults" [personal communication]. Email to: A Agarwal 06 May 2016. TroySB , KouiavskaiaD , SiikJ , KochbaE , BeydounH , MirochnitchenkoO , et al. Comparison of the immunogenicity of various booster doses of inactivated polio vaccine delivered intradermally versus intramuscularly to HIV‐infected adults. Journal of Infectious Diseases2015;211(12):1969‐76. [DOI: 10.1093/infdis/jiu841; PMC4539908; PUBMED: 25567841] '>Troy 2015</a>). One trial included males only (<a href="./references#CD011780-bbs2-0010" title="ResikS , TejedaA , DiazM , OkayasuH , SeinC , MolodeckyNA , et al. Boosting immune responses following fractional‐dose inactivated poliovirus vaccine: a randomized, controlled trial. Journal of Infectious Diseases2017;215(2):175‐82. [DOI: 10.1093/infdis/jiw492; PUBMED: 28073858] ">Resik 2017</a>). None of these trials included children or infants who were HIV positive. </p> <p>See the <a href="./references#CD011780-sec-0142" title="">Characteristics of included studies</a> tables for further details on the participants included in each trial. </p> </section> <section id="CD011780-sec-0064"> <h5 class="title">Location, setting, and duration of studies</h5> <p>One study was from a low‐income country (<a href="./references#CD011780-bbs2-0003" title="ClarkeE , SaiduY , AdetifaJU , AdigwemeI , HydaraMB , BashorunAO , et al. Safety and immunogenicity of inactivated poliovirus vaccine when given with measles–rubella combined vaccine and yellow fever vaccine and when given via different administration routes: a phase 4, randomised, non‐inferiority trial in The Gambia. Lancet. Global Health2016;4(8):e534‐47. [DOI: 10.1016/S2214‐109X(16)30075‐4; PUBMED: 27364568] NCT01847872 . IPV clinical trial ‐ The Gambia (IPV) [A phase 4, randomized trial to assess the safety and immunogenicity of inactivated poliovirus vaccine when given concomitantly with measles and rubella combined vaccine and yellow fever vaccine at nine months and when administered via different vaccination routes]. clinicaltrials.gov/ct2/show/NCT01847872 (first received 19 April 2013). ">Clarke 2016</a>), and three studies were from high‐income countries according to the World Bank classification (<a href="./references#CD011780-bbs2-0006" title="MohammedAJ , AlAwaidyS , BawikarS , KurupPJ , ElamirE , ShabanMMA , et al. Fractional doses of inactivated poliovirus vaccine in Oman. New England Journal of Medicine2010;362(25):2351‐9. [DOI: 10.1056/NEJMoa0909383; PUBMED: 20573923] ">Mohammed 2010</a>; <a href="./references#CD011780-bbs2-0011" title="SoonawalaD , VerdijkP , Wijmenga‐MonsuurAJ , BoogCJ , KoedamP , VisserLG , et al. Intradermal fractional booster dose of inactivated poliomyelitis vaccine with a jet injector in healthy adults. Vaccine2013;31(36):3688‐94. [DOI: 10.1016/j.vaccine.2013.05.104; PUBMED: 23770332] ">Soonawala 2013</a>; <a href="./references#CD011780-bbs2-0013" title='TroyS . Regarding your paper "Comparison of the Immunogenicity of Various Booster Doses of Inactivated Polio Vaccine Delivered Intradermally Versus Intramuscularly to HIV‐Infected Adults" [personal communication]. Email to: A Agarwal 06 May 2016. TroySB , KouiavskaiaD , SiikJ , KochbaE , BeydounH , MirochnitchenkoO , et al. Comparison of the immunogenicity of various booster doses of inactivated polio vaccine delivered intradermally versus intramuscularly to HIV‐infected adults. Journal of Infectious Diseases2015;211(12):1969‐76. [DOI: 10.1093/infdis/jiu841; PMC4539908; PUBMED: 25567841] '>Troy 2015</a>). The remaining nine studies were conducted in middle‐income countries (both low‐middle and high‐middle) (<a href="./references#CD011780-bbs2-0001" title="AnandA . Regarding your published trial on IPV in the Vaccine journal [personal communication]. Email to: N Jaiswal 04 May 2016. AnandA , ZamanK , EstívarizCF , YunusM , GaryHE , WeldonWC , et al. Early priming with inactivated poliovirus vaccine (IPV) and intradermal fractional dose IPV administered by a microneedle device: a randomized controlled trial. Vaccine2015;33(48):6816‐22. [DOI: 10.1016/j.vaccine.2015.09.039; PUBMED: 26476367] ">Anand 2015</a>; <a href="./references#CD011780-bbs2-0002" title="Cadorna‐CarlosJ , VidorE , BonnetMC . Randomized controlled study of fractional doses of inactivated poliovirus vaccine administered intradermally with a needle in the Philippines. International Journal of Infectious Diseases2012;16(2):e110‐6. [DOI: 10.1016/j.ijid.2011.10.002; PUBMED: 22153001] ">Cadorna‐Carlos 2012</a>; <a href="./references#CD011780-bbs2-0004" title='EstívarezCF . Details regarding your published paper about "Immunogenicity of supplemental doses of poliovirus vaccine for children aged 6‐9 months in Moradabad, India: a community‐based, randomised controlled trial. Lancet 2012 [personal communication]. Email to: KK Thumburu 11 March 2016. EstívarizCF , JafariH , SutterRW , JohnTJ , JainV , AgarwalA , et al. Immunogenicity of supplemental doses of poliovirus vaccine for children aged 6‐9 months in Moradabad, India: a community‐based, randomised controlled trial. Lancet. Infectious Diseases2012;12(2):128‐35. [DOI: 10.1016/S1473‐3099(11)70190‐6; PUBMED: 22071249] '>Estívariz 2012</a>; <a href="./references#CD011780-bbs2-0005" title="ACTRN12616000124437p . Comparison of boosting of mucosal immunity after full and fractional dose of inactivated poliovirus vaccine, clinical trial in children in Sri Lanka, 2016 [Comparison of boosting of mucosal immunity after full and fractional dose of inactivated poliovirus vaccine, a randomized clinical trial in 300 children aged 10‐12 years of age living in Kalutara district of Sri Lanka, 2016]. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=369725 (first received 3 December 2015). GamageD , MachO , PalihawadanaP , ZhangY , WeldonWC , ObersteMS , et al. Boosting of mucosal immunity after fractional‐dose inactivated poliovirus vaccine. Journal of Infectious Diseases2018;218(12):1876‐82. [DOI: 10.1093/infdis/jiy389; PUBMED: 29982532] ">Gamage 2018</a>; <a href="./references#CD011780-bbs2-0007" title="ResikS , TejedaA , LagoPM , DiazM , CarmenatesA , SarmientoL , et al. Randomized controlled clinical trial of fractional doses of inactivated poliovirus vaccine administered intradermally by needle‐free device in Cuba. Journal of Infectious Diseases2010;201(9):1344‐52. [DOI: 10.1086/651611; PUBMED: 20350164] ">Resik 2010</a>; <a href="./references#CD011780-bbs2-0008" title='ResikS , TejedaA , SutterRW , DiazM , SarmientoL , AlemañiN , et al. Priming after a fractional dose of inactivated poliovirus vaccine. New England Journal of Medicine2013;368(5):416‐24. [DOI: 10.1056/NEJMoa1202541; PUBMED: 23363495] SutterRW . Regarding your published paper about "Priming after a Fractional Dose of Inactivated Poliovirus Vaccine" published in NEJM 2013 [personal communication]. Email to: KK Thumburu 04 February 2016. '>Resik 2013</a>; <a href="./references#CD011780-bbs2-0009" title="ResikS , TejedaA , MachO , FonsecaM , DiazM , AlemanyN , et al. Immune responses after fractional doses of inactivated poliovirus vaccine using newly developed intradermal jet injectors: a randomized controlled trial in Cuba. Vaccine2015;33(2):307‐13. [DOI: 10.1016/j.vaccine.2014.11.025; PUBMED: 25448109] ">Resik 2015</a>; <a href="./references#CD011780-bbs2-0010" title="ResikS , TejedaA , DiazM , OkayasuH , SeinC , MolodeckyNA , et al. Boosting immune responses following fractional‐dose inactivated poliovirus vaccine: a randomized, controlled trial. Journal of Infectious Diseases2017;215(2):175‐82. [DOI: 10.1093/infdis/jiw492; PUBMED: 28073858] ">Resik 2017</a>; <a href="./references#CD011780-bbs2-0012" title="Tejeda FuentesA , DeArmas LópezJ , Silva SosaM , Alemañy BuenoN , Carmenate GarcíaA , García GonzálezG , et al. Reactogenicity associated to the intradermally administered inactivated poliovirus vaccine with a needle‐free injector [Reactogenicidad asociada a la vacuna de poliovirus inactivada administrada por vía intradérmica con un inyector sin aguja]. Revista Cubana de Medicina Tropical2011;63(1):38‐43. [PUBMED: 23437535] ">Tejeda Fuentes 2011</a>). </p> <p>The duration of studies ranged from two months in two studies, <a href="./references#CD011780-bbs2-0005" title="ACTRN12616000124437p . Comparison of boosting of mucosal immunity after full and fractional dose of inactivated poliovirus vaccine, clinical trial in children in Sri Lanka, 2016 [Comparison of boosting of mucosal immunity after full and fractional dose of inactivated poliovirus vaccine, a randomized clinical trial in 300 children aged 10‐12 years of age living in Kalutara district of Sri Lanka, 2016]. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=369725 (first received 3 December 2015). GamageD , MachO , PalihawadanaP , ZhangY , WeldonWC , ObersteMS , et al. Boosting of mucosal immunity after fractional‐dose inactivated poliovirus vaccine. Journal of Infectious Diseases2018;218(12):1876‐82. [DOI: 10.1093/infdis/jiy389; PUBMED: 29982532] ">Gamage 2018</a>; <a href="./references#CD011780-bbs2-0009" title="ResikS , TejedaA , MachO , FonsecaM , DiazM , AlemanyN , et al. Immune responses after fractional doses of inactivated poliovirus vaccine using newly developed intradermal jet injectors: a randomized controlled trial in Cuba. Vaccine2015;33(2):307‐13. [DOI: 10.1016/j.vaccine.2014.11.025; PUBMED: 25448109] ">Resik 2015</a>, to 19 months in one study (<a href="./references#CD011780-bbs2-0011" title="SoonawalaD , VerdijkP , Wijmenga‐MonsuurAJ , BoogCJ , KoedamP , VisserLG , et al. Intradermal fractional booster dose of inactivated poliomyelitis vaccine with a jet injector in healthy adults. Vaccine2013;31(36):3688‐94. [DOI: 10.1016/j.vaccine.2013.05.104; PUBMED: 23770332] ">Soonawala 2013</a>). </p> </section> <section id="CD011780-sec-0065"> <h5 class="title">Interventions</h5> <p>Six studies compared single doses of the intended interventions (intradermal fractional‐dose IPV and intramuscular full‐dose IPV) (<a href="./references#CD011780-bbs2-0002" title="Cadorna‐CarlosJ , VidorE , BonnetMC . Randomized controlled study of fractional doses of inactivated poliovirus vaccine administered intradermally with a needle in the Philippines. International Journal of Infectious Diseases2012;16(2):e110‐6. [DOI: 10.1016/j.ijid.2011.10.002; PUBMED: 22153001] ">Cadorna‐Carlos 2012</a>; <a href="./references#CD011780-bbs2-0003" title="ClarkeE , SaiduY , AdetifaJU , AdigwemeI , HydaraMB , BashorunAO , et al. Safety and immunogenicity of inactivated poliovirus vaccine when given with measles–rubella combined vaccine and yellow fever vaccine and when given via different administration routes: a phase 4, randomised, non‐inferiority trial in The Gambia. Lancet. Global Health2016;4(8):e534‐47. [DOI: 10.1016/S2214‐109X(16)30075‐4; PUBMED: 27364568] NCT01847872 . IPV clinical trial ‐ The Gambia (IPV) [A phase 4, randomized trial to assess the safety and immunogenicity of inactivated poliovirus vaccine when given concomitantly with measles and rubella combined vaccine and yellow fever vaccine at nine months and when administered via different vaccination routes]. clinicaltrials.gov/ct2/show/NCT01847872 (first received 19 April 2013). ">Clarke 2016</a>; <a href="./references#CD011780-bbs2-0004" title='EstívarezCF . Details regarding your published paper about "Immunogenicity of supplemental doses of poliovirus vaccine for children aged 6‐9 months in Moradabad, India: a community‐based, randomised controlled trial. Lancet 2012 [personal communication]. Email to: KK Thumburu 11 March 2016. EstívarizCF , JafariH , SutterRW , JohnTJ , JainV , AgarwalA , et al. Immunogenicity of supplemental doses of poliovirus vaccine for children aged 6‐9 months in Moradabad, India: a community‐based, randomised controlled trial. Lancet. Infectious Diseases2012;12(2):128‐35. [DOI: 10.1016/S1473‐3099(11)70190‐6; PUBMED: 22071249] '>Estívariz 2012</a>; <a href="./references#CD011780-bbs2-0005" title="ACTRN12616000124437p . Comparison of boosting of mucosal immunity after full and fractional dose of inactivated poliovirus vaccine, clinical trial in children in Sri Lanka, 2016 [Comparison of boosting of mucosal immunity after full and fractional dose of inactivated poliovirus vaccine, a randomized clinical trial in 300 children aged 10‐12 years of age living in Kalutara district of Sri Lanka, 2016]. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=369725 (first received 3 December 2015). GamageD , MachO , PalihawadanaP , ZhangY , WeldonWC , ObersteMS , et al. Boosting of mucosal immunity after fractional‐dose inactivated poliovirus vaccine. Journal of Infectious Diseases2018;218(12):1876‐82. [DOI: 10.1093/infdis/jiy389; PUBMED: 29982532] ">Gamage 2018</a>; <a href="./references#CD011780-bbs2-0009" title="ResikS , TejedaA , MachO , FonsecaM , DiazM , AlemanyN , et al. Immune responses after fractional doses of inactivated poliovirus vaccine using newly developed intradermal jet injectors: a randomized controlled trial in Cuba. Vaccine2015;33(2):307‐13. [DOI: 10.1016/j.vaccine.2014.11.025; PUBMED: 25448109] ">Resik 2015</a>; <a href="./references#CD011780-bbs2-0010" title="ResikS , TejedaA , DiazM , OkayasuH , SeinC , MolodeckyNA , et al. Boosting immune responses following fractional‐dose inactivated poliovirus vaccine: a randomized, controlled trial. Journal of Infectious Diseases2017;215(2):175‐82. [DOI: 10.1093/infdis/jiw492; PUBMED: 28073858] ">Resik 2017</a>). Two studies compared booster doses of the intended interventions in adults (<a href="./references#CD011780-bbs2-0011" title="SoonawalaD , VerdijkP , Wijmenga‐MonsuurAJ , BoogCJ , KoedamP , VisserLG , et al. Intradermal fractional booster dose of inactivated poliomyelitis vaccine with a jet injector in healthy adults. Vaccine2013;31(36):3688‐94. [DOI: 10.1016/j.vaccine.2013.05.104; PUBMED: 23770332] ">Soonawala 2013</a>; <a href="./references#CD011780-bbs2-0013" title='TroyS . Regarding your paper "Comparison of the Immunogenicity of Various Booster Doses of Inactivated Polio Vaccine Delivered Intradermally Versus Intramuscularly to HIV‐Infected Adults" [personal communication]. Email to: A Agarwal 06 May 2016. TroySB , KouiavskaiaD , SiikJ , KochbaE , BeydounH , MirochnitchenkoO , et al. Comparison of the immunogenicity of various booster doses of inactivated polio vaccine delivered intradermally versus intramuscularly to HIV‐infected adults. Journal of Infectious Diseases2015;211(12):1969‐76. [DOI: 10.1093/infdis/jiu841; PMC4539908; PUBMED: 25567841] '>Troy 2015</a>). One study, <a href="./references#CD011780-bbs2-0008" title='ResikS , TejedaA , SutterRW , DiazM , SarmientoL , AlemañiN , et al. Priming after a fractional dose of inactivated poliovirus vaccine. New England Journal of Medicine2013;368(5):416‐24. [DOI: 10.1056/NEJMoa1202541; PUBMED: 23363495] SutterRW . Regarding your published paper about "Priming after a Fractional Dose of Inactivated Poliovirus Vaccine" published in NEJM 2013 [personal communication]. Email to: KK Thumburu 04 February 2016. '>Resik 2013</a>, compared two doses of intradermal fractional‐dose IPV to two doses of intramuscular full‐dose IPV. The four remaining studies compared three doses of intradermal fractional‐dose IPV to intramuscular full‐dose IPV (<a href="./references#CD011780-bbs2-0001" title="AnandA . Regarding your published trial on IPV in the Vaccine journal [personal communication]. Email to: N Jaiswal 04 May 2016. AnandA , ZamanK , EstívarizCF , YunusM , GaryHE , WeldonWC , et al. Early priming with inactivated poliovirus vaccine (IPV) and intradermal fractional dose IPV administered by a microneedle device: a randomized controlled trial. Vaccine2015;33(48):6816‐22. [DOI: 10.1016/j.vaccine.2015.09.039; PUBMED: 26476367] ">Anand 2015</a>; <a href="./references#CD011780-bbs2-0006" title="MohammedAJ , AlAwaidyS , BawikarS , KurupPJ , ElamirE , ShabanMMA , et al. Fractional doses of inactivated poliovirus vaccine in Oman. New England Journal of Medicine2010;362(25):2351‐9. [DOI: 10.1056/NEJMoa0909383; PUBMED: 20573923] ">Mohammed 2010</a>; <a href="./references#CD011780-bbs2-0007" title="ResikS , TejedaA , LagoPM , DiazM , CarmenatesA , SarmientoL , et al. Randomized controlled clinical trial of fractional doses of inactivated poliovirus vaccine administered intradermally by needle‐free device in Cuba. Journal of Infectious Diseases2010;201(9):1344‐52. [DOI: 10.1086/651611; PUBMED: 20350164] ">Resik 2010</a>; <a href="./references#CD011780-bbs2-0012" title="Tejeda FuentesA , DeArmas LópezJ , Silva SosaM , Alemañy BuenoN , Carmenate GarcíaA , García GonzálezG , et al. Reactogenicity associated to the intradermally administered inactivated poliovirus vaccine with a needle‐free injector [Reactogenicidad asociada a la vacuna de poliovirus inactivada administrada por vía intradérmica con un inyector sin aguja]. Revista Cubana de Medicina Tropical2011;63(1):38‐43. [PUBMED: 23437535] ">Tejeda Fuentes 2011</a>). The different dosing schedules and different number of doses given in the studies brought an element of heterogeneity to the results of this systematic review. </p> </section> <section id="CD011780-sec-0066"> <h5 class="title">Outcomes</h5> <section id="CD011780-sec-0067"> <h6 class="title">Primary outcomes</h6> <p>None of the included studies measured paralytic poliomyelitis. Eight studies assessed seroconversion rates after each dose of the vaccines (intramuscular IPV or intradermal fractional‐dose IPV): six in children, <a href="./references#CD011780-bbs2-0001" title="AnandA . Regarding your published trial on IPV in the Vaccine journal [personal communication]. Email to: N Jaiswal 04 May 2016. AnandA , ZamanK , EstívarizCF , YunusM , GaryHE , WeldonWC , et al. Early priming with inactivated poliovirus vaccine (IPV) and intradermal fractional dose IPV administered by a microneedle device: a randomized controlled trial. Vaccine2015;33(48):6816‐22. [DOI: 10.1016/j.vaccine.2015.09.039; PUBMED: 26476367] ">Anand 2015</a>; <a href="./references#CD011780-bbs2-0003" title="ClarkeE , SaiduY , AdetifaJU , AdigwemeI , HydaraMB , BashorunAO , et al. Safety and immunogenicity of inactivated poliovirus vaccine when given with measles–rubella combined vaccine and yellow fever vaccine and when given via different administration routes: a phase 4, randomised, non‐inferiority trial in The Gambia. Lancet. Global Health2016;4(8):e534‐47. [DOI: 10.1016/S2214‐109X(16)30075‐4; PUBMED: 27364568] NCT01847872 . IPV clinical trial ‐ The Gambia (IPV) [A phase 4, randomized trial to assess the safety and immunogenicity of inactivated poliovirus vaccine when given concomitantly with measles and rubella combined vaccine and yellow fever vaccine at nine months and when administered via different vaccination routes]. clinicaltrials.gov/ct2/show/NCT01847872 (first received 19 April 2013). ">Clarke 2016</a>; <a href="./references#CD011780-bbs2-0004" title='EstívarezCF . Details regarding your published paper about "Immunogenicity of supplemental doses of poliovirus vaccine for children aged 6‐9 months in Moradabad, India: a community‐based, randomised controlled trial. Lancet 2012 [personal communication]. Email to: KK Thumburu 11 March 2016. EstívarizCF , JafariH , SutterRW , JohnTJ , JainV , AgarwalA , et al. Immunogenicity of supplemental doses of poliovirus vaccine for children aged 6‐9 months in Moradabad, India: a community‐based, randomised controlled trial. Lancet. Infectious Diseases2012;12(2):128‐35. [DOI: 10.1016/S1473‐3099(11)70190‐6; PUBMED: 22071249] '>Estívariz 2012</a>; <a href="./references#CD011780-bbs2-0006" title="MohammedAJ , AlAwaidyS , BawikarS , KurupPJ , ElamirE , ShabanMMA , et al. Fractional doses of inactivated poliovirus vaccine in Oman. New England Journal of Medicine2010;362(25):2351‐9. [DOI: 10.1056/NEJMoa0909383; PUBMED: 20573923] ">Mohammed 2010</a>; <a href="./references#CD011780-bbs2-0007" title="ResikS , TejedaA , LagoPM , DiazM , CarmenatesA , SarmientoL , et al. Randomized controlled clinical trial of fractional doses of inactivated poliovirus vaccine administered intradermally by needle‐free device in Cuba. Journal of Infectious Diseases2010;201(9):1344‐52. [DOI: 10.1086/651611; PUBMED: 20350164] ">Resik 2010</a>; <a href="./references#CD011780-bbs2-0008" title='ResikS , TejedaA , SutterRW , DiazM , SarmientoL , AlemañiN , et al. Priming after a fractional dose of inactivated poliovirus vaccine. New England Journal of Medicine2013;368(5):416‐24. [DOI: 10.1056/NEJMoa1202541; PUBMED: 23363495] SutterRW . Regarding your published paper about "Priming after a Fractional Dose of Inactivated Poliovirus Vaccine" published in NEJM 2013 [personal communication]. Email to: KK Thumburu 04 February 2016. '>Resik 2013</a>, and two in adults, <a href="./references#CD011780-bbs2-0010" title="ResikS , TejedaA , DiazM , OkayasuH , SeinC , MolodeckyNA , et al. Boosting immune responses following fractional‐dose inactivated poliovirus vaccine: a randomized, controlled trial. Journal of Infectious Diseases2017;215(2):175‐82. [DOI: 10.1093/infdis/jiw492; PUBMED: 28073858] ">Resik 2017</a>; <a href="./references#CD011780-bbs2-0013" title='TroyS . Regarding your paper "Comparison of the Immunogenicity of Various Booster Doses of Inactivated Polio Vaccine Delivered Intradermally Versus Intramuscularly to HIV‐Infected Adults" [personal communication]. Email to: A Agarwal 06 May 2016. TroySB , KouiavskaiaD , SiikJ , KochbaE , BeydounH , MirochnitchenkoO , et al. Comparison of the immunogenicity of various booster doses of inactivated polio vaccine delivered intradermally versus intramuscularly to HIV‐infected adults. Journal of Infectious Diseases2015;211(12):1969‐76. [DOI: 10.1093/infdis/jiu841; PMC4539908; PUBMED: 25567841] '>Troy 2015</a>. Seven studies assessed geometric median titres (<a href="./references#CD011780-bbs2-0002" title="Cadorna‐CarlosJ , VidorE , BonnetMC . Randomized controlled study of fractional doses of inactivated poliovirus vaccine administered intradermally with a needle in the Philippines. International Journal of Infectious Diseases2012;16(2):e110‐6. [DOI: 10.1016/j.ijid.2011.10.002; PUBMED: 22153001] ">Cadorna‐Carlos 2012</a>; <a href="./references#CD011780-bbs2-0003" title="ClarkeE , SaiduY , AdetifaJU , AdigwemeI , HydaraMB , BashorunAO , et al. Safety and immunogenicity of inactivated poliovirus vaccine when given with measles–rubella combined vaccine and yellow fever vaccine and when given via different administration routes: a phase 4, randomised, non‐inferiority trial in The Gambia. Lancet. Global Health2016;4(8):e534‐47. [DOI: 10.1016/S2214‐109X(16)30075‐4; PUBMED: 27364568] NCT01847872 . IPV clinical trial ‐ The Gambia (IPV) [A phase 4, randomized trial to assess the safety and immunogenicity of inactivated poliovirus vaccine when given concomitantly with measles and rubella combined vaccine and yellow fever vaccine at nine months and when administered via different vaccination routes]. clinicaltrials.gov/ct2/show/NCT01847872 (first received 19 April 2013). ">Clarke 2016</a>; <a href="./references#CD011780-bbs2-0004" title='EstívarezCF . Details regarding your published paper about "Immunogenicity of supplemental doses of poliovirus vaccine for children aged 6‐9 months in Moradabad, India: a community‐based, randomised controlled trial. Lancet 2012 [personal communication]. Email to: KK Thumburu 11 March 2016. EstívarizCF , JafariH , SutterRW , JohnTJ , JainV , AgarwalA , et al. Immunogenicity of supplemental doses of poliovirus vaccine for children aged 6‐9 months in Moradabad, India: a community‐based, randomised controlled trial. Lancet. Infectious Diseases2012;12(2):128‐35. [DOI: 10.1016/S1473‐3099(11)70190‐6; PUBMED: 22071249] '>Estívariz 2012</a>; <a href="./references#CD011780-bbs2-0006" title="MohammedAJ , AlAwaidyS , BawikarS , KurupPJ , ElamirE , ShabanMMA , et al. Fractional doses of inactivated poliovirus vaccine in Oman. New England Journal of Medicine2010;362(25):2351‐9. [DOI: 10.1056/NEJMoa0909383; PUBMED: 20573923] ">Mohammed 2010</a>; <a href="./references#CD011780-bbs2-0007" title="ResikS , TejedaA , LagoPM , DiazM , CarmenatesA , SarmientoL , et al. Randomized controlled clinical trial of fractional doses of inactivated poliovirus vaccine administered intradermally by needle‐free device in Cuba. Journal of Infectious Diseases2010;201(9):1344‐52. [DOI: 10.1086/651611; PUBMED: 20350164] ">Resik 2010</a>; <a href="./references#CD011780-bbs2-0008" title='ResikS , TejedaA , SutterRW , DiazM , SarmientoL , AlemañiN , et al. Priming after a fractional dose of inactivated poliovirus vaccine. New England Journal of Medicine2013;368(5):416‐24. [DOI: 10.1056/NEJMoa1202541; PUBMED: 23363495] SutterRW . Regarding your published paper about "Priming after a Fractional Dose of Inactivated Poliovirus Vaccine" published in NEJM 2013 [personal communication]. Email to: KK Thumburu 04 February 2016. '>Resik 2013</a>; <a href="./references#CD011780-bbs2-0009" title="ResikS , TejedaA , MachO , FonsecaM , DiazM , AlemanyN , et al. Immune responses after fractional doses of inactivated poliovirus vaccine using newly developed intradermal jet injectors: a randomized controlled trial in Cuba. Vaccine2015;33(2):307‐13. [DOI: 10.1016/j.vaccine.2014.11.025; PUBMED: 25448109] ">Resik 2015</a>). Ten studies assessed adverse events: seven in children, <a href="./references#CD011780-bbs2-0002" title="Cadorna‐CarlosJ , VidorE , BonnetMC . Randomized controlled study of fractional doses of inactivated poliovirus vaccine administered intradermally with a needle in the Philippines. International Journal of Infectious Diseases2012;16(2):e110‐6. [DOI: 10.1016/j.ijid.2011.10.002; PUBMED: 22153001] ">Cadorna‐Carlos 2012</a>; <a href="./references#CD011780-bbs2-0003" title="ClarkeE , SaiduY , AdetifaJU , AdigwemeI , HydaraMB , BashorunAO , et al. Safety and immunogenicity of inactivated poliovirus vaccine when given with measles–rubella combined vaccine and yellow fever vaccine and when given via different administration routes: a phase 4, randomised, non‐inferiority trial in The Gambia. Lancet. Global Health2016;4(8):e534‐47. [DOI: 10.1016/S2214‐109X(16)30075‐4; PUBMED: 27364568] NCT01847872 . IPV clinical trial ‐ The Gambia (IPV) [A phase 4, randomized trial to assess the safety and immunogenicity of inactivated poliovirus vaccine when given concomitantly with measles and rubella combined vaccine and yellow fever vaccine at nine months and when administered via different vaccination routes]. clinicaltrials.gov/ct2/show/NCT01847872 (first received 19 April 2013). ">Clarke 2016</a>; <a href="./references#CD011780-bbs2-0006" title="MohammedAJ , AlAwaidyS , BawikarS , KurupPJ , ElamirE , ShabanMMA , et al. Fractional doses of inactivated poliovirus vaccine in Oman. New England Journal of Medicine2010;362(25):2351‐9. [DOI: 10.1056/NEJMoa0909383; PUBMED: 20573923] ">Mohammed 2010</a>; <a href="./references#CD011780-bbs2-0007" title="ResikS , TejedaA , LagoPM , DiazM , CarmenatesA , SarmientoL , et al. Randomized controlled clinical trial of fractional doses of inactivated poliovirus vaccine administered intradermally by needle‐free device in Cuba. Journal of Infectious Diseases2010;201(9):1344‐52. [DOI: 10.1086/651611; PUBMED: 20350164] ">Resik 2010</a>; <a href="./references#CD011780-bbs2-0008" title='ResikS , TejedaA , SutterRW , DiazM , SarmientoL , AlemañiN , et al. Priming after a fractional dose of inactivated poliovirus vaccine. New England Journal of Medicine2013;368(5):416‐24. [DOI: 10.1056/NEJMoa1202541; PUBMED: 23363495] SutterRW . Regarding your published paper about "Priming after a Fractional Dose of Inactivated Poliovirus Vaccine" published in NEJM 2013 [personal communication]. Email to: KK Thumburu 04 February 2016. '>Resik 2013</a>; <a href="./references#CD011780-bbs2-0009" title="ResikS , TejedaA , MachO , FonsecaM , DiazM , AlemanyN , et al. Immune responses after fractional doses of inactivated poliovirus vaccine using newly developed intradermal jet injectors: a randomized controlled trial in Cuba. Vaccine2015;33(2):307‐13. [DOI: 10.1016/j.vaccine.2014.11.025; PUBMED: 25448109] ">Resik 2015</a>; <a href="./references#CD011780-bbs2-0012" title="Tejeda FuentesA , DeArmas LópezJ , Silva SosaM , Alemañy BuenoN , Carmenate GarcíaA , García GonzálezG , et al. Reactogenicity associated to the intradermally administered inactivated poliovirus vaccine with a needle‐free injector [Reactogenicidad asociada a la vacuna de poliovirus inactivada administrada por vía intradérmica con un inyector sin aguja]. Revista Cubana de Medicina Tropical2011;63(1):38‐43. [PUBMED: 23437535] ">Tejeda Fuentes 2011</a>, and three in adults, <a href="./references#CD011780-bbs2-0010" title="ResikS , TejedaA , DiazM , OkayasuH , SeinC , MolodeckyNA , et al. Boosting immune responses following fractional‐dose inactivated poliovirus vaccine: a randomized, controlled trial. Journal of Infectious Diseases2017;215(2):175‐82. [DOI: 10.1093/infdis/jiw492; PUBMED: 28073858] ">Resik 2017</a>; <a href="./references#CD011780-bbs2-0011" title="SoonawalaD , VerdijkP , Wijmenga‐MonsuurAJ , BoogCJ , KoedamP , VisserLG , et al. Intradermal fractional booster dose of inactivated poliomyelitis vaccine with a jet injector in healthy adults. Vaccine2013;31(36):3688‐94. [DOI: 10.1016/j.vaccine.2013.05.104; PUBMED: 23770332] ">Soonawala 2013</a>; <a href="./references#CD011780-bbs2-0013" title='TroyS . Regarding your paper "Comparison of the Immunogenicity of Various Booster Doses of Inactivated Polio Vaccine Delivered Intradermally Versus Intramuscularly to HIV‐Infected Adults" [personal communication]. Email to: A Agarwal 06 May 2016. TroySB , KouiavskaiaD , SiikJ , KochbaE , BeydounH , MirochnitchenkoO , et al. Comparison of the immunogenicity of various booster doses of inactivated polio vaccine delivered intradermally versus intramuscularly to HIV‐infected adults. Journal of Infectious Diseases2015;211(12):1969‐76. [DOI: 10.1093/infdis/jiu841; PMC4539908; PUBMED: 25567841] '>Troy 2015</a>. </p> </section> <section id="CD011780-sec-0068"> <h6 class="title">Secondary outcomes</h6> <p>Three studies measured reciprocal antibody titres (<a href="./references#CD011780-bbs2-0002" title="Cadorna‐CarlosJ , VidorE , BonnetMC . Randomized controlled study of fractional doses of inactivated poliovirus vaccine administered intradermally with a needle in the Philippines. International Journal of Infectious Diseases2012;16(2):e110‐6. [DOI: 10.1016/j.ijid.2011.10.002; PUBMED: 22153001] ">Cadorna‐Carlos 2012</a>; <a href="./references#CD011780-bbs2-0003" title="ClarkeE , SaiduY , AdetifaJU , AdigwemeI , HydaraMB , BashorunAO , et al. Safety and immunogenicity of inactivated poliovirus vaccine when given with measles–rubella combined vaccine and yellow fever vaccine and when given via different administration routes: a phase 4, randomised, non‐inferiority trial in The Gambia. Lancet. Global Health2016;4(8):e534‐47. [DOI: 10.1016/S2214‐109X(16)30075‐4; PUBMED: 27364568] NCT01847872 . IPV clinical trial ‐ The Gambia (IPV) [A phase 4, randomized trial to assess the safety and immunogenicity of inactivated poliovirus vaccine when given concomitantly with measles and rubella combined vaccine and yellow fever vaccine at nine months and when administered via different vaccination routes]. clinicaltrials.gov/ct2/show/NCT01847872 (first received 19 April 2013). ">Clarke 2016</a>; <a href="./references#CD011780-bbs2-0009" title="ResikS , TejedaA , MachO , FonsecaM , DiazM , AlemanyN , et al. Immune responses after fractional doses of inactivated poliovirus vaccine using newly developed intradermal jet injectors: a randomized controlled trial in Cuba. Vaccine2015;33(2):307‐13. [DOI: 10.1016/j.vaccine.2014.11.025; PUBMED: 25448109] ">Resik 2015</a>). None of the studies assessed serum IgA levels or VAPP. Only two studies assessed poliovirus shedding after an OPV challenge dose (<a href="./references#CD011780-bbs2-0005" title="ACTRN12616000124437p . Comparison of boosting of mucosal immunity after full and fractional dose of inactivated poliovirus vaccine, clinical trial in children in Sri Lanka, 2016 [Comparison of boosting of mucosal immunity after full and fractional dose of inactivated poliovirus vaccine, a randomized clinical trial in 300 children aged 10‐12 years of age living in Kalutara district of Sri Lanka, 2016]. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=369725 (first received 3 December 2015). GamageD , MachO , PalihawadanaP , ZhangY , WeldonWC , ObersteMS , et al. Boosting of mucosal immunity after fractional‐dose inactivated poliovirus vaccine. Journal of Infectious Diseases2018;218(12):1876‐82. [DOI: 10.1093/infdis/jiy389; PUBMED: 29982532] ">Gamage 2018</a>; <a href="./references#CD011780-bbs2-0006" title="MohammedAJ , AlAwaidyS , BawikarS , KurupPJ , ElamirE , ShabanMMA , et al. Fractional doses of inactivated poliovirus vaccine in Oman. New England Journal of Medicine2010;362(25):2351‐9. [DOI: 10.1056/NEJMoa0909383; PUBMED: 20573923] ">Mohammed 2010</a>). </p> </section> </section> <section id="CD011780-sec-0069"> <h5 class="title">Source of funding and conflict of interests</h5> <p>None of the included studies mentioned any conflicts of interest. Two studies were supported by drug companies (<a href="./references#CD011780-bbs2-0002" title="Cadorna‐CarlosJ , VidorE , BonnetMC . Randomized controlled study of fractional doses of inactivated poliovirus vaccine administered intradermally with a needle in the Philippines. International Journal of Infectious Diseases2012;16(2):e110‐6. [DOI: 10.1016/j.ijid.2011.10.002; PUBMED: 22153001] ">Cadorna‐Carlos 2012</a>; <a href="./references#CD011780-bbs2-0004" title='EstívarezCF . Details regarding your published paper about "Immunogenicity of supplemental doses of poliovirus vaccine for children aged 6‐9 months in Moradabad, India: a community‐based, randomised controlled trial. Lancet 2012 [personal communication]. Email to: KK Thumburu 11 March 2016. EstívarizCF , JafariH , SutterRW , JohnTJ , JainV , AgarwalA , et al. Immunogenicity of supplemental doses of poliovirus vaccine for children aged 6‐9 months in Moradabad, India: a community‐based, randomised controlled trial. Lancet. Infectious Diseases2012;12(2):128‐35. [DOI: 10.1016/S1473‐3099(11)70190‐6; PUBMED: 22071249] '>Estívariz 2012</a>), and in one study, <a href="./references#CD011780-bbs2-0004" title='EstívarezCF . Details regarding your published paper about "Immunogenicity of supplemental doses of poliovirus vaccine for children aged 6‐9 months in Moradabad, India: a community‐based, randomised controlled trial. Lancet 2012 [personal communication]. Email to: KK Thumburu 11 March 2016. EstívarizCF , JafariH , SutterRW , JohnTJ , JainV , AgarwalA , et al. Immunogenicity of supplemental doses of poliovirus vaccine for children aged 6‐9 months in Moradabad, India: a community‐based, randomised controlled trial. Lancet. Infectious Diseases2012;12(2):128‐35. [DOI: 10.1016/S1473‐3099(11)70190‐6; PUBMED: 22071249] '>Estívariz 2012</a>, the funding agency was listed as an affiliation of those authors providing statistical amongst other support to the study. Pharmaceutical companies supplied the vaccines in three studies (<a href="./references#CD011780-bbs2-0004" title='EstívarezCF . Details regarding your published paper about "Immunogenicity of supplemental doses of poliovirus vaccine for children aged 6‐9 months in Moradabad, India: a community‐based, randomised controlled trial. Lancet 2012 [personal communication]. Email to: KK Thumburu 11 March 2016. EstívarizCF , JafariH , SutterRW , JohnTJ , JainV , AgarwalA , et al. Immunogenicity of supplemental doses of poliovirus vaccine for children aged 6‐9 months in Moradabad, India: a community‐based, randomised controlled trial. Lancet. Infectious Diseases2012;12(2):128‐35. [DOI: 10.1016/S1473‐3099(11)70190‐6; PUBMED: 22071249] '>Estívariz 2012</a>; <a href="./references#CD011780-bbs2-0006" title="MohammedAJ , AlAwaidyS , BawikarS , KurupPJ , ElamirE , ShabanMMA , et al. Fractional doses of inactivated poliovirus vaccine in Oman. New England Journal of Medicine2010;362(25):2351‐9. [DOI: 10.1056/NEJMoa0909383; PUBMED: 20573923] ">Mohammed 2010</a>; <a href="./references#CD011780-bbs2-0010" title="ResikS , TejedaA , DiazM , OkayasuH , SeinC , MolodeckyNA , et al. Boosting immune responses following fractional‐dose inactivated poliovirus vaccine: a randomized, controlled trial. Journal of Infectious Diseases2017;215(2):175‐82. [DOI: 10.1093/infdis/jiw492; PUBMED: 28073858] ">Resik 2017</a>), and manufacturing companies supplied the needle‐free devices in two studies (<a href="./references#CD011780-bbs2-0007" title="ResikS , TejedaA , LagoPM , DiazM , CarmenatesA , SarmientoL , et al. Randomized controlled clinical trial of fractional doses of inactivated poliovirus vaccine administered intradermally by needle‐free device in Cuba. Journal of Infectious Diseases2010;201(9):1344‐52. [DOI: 10.1086/651611; PUBMED: 20350164] ">Resik 2010</a>; <a href="./references#CD011780-bbs2-0013" title='TroyS . Regarding your paper "Comparison of the Immunogenicity of Various Booster Doses of Inactivated Polio Vaccine Delivered Intradermally Versus Intramuscularly to HIV‐Infected Adults" [personal communication]. Email to: A Agarwal 06 May 2016. TroySB , KouiavskaiaD , SiikJ , KochbaE , BeydounH , MirochnitchenkoO , et al. Comparison of the immunogenicity of various booster doses of inactivated polio vaccine delivered intradermally versus intramuscularly to HIV‐infected adults. Journal of Infectious Diseases2015;211(12):1969‐76. [DOI: 10.1093/infdis/jiu841; PMC4539908; PUBMED: 25567841] '>Troy 2015</a>). In <a href="./references#CD011780-bbs2-0013" title='TroyS . Regarding your paper "Comparison of the Immunogenicity of Various Booster Doses of Inactivated Polio Vaccine Delivered Intradermally Versus Intramuscularly to HIV‐Infected Adults" [personal communication]. Email to: A Agarwal 06 May 2016. TroySB , KouiavskaiaD , SiikJ , KochbaE , BeydounH , MirochnitchenkoO , et al. Comparison of the immunogenicity of various booster doses of inactivated polio vaccine delivered intradermally versus intramuscularly to HIV‐infected adults. Journal of Infectious Diseases2015;211(12):1969‐76. [DOI: 10.1093/infdis/jiu841; PMC4539908; PUBMED: 25567841] '>Troy 2015</a>, the manufacturing company also supported the salaries of two of the authors. </p> </section> </section> <section id="CD011780-sec-0070"> <h4 class="title">Excluded studies</h4> <p>See the <a href="./references#CD011780-sec-0143" title="">Characteristics of excluded studies</a> tables for further details. </p> <p>We excluded 13 studies that did not meet our inclusion criteria after full‐text screening (<a href="./references#CD011780-bbs2-0014" title="AabyP , GarlyML , NielsenJ , RavnH , MartinsC , BaléC , et al. Increased female‐male mortality ratio associated with inactivated polio and diphtheria‐tetanus‐pertussis vaccines: observations from vaccination trials in Guinea‐Bissau. Pediatric Infectious Disease Journal2007;26(3):247‐52. [DOI: 10.1097/01.inf.0000256735.05098.01; PUBMED: 17484223] ">Aaby 2007</a>; <a href="./references#CD011780-bbs2-0015" title="BakkerWA , ThomassenYE , Van't OeverAG , WestdijkJ , VanOijenMG , SundermannLC , et al. Inactivated polio vaccine development for technology transfer using attenuated Sabin poliovirus strains to shift from Salk‐IPV to Sabin‐IPV. Vaccine2011;29(41):7188‐96. [DOI: 10.1016/j.vaccine.2011.05.079; PUBMED: 21651934] ">Bakker 2011</a>; <a href="./references#CD011780-bbs2-0016" title="BéguéPC , GrimprelEM , GiovannangeliMD , AbitbolVI . Comparative reactogenicity and immunogenicity of booster doses of diphtheria‐tetanus‐acellular pertussis‐inactivated poliovirus vaccine and diphtheria‐tetanus‐inactivated poliovirus vaccine in preadolescents. Pediatric Infectious Disease Journal1998;17(9):804‐9. [DOI: 10.1097/00006454‐199809000‐00011; PUBMED: 9779766] ">Bégué 1998</a>; <a href="./references#CD011780-bbs2-0017" title="ChoudhuryP , ThackerN , GarganoLM , WeissPS , VashishthaVM , AmladiT , et al. Attitudes and perceptions of private paediatricians regarding polio immunization in India. Vaccine2011;29(46):8317‐22. [DOI: 10.1016/j.vaccine.2011.08.099; PUBMED: 21893150] ">Choudhury 2011</a>; <a href="./references#CD011780-bbs2-0018" title="The Cuba IPV Study Collaborative Group. Randomized, placebo‐controlled trial of inactivated poliovirus vaccine in Cuba. New England Journal of Medicine2007;356(15):1536‐44. [DOI: 10.1056/NEJMoa054960; PUBMED: 17429085] ">Cuba IPV Study Group 2007</a>; <a href="./references#CD011780-bbs2-0020" title="GrasslyNC . Immunogenicity and effectiveness of routine immunization with 1 or 2 doses of inactivated poliovirus vaccine: systematic review and meta‐analysis. Journal of Infectious Diseases2014;210(Suppl 1):S439‐46. [DOI: 10.1093/infdis/jit601; PMC4197908; PUBMED: 24634499] ">Grassly 2014</a>; <a href="./references#CD011780-bbs2-0021" title="KleinNP , WestonWM , KuriyakoseS , KolheD , HoweB , FriedlandLR , et al. An open‐label, randomized, multi‐center study of the immunogenicity and safety of DTaP‐IPV (KinrixTM) co‐administered with MMR vaccine with or without varicella vaccine in healthy pre‐school age children. Vaccine2012;30(3):668‐74. [DOI: 10.1016/j.vaccine.2011.10.065; PUBMED: 22064267] ">Klein 2012</a>; <a href="./references#CD011780-bbs2-0022" title="LiR , LiCG , LiY , LiuY , ZhaoH , ChenX , et al. Primary and booster vaccination with an inactivated poliovirus vaccine (IPV) is immunogenic and well‐tolerated in infants and toddlers in China. Vaccine2016;34(12):1436‐43. [DOI: 10.1016/j.vaccine.2016.02.010; PUBMED: 26873055] ">Li 2016</a>; <a href="./references#CD011780-bbs2-0023" title="NCT00871000 . Immunogenicity and safety of Boostrix polio vaccine as a booster dose in 5 to 6‐year‐old children [Immunogenicity and safety of GSK Biologicals' dTpa‐IPV vaccine (Boostrix polio) as a booster dose in 5 to 6‐year‐old children]. clinicaltrials.gov/ct2/show/NCT00871000 (first received 26 March 2009). ">NCT00871000</a>; <a href="./references#CD011780-bbs2-0024" title="NirmalS , CherianT , SamuelBU , RajasinghJ , RaghupathyP , JohnTJ . Immune response of infants to fractional doses of intradermally administered inactivated poliovirus vaccine. Vaccine1998;16(9‐10):928‐31. [DOI: 10.1016/s0264‐410x(97)00293‐4; PUBMED: 9682339] ">Nirmal 1998</a>; <a href="./references#CD011780-bbs2-0025" title="O'RyanM , BandyopadhyayAS , VillenaR , EspinozaM , NovoaJ , WeldonWC , et al. Inactivated poliovirus vaccine given alone or in a sequential schedule with bivalent oral poliovirus vaccine in Chilean infants: a randomised, controlled, open‐label, phase 4, non‐inferiority study. Lancet. Infectious Diseases2015;15(11):1273‐82. [DOI: 10.1016/S1473‐3099(15)00219‐4] ">O’Ryan 2015</a>; <a href="./references#CD011780-bbs2-0026" title="VerdijkP , RotsNY , VanOijenMG , ObersteMS , BoogCJ , OkayasuH , et al. Safety and immunogenicity of inactivated poliovirus vaccine based on Sabin strains with and without aluminium hydroxide: a phase I trial in healthy adults. Vaccine2013;31(47):5531‐6. [DOI: 10.1016/j.vaccine.2013.09.021; PUBMED: 24063976] ">Verdijk 2013</a>; <a href="./references#CD011780-bbs2-0027" title="WHO Collaborative Study Group on Oral and Inactivated Poliovirus Vaccines. Combined immunization of infants with oral and inactivated poliovirus vaccines: results of a randomized trial in The Gambia, Oman, and Thailand. Bulleten of the World Health Organization1996;74(3):253‐68. [PMC2486925] WHO Collaborative Study Group on Oral and Inactivated Poliovirus Vaccines. Combined immunization of infants with oral and inactivated poliovirus vaccines: results of a randomized trial in The Gambia, Oman, and Thailand. Journal of Infectious Diseases1997;175(Suppl 1):S215‐27. [DOI: 10.1093/infdis/175.supplement_1.s215; PUBMED: 9203720] ">WHO Collaborative Study 1996</a>). Of these studies, 10 used different interventions (i.e. they did not use intradermal IPV) (<a href="./references#CD011780-bbs2-0014" title="AabyP , GarlyML , NielsenJ , RavnH , MartinsC , BaléC , et al. Increased female‐male mortality ratio associated with inactivated polio and diphtheria‐tetanus‐pertussis vaccines: observations from vaccination trials in Guinea‐Bissau. Pediatric Infectious Disease Journal2007;26(3):247‐52. [DOI: 10.1097/01.inf.0000256735.05098.01; PUBMED: 17484223] ">Aaby 2007</a>; <a href="./references#CD011780-bbs2-0015" title="BakkerWA , ThomassenYE , Van't OeverAG , WestdijkJ , VanOijenMG , SundermannLC , et al. Inactivated polio vaccine development for technology transfer using attenuated Sabin poliovirus strains to shift from Salk‐IPV to Sabin‐IPV. Vaccine2011;29(41):7188‐96. [DOI: 10.1016/j.vaccine.2011.05.079; PUBMED: 21651934] ">Bakker 2011</a>; <a href="./references#CD011780-bbs2-0016" title="BéguéPC , GrimprelEM , GiovannangeliMD , AbitbolVI . Comparative reactogenicity and immunogenicity of booster doses of diphtheria‐tetanus‐acellular pertussis‐inactivated poliovirus vaccine and diphtheria‐tetanus‐inactivated poliovirus vaccine in preadolescents. Pediatric Infectious Disease Journal1998;17(9):804‐9. [DOI: 10.1097/00006454‐199809000‐00011; PUBMED: 9779766] ">Bégué 1998</a>; <a href="./references#CD011780-bbs2-0017" title="ChoudhuryP , ThackerN , GarganoLM , WeissPS , VashishthaVM , AmladiT , et al. Attitudes and perceptions of private paediatricians regarding polio immunization in India. Vaccine2011;29(46):8317‐22. [DOI: 10.1016/j.vaccine.2011.08.099; PUBMED: 21893150] ">Choudhury 2011</a>; <a href="./references#CD011780-bbs2-0018" title="The Cuba IPV Study Collaborative Group. Randomized, placebo‐controlled trial of inactivated poliovirus vaccine in Cuba. New England Journal of Medicine2007;356(15):1536‐44. [DOI: 10.1056/NEJMoa054960; PUBMED: 17429085] ">Cuba IPV Study Group 2007</a>; <a href="./references#CD011780-bbs2-0021" title="KleinNP , WestonWM , KuriyakoseS , KolheD , HoweB , FriedlandLR , et al. An open‐label, randomized, multi‐center study of the immunogenicity and safety of DTaP‐IPV (KinrixTM) co‐administered with MMR vaccine with or without varicella vaccine in healthy pre‐school age children. Vaccine2012;30(3):668‐74. [DOI: 10.1016/j.vaccine.2011.10.065; PUBMED: 22064267] ">Klein 2012</a>; <a href="./references#CD011780-bbs2-0022" title="LiR , LiCG , LiY , LiuY , ZhaoH , ChenX , et al. Primary and booster vaccination with an inactivated poliovirus vaccine (IPV) is immunogenic and well‐tolerated in infants and toddlers in China. Vaccine2016;34(12):1436‐43. [DOI: 10.1016/j.vaccine.2016.02.010; PUBMED: 26873055] ">Li 2016</a>; <a href="./references#CD011780-bbs2-0023" title="NCT00871000 . Immunogenicity and safety of Boostrix polio vaccine as a booster dose in 5 to 6‐year‐old children [Immunogenicity and safety of GSK Biologicals' dTpa‐IPV vaccine (Boostrix polio) as a booster dose in 5 to 6‐year‐old children]. clinicaltrials.gov/ct2/show/NCT00871000 (first received 26 March 2009). ">NCT00871000</a>; <a href="./references#CD011780-bbs2-0025" title="O'RyanM , BandyopadhyayAS , VillenaR , EspinozaM , NovoaJ , WeldonWC , et al. Inactivated poliovirus vaccine given alone or in a sequential schedule with bivalent oral poliovirus vaccine in Chilean infants: a randomised, controlled, open‐label, phase 4, non‐inferiority study. Lancet. Infectious Diseases2015;15(11):1273‐82. [DOI: 10.1016/S1473‐3099(15)00219‐4] ">O’Ryan 2015</a>; <a href="./references#CD011780-bbs2-0027" title="WHO Collaborative Study Group on Oral and Inactivated Poliovirus Vaccines. Combined immunization of infants with oral and inactivated poliovirus vaccines: results of a randomized trial in The Gambia, Oman, and Thailand. Bulleten of the World Health Organization1996;74(3):253‐68. [PMC2486925] WHO Collaborative Study Group on Oral and Inactivated Poliovirus Vaccines. Combined immunization of infants with oral and inactivated poliovirus vaccines: results of a randomized trial in The Gambia, Oman, and Thailand. Journal of Infectious Diseases1997;175(Suppl 1):S215‐27. [DOI: 10.1093/infdis/175.supplement_1.s215; PUBMED: 9203720] ">WHO Collaborative Study 1996</a>); one was a systematic review and not an RCT (<a href="./references#CD011780-bbs2-0020" title="GrasslyNC . Immunogenicity and effectiveness of routine immunization with 1 or 2 doses of inactivated poliovirus vaccine: systematic review and meta‐analysis. Journal of Infectious Diseases2014;210(Suppl 1):S439‐46. [DOI: 10.1093/infdis/jit601; PMC4197908; PUBMED: 24634499] ">Grassly 2014</a>); one compared two different schedules of intradermal IPV (<a href="./references#CD011780-bbs2-0024" title="NirmalS , CherianT , SamuelBU , RajasinghJ , RaghupathyP , JohnTJ . Immune response of infants to fractional doses of intradermally administered inactivated poliovirus vaccine. Vaccine1998;16(9‐10):928‐31. [DOI: 10.1016/s0264‐410x(97)00293‐4; PUBMED: 9682339] ">Nirmal 1998</a>); and one compared two different types of intramuscular IPV (<a href="./references#CD011780-bbs2-0026" title="VerdijkP , RotsNY , VanOijenMG , ObersteMS , BoogCJ , OkayasuH , et al. Safety and immunogenicity of inactivated poliovirus vaccine based on Sabin strains with and without aluminium hydroxide: a phase I trial in healthy adults. Vaccine2013;31(47):5531‐6. [DOI: 10.1016/j.vaccine.2013.09.021; PUBMED: 24063976] ">Verdijk 2013</a>). See <a href="#CD011780-fig-0001">Figure 1</a>. </p> <section id="CD011780-sec-0071"> <h5 class="title">Studies awaiting classification</h5> <p>One RCT is awaiting classification (<a href="./references#CD011780-bbs2-0028" title="NCT02347423 . 3 adjuvated reduced dose IPV‐Al SSI and non‐adjuvated full dose IPV SSI given as primary vaccinations to infants [Immunogenicity and safety of 3 adjuvated reduced dose inactivated polio vaccines (IPV‐Al SSI) and non‐adjuvated full dose IPV SSI, given as primary vaccinations to infants at 6, 10 and 14 weeks of age]. clinicaltrials.gov/ct2/show/record/NCT02347423 (first received 15 January 2015). ">NCT02347423</a>). It is a multicentric, phase 2 trial conducted in the Dominican Republic comparing three reduced doses of aluminium hydroxide‐based inactivated poliovirus vaccines from the Statens Serum Institut (IPV‐AI‐SSI) with a full dose of non‐adjuvated IPV‐AI‐SSI. This trial included 824 six‐week‐old infants of both sexes who received either intervention or control at 6, 10, and 14 weeks of age. The trial measured seroconversion rates, type‐specific geometric mean titres, type‐specific seroprotection rates, reverse cumulative titre distribution, and adverse events following each dose. It was supported by the Bill &amp; Melinda Gates Foundation, Quintiles Inc, Larix A/S, and Statens Serum Institut. See the <a href="./references#CD011780-sec-0144" title="">Characteristics of studies awaiting classification</a> table for further details. </p> </section> <section id="CD011780-sec-0072"> <h5 class="title">Ongoing studies</h5> <p>We found two ongoing studies: one from Bangladesh, <a href="./references#CD011780-bbs2-0029" title="NCT02847026 . Fractional inactivated poliovirus vaccine booster and rotavirus study (fIPV) [Immunogenicity of a booster dose of fractional inactivated poliovirus vaccine (fIPV) delivered intradermally concomitantly with rotavirus vaccines]. clinicaltrials.gov/ct2/show/NCT02847026 (first received 25 July 2016). ">NCT02847026</a>, and one from Uruguay, <a href="./references#CD011780-bbs2-0030" title="NCT03016949 . A study to evaluate immunogenicity of various schedules of inactivated polio vaccine [A phase 3, open‐label, randomized trial to evaluate humoral immunogenicity of various schedules of intramuscular full dose and intradermal fractional dose of inactivated polio vaccine in infants]. clinicaltrials.gov/ct2/show/NCT03016949 (first received 5 January 2017). ">NCT03016949</a>. </p> <p>The Bangladesh study enrolled 1144 infants of both sexes at six weeks of age (<a href="./references#CD011780-bbs2-0029" title="NCT02847026 . Fractional inactivated poliovirus vaccine booster and rotavirus study (fIPV) [Immunogenicity of a booster dose of fractional inactivated poliovirus vaccine (fIPV) delivered intradermally concomitantly with rotavirus vaccines]. clinicaltrials.gov/ct2/show/NCT02847026 (first received 25 July 2016). ">NCT02847026</a>). This multi‐arm study compared different schedules of IPV in combination with two different rotavirus vaccines. </p> <p>The Uruguay study, another multi‐arm study, intends to include 1493 infants aged between five and seven weeks old (<a href="./references#CD011780-bbs2-0030" title="NCT03016949 . A study to evaluate immunogenicity of various schedules of inactivated polio vaccine [A phase 3, open‐label, randomized trial to evaluate humoral immunogenicity of various schedules of intramuscular full dose and intradermal fractional dose of inactivated polio vaccine in infants]. clinicaltrials.gov/ct2/show/NCT03016949 (first received 5 January 2017). ">NCT03016949</a>). It will compare two or three doses of full‐dose IPV given intramuscularly with two or three fractional doses of IPV given intradermally in the following schedule combinations: 6 and 14 weeks; 10 and 14 weeks; 14 and 36 weeks; 6, 14, and 36 weeks; and 10, 14, and 36 weeks. This study is supported by the Bill &amp; Melinda Gates Foundation and the Fedic Corporation. </p> <p>See the <a href="./references#CD011780-sec-0145" title="">Characteristics of ongoing studies</a> tables for further details. </p> </section> </section> </section> <section id="CD011780-sec-0073"> <h3 class="title">Risk of bias in included studies</h3> <p>We assessed the risk of bias in each included study for each of domains provided in the <a href="#CD011780-sec-0045">Assessment of risk of bias in included studies</a> section. We summarised the findings of this assessment in <a href="#CD011780-fig-0002">Figure 2</a> and <a href="#CD011780-fig-0003">Figure 3</a>. See the 'Risk of bias' tables beneath the <a href="./references#CD011780-sec-0142" title="">Characteristics of included studies</a> tables for further details. </p> <div class="figure" id="CD011780-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each 'Risk of bias' item for each included study." data-id="CD011780-fig-0002" src="/cdsr/doi/10.1002/14651858.CD011780.pub2/media/CDSR/CD011780/image_n/nCD011780-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each 'Risk of bias' item for each included study. </p> </div> </div> </div> <div class="figure" id="CD011780-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Risk of bias graph: review authors' judgements about each 'Risk of bias' item presented as percentages across all included studies." data-id="CD011780-fig-0003" src="/cdsr/doi/10.1002/14651858.CD011780.pub2/media/CDSR/CD011780/image_n/nCD011780-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each 'Risk of bias' item presented as percentages across all included studies. </p> </div> </div> </div> <section id="CD011780-sec-0074"> <h4 class="title">Allocation</h4> <section id="CD011780-sec-0075"> <h5 class="title">Random sequence generation (selection bias)</h5> <p>We judged five studies as at unclear risk of bias for this domain as they did not mention the method of randomisation (<a href="./references#CD011780-bbs2-0002" title="Cadorna‐CarlosJ , VidorE , BonnetMC . Randomized controlled study of fractional doses of inactivated poliovirus vaccine administered intradermally with a needle in the Philippines. International Journal of Infectious Diseases2012;16(2):e110‐6. [DOI: 10.1016/j.ijid.2011.10.002; PUBMED: 22153001] ">Cadorna‐Carlos 2012</a>; <a href="./references#CD011780-bbs2-0005" title="ACTRN12616000124437p . Comparison of boosting of mucosal immunity after full and fractional dose of inactivated poliovirus vaccine, clinical trial in children in Sri Lanka, 2016 [Comparison of boosting of mucosal immunity after full and fractional dose of inactivated poliovirus vaccine, a randomized clinical trial in 300 children aged 10‐12 years of age living in Kalutara district of Sri Lanka, 2016]. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=369725 (first received 3 December 2015). GamageD , MachO , PalihawadanaP , ZhangY , WeldonWC , ObersteMS , et al. Boosting of mucosal immunity after fractional‐dose inactivated poliovirus vaccine. Journal of Infectious Diseases2018;218(12):1876‐82. [DOI: 10.1093/infdis/jiy389; PUBMED: 29982532] ">Gamage 2018</a>; <a href="./references#CD011780-bbs2-0006" title="MohammedAJ , AlAwaidyS , BawikarS , KurupPJ , ElamirE , ShabanMMA , et al. Fractional doses of inactivated poliovirus vaccine in Oman. New England Journal of Medicine2010;362(25):2351‐9. [DOI: 10.1056/NEJMoa0909383; PUBMED: 20573923] ">Mohammed 2010</a>; <a href="./references#CD011780-bbs2-0007" title="ResikS , TejedaA , LagoPM , DiazM , CarmenatesA , SarmientoL , et al. Randomized controlled clinical trial of fractional doses of inactivated poliovirus vaccine administered intradermally by needle‐free device in Cuba. Journal of Infectious Diseases2010;201(9):1344‐52. [DOI: 10.1086/651611; PUBMED: 20350164] ">Resik 2010</a>; <a href="./references#CD011780-bbs2-0012" title="Tejeda FuentesA , DeArmas LópezJ , Silva SosaM , Alemañy BuenoN , Carmenate GarcíaA , García GonzálezG , et al. Reactogenicity associated to the intradermally administered inactivated poliovirus vaccine with a needle‐free injector [Reactogenicidad asociada a la vacuna de poliovirus inactivada administrada por vía intradérmica con un inyector sin aguja]. Revista Cubana de Medicina Tropical2011;63(1):38‐43. [PUBMED: 23437535] ">Tejeda Fuentes 2011</a>). We assessed the remaining eight studies as at low risk of selection bias due to random sequence generation as details describing a satisfactory method were provided (<a href="./references#CD011780-bbs2-0001" title="AnandA . Regarding your published trial on IPV in the Vaccine journal [personal communication]. Email to: N Jaiswal 04 May 2016. AnandA , ZamanK , EstívarizCF , YunusM , GaryHE , WeldonWC , et al. Early priming with inactivated poliovirus vaccine (IPV) and intradermal fractional dose IPV administered by a microneedle device: a randomized controlled trial. Vaccine2015;33(48):6816‐22. [DOI: 10.1016/j.vaccine.2015.09.039; PUBMED: 26476367] ">Anand 2015</a>; <a href="./references#CD011780-bbs2-0003" title="ClarkeE , SaiduY , AdetifaJU , AdigwemeI , HydaraMB , BashorunAO , et al. Safety and immunogenicity of inactivated poliovirus vaccine when given with measles–rubella combined vaccine and yellow fever vaccine and when given via different administration routes: a phase 4, randomised, non‐inferiority trial in The Gambia. Lancet. Global Health2016;4(8):e534‐47. [DOI: 10.1016/S2214‐109X(16)30075‐4; PUBMED: 27364568] NCT01847872 . IPV clinical trial ‐ The Gambia (IPV) [A phase 4, randomized trial to assess the safety and immunogenicity of inactivated poliovirus vaccine when given concomitantly with measles and rubella combined vaccine and yellow fever vaccine at nine months and when administered via different vaccination routes]. clinicaltrials.gov/ct2/show/NCT01847872 (first received 19 April 2013). ">Clarke 2016</a>; <a href="./references#CD011780-bbs2-0004" title='EstívarezCF . Details regarding your published paper about "Immunogenicity of supplemental doses of poliovirus vaccine for children aged 6‐9 months in Moradabad, India: a community‐based, randomised controlled trial. Lancet 2012 [personal communication]. Email to: KK Thumburu 11 March 2016. EstívarizCF , JafariH , SutterRW , JohnTJ , JainV , AgarwalA , et al. Immunogenicity of supplemental doses of poliovirus vaccine for children aged 6‐9 months in Moradabad, India: a community‐based, randomised controlled trial. Lancet. Infectious Diseases2012;12(2):128‐35. [DOI: 10.1016/S1473‐3099(11)70190‐6; PUBMED: 22071249] '>Estívariz 2012</a>; <a href="./references#CD011780-bbs2-0008" title='ResikS , TejedaA , SutterRW , DiazM , SarmientoL , AlemañiN , et al. Priming after a fractional dose of inactivated poliovirus vaccine. New England Journal of Medicine2013;368(5):416‐24. [DOI: 10.1056/NEJMoa1202541; PUBMED: 23363495] SutterRW . Regarding your published paper about "Priming after a Fractional Dose of Inactivated Poliovirus Vaccine" published in NEJM 2013 [personal communication]. Email to: KK Thumburu 04 February 2016. '>Resik 2013</a>; <a href="./references#CD011780-bbs2-0009" title="ResikS , TejedaA , MachO , FonsecaM , DiazM , AlemanyN , et al. Immune responses after fractional doses of inactivated poliovirus vaccine using newly developed intradermal jet injectors: a randomized controlled trial in Cuba. Vaccine2015;33(2):307‐13. [DOI: 10.1016/j.vaccine.2014.11.025; PUBMED: 25448109] ">Resik 2015</a>; <a href="./references#CD011780-bbs2-0010" title="ResikS , TejedaA , DiazM , OkayasuH , SeinC , MolodeckyNA , et al. Boosting immune responses following fractional‐dose inactivated poliovirus vaccine: a randomized, controlled trial. Journal of Infectious Diseases2017;215(2):175‐82. [DOI: 10.1093/infdis/jiw492; PUBMED: 28073858] ">Resik 2017</a>; <a href="./references#CD011780-bbs2-0011" title="SoonawalaD , VerdijkP , Wijmenga‐MonsuurAJ , BoogCJ , KoedamP , VisserLG , et al. Intradermal fractional booster dose of inactivated poliomyelitis vaccine with a jet injector in healthy adults. Vaccine2013;31(36):3688‐94. [DOI: 10.1016/j.vaccine.2013.05.104; PUBMED: 23770332] ">Soonawala 2013</a>; <a href="./references#CD011780-bbs2-0013" title='TroyS . Regarding your paper "Comparison of the Immunogenicity of Various Booster Doses of Inactivated Polio Vaccine Delivered Intradermally Versus Intramuscularly to HIV‐Infected Adults" [personal communication]. Email to: A Agarwal 06 May 2016. TroySB , KouiavskaiaD , SiikJ , KochbaE , BeydounH , MirochnitchenkoO , et al. Comparison of the immunogenicity of various booster doses of inactivated polio vaccine delivered intradermally versus intramuscularly to HIV‐infected adults. Journal of Infectious Diseases2015;211(12):1969‐76. [DOI: 10.1093/infdis/jiu841; PMC4539908; PUBMED: 25567841] '>Troy 2015</a>). </p> </section> <section id="CD011780-sec-0076"> <h5 class="title">Allocation concealment (selection bias)</h5> <p>We evaluated one study, <a href="./references#CD011780-bbs2-0006" title="MohammedAJ , AlAwaidyS , BawikarS , KurupPJ , ElamirE , ShabanMMA , et al. Fractional doses of inactivated poliovirus vaccine in Oman. New England Journal of Medicine2010;362(25):2351‐9. [DOI: 10.1056/NEJMoa0909383; PUBMED: 20573923] ">Mohammed 2010</a>, as at high risk of bias for this domain as the parents knew which vaccine their children would be given. We rated five studies as at unclear risk of bias (<a href="./references#CD011780-bbs2-0002" title="Cadorna‐CarlosJ , VidorE , BonnetMC . Randomized controlled study of fractional doses of inactivated poliovirus vaccine administered intradermally with a needle in the Philippines. International Journal of Infectious Diseases2012;16(2):e110‐6. [DOI: 10.1016/j.ijid.2011.10.002; PUBMED: 22153001] ">Cadorna‐Carlos 2012</a>; <a href="./references#CD011780-bbs2-0005" title="ACTRN12616000124437p . Comparison of boosting of mucosal immunity after full and fractional dose of inactivated poliovirus vaccine, clinical trial in children in Sri Lanka, 2016 [Comparison of boosting of mucosal immunity after full and fractional dose of inactivated poliovirus vaccine, a randomized clinical trial in 300 children aged 10‐12 years of age living in Kalutara district of Sri Lanka, 2016]. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=369725 (first received 3 December 2015). GamageD , MachO , PalihawadanaP , ZhangY , WeldonWC , ObersteMS , et al. Boosting of mucosal immunity after fractional‐dose inactivated poliovirus vaccine. Journal of Infectious Diseases2018;218(12):1876‐82. [DOI: 10.1093/infdis/jiy389; PUBMED: 29982532] ">Gamage 2018</a>; <a href="./references#CD011780-bbs2-0007" title="ResikS , TejedaA , LagoPM , DiazM , CarmenatesA , SarmientoL , et al. Randomized controlled clinical trial of fractional doses of inactivated poliovirus vaccine administered intradermally by needle‐free device in Cuba. Journal of Infectious Diseases2010;201(9):1344‐52. [DOI: 10.1086/651611; PUBMED: 20350164] ">Resik 2010</a>; <a href="./references#CD011780-bbs2-0011" title="SoonawalaD , VerdijkP , Wijmenga‐MonsuurAJ , BoogCJ , KoedamP , VisserLG , et al. Intradermal fractional booster dose of inactivated poliomyelitis vaccine with a jet injector in healthy adults. Vaccine2013;31(36):3688‐94. [DOI: 10.1016/j.vaccine.2013.05.104; PUBMED: 23770332] ">Soonawala 2013</a>; <a href="./references#CD011780-bbs2-0012" title="Tejeda FuentesA , DeArmas LópezJ , Silva SosaM , Alemañy BuenoN , Carmenate GarcíaA , García GonzálezG , et al. Reactogenicity associated to the intradermally administered inactivated poliovirus vaccine with a needle‐free injector [Reactogenicidad asociada a la vacuna de poliovirus inactivada administrada por vía intradérmica con un inyector sin aguja]. Revista Cubana de Medicina Tropical2011;63(1):38‐43. [PUBMED: 23437535] ">Tejeda Fuentes 2011</a>). <a href="./references#CD011780-bbs2-0011" title="SoonawalaD , VerdijkP , Wijmenga‐MonsuurAJ , BoogCJ , KoedamP , VisserLG , et al. Intradermal fractional booster dose of inactivated poliomyelitis vaccine with a jet injector in healthy adults. Vaccine2013;31(36):3688‐94. [DOI: 10.1016/j.vaccine.2013.05.104; PUBMED: 23770332] ">Soonawala 2013</a> used sealed envelopes but did not specify whether or not the envelopes were opaque. The other four studies did not report on allocation concealment. We judged the remaining seven trials to be at low risk of bias as the studies concealed the allocations satisfactorily (<a href="./references#CD011780-bbs2-0001" title="AnandA . Regarding your published trial on IPV in the Vaccine journal [personal communication]. Email to: N Jaiswal 04 May 2016. AnandA , ZamanK , EstívarizCF , YunusM , GaryHE , WeldonWC , et al. Early priming with inactivated poliovirus vaccine (IPV) and intradermal fractional dose IPV administered by a microneedle device: a randomized controlled trial. Vaccine2015;33(48):6816‐22. [DOI: 10.1016/j.vaccine.2015.09.039; PUBMED: 26476367] ">Anand 2015</a>; <a href="./references#CD011780-bbs2-0003" title="ClarkeE , SaiduY , AdetifaJU , AdigwemeI , HydaraMB , BashorunAO , et al. Safety and immunogenicity of inactivated poliovirus vaccine when given with measles–rubella combined vaccine and yellow fever vaccine and when given via different administration routes: a phase 4, randomised, non‐inferiority trial in The Gambia. Lancet. Global Health2016;4(8):e534‐47. [DOI: 10.1016/S2214‐109X(16)30075‐4; PUBMED: 27364568] NCT01847872 . IPV clinical trial ‐ The Gambia (IPV) [A phase 4, randomized trial to assess the safety and immunogenicity of inactivated poliovirus vaccine when given concomitantly with measles and rubella combined vaccine and yellow fever vaccine at nine months and when administered via different vaccination routes]. clinicaltrials.gov/ct2/show/NCT01847872 (first received 19 April 2013). ">Clarke 2016</a>; <a href="./references#CD011780-bbs2-0004" title='EstívarezCF . Details regarding your published paper about "Immunogenicity of supplemental doses of poliovirus vaccine for children aged 6‐9 months in Moradabad, India: a community‐based, randomised controlled trial. Lancet 2012 [personal communication]. Email to: KK Thumburu 11 March 2016. EstívarizCF , JafariH , SutterRW , JohnTJ , JainV , AgarwalA , et al. Immunogenicity of supplemental doses of poliovirus vaccine for children aged 6‐9 months in Moradabad, India: a community‐based, randomised controlled trial. Lancet. Infectious Diseases2012;12(2):128‐35. [DOI: 10.1016/S1473‐3099(11)70190‐6; PUBMED: 22071249] '>Estívariz 2012</a>; <a href="./references#CD011780-bbs2-0008" title='ResikS , TejedaA , SutterRW , DiazM , SarmientoL , AlemañiN , et al. Priming after a fractional dose of inactivated poliovirus vaccine. New England Journal of Medicine2013;368(5):416‐24. [DOI: 10.1056/NEJMoa1202541; PUBMED: 23363495] SutterRW . Regarding your published paper about "Priming after a Fractional Dose of Inactivated Poliovirus Vaccine" published in NEJM 2013 [personal communication]. Email to: KK Thumburu 04 February 2016. '>Resik 2013</a>; <a href="./references#CD011780-bbs2-0009" title="ResikS , TejedaA , MachO , FonsecaM , DiazM , AlemanyN , et al. Immune responses after fractional doses of inactivated poliovirus vaccine using newly developed intradermal jet injectors: a randomized controlled trial in Cuba. Vaccine2015;33(2):307‐13. [DOI: 10.1016/j.vaccine.2014.11.025; PUBMED: 25448109] ">Resik 2015</a>; <a href="./references#CD011780-bbs2-0010" title="ResikS , TejedaA , DiazM , OkayasuH , SeinC , MolodeckyNA , et al. Boosting immune responses following fractional‐dose inactivated poliovirus vaccine: a randomized, controlled trial. Journal of Infectious Diseases2017;215(2):175‐82. [DOI: 10.1093/infdis/jiw492; PUBMED: 28073858] ">Resik 2017</a>; <a href="./references#CD011780-bbs2-0013" title='TroyS . Regarding your paper "Comparison of the Immunogenicity of Various Booster Doses of Inactivated Polio Vaccine Delivered Intradermally Versus Intramuscularly to HIV‐Infected Adults" [personal communication]. Email to: A Agarwal 06 May 2016. TroySB , KouiavskaiaD , SiikJ , KochbaE , BeydounH , MirochnitchenkoO , et al. Comparison of the immunogenicity of various booster doses of inactivated polio vaccine delivered intradermally versus intramuscularly to HIV‐infected adults. Journal of Infectious Diseases2015;211(12):1969‐76. [DOI: 10.1093/infdis/jiu841; PMC4539908; PUBMED: 25567841] '>Troy 2015</a>). </p> </section> </section> <section id="CD011780-sec-0077"> <h4 class="title">Blinding</h4> <section id="CD011780-sec-0078"> <h5 class="title">Blinding of participants and personnel (performance bias)</h5> <p>We assessed 11 studies as at high risk of performance bias since the participants were not blinded (<a href="./references#CD011780-bbs2-0001" title="AnandA . Regarding your published trial on IPV in the Vaccine journal [personal communication]. Email to: N Jaiswal 04 May 2016. AnandA , ZamanK , EstívarizCF , YunusM , GaryHE , WeldonWC , et al. Early priming with inactivated poliovirus vaccine (IPV) and intradermal fractional dose IPV administered by a microneedle device: a randomized controlled trial. Vaccine2015;33(48):6816‐22. [DOI: 10.1016/j.vaccine.2015.09.039; PUBMED: 26476367] ">Anand 2015</a>; <a href="./references#CD011780-bbs2-0002" title="Cadorna‐CarlosJ , VidorE , BonnetMC . Randomized controlled study of fractional doses of inactivated poliovirus vaccine administered intradermally with a needle in the Philippines. International Journal of Infectious Diseases2012;16(2):e110‐6. [DOI: 10.1016/j.ijid.2011.10.002; PUBMED: 22153001] ">Cadorna‐Carlos 2012</a>; <a href="./references#CD011780-bbs2-0003" title="ClarkeE , SaiduY , AdetifaJU , AdigwemeI , HydaraMB , BashorunAO , et al. Safety and immunogenicity of inactivated poliovirus vaccine when given with measles–rubella combined vaccine and yellow fever vaccine and when given via different administration routes: a phase 4, randomised, non‐inferiority trial in The Gambia. Lancet. Global Health2016;4(8):e534‐47. [DOI: 10.1016/S2214‐109X(16)30075‐4; PUBMED: 27364568] NCT01847872 . IPV clinical trial ‐ The Gambia (IPV) [A phase 4, randomized trial to assess the safety and immunogenicity of inactivated poliovirus vaccine when given concomitantly with measles and rubella combined vaccine and yellow fever vaccine at nine months and when administered via different vaccination routes]. clinicaltrials.gov/ct2/show/NCT01847872 (first received 19 April 2013). ">Clarke 2016</a>; <a href="./references#CD011780-bbs2-0004" title='EstívarezCF . Details regarding your published paper about "Immunogenicity of supplemental doses of poliovirus vaccine for children aged 6‐9 months in Moradabad, India: a community‐based, randomised controlled trial. Lancet 2012 [personal communication]. Email to: KK Thumburu 11 March 2016. EstívarizCF , JafariH , SutterRW , JohnTJ , JainV , AgarwalA , et al. Immunogenicity of supplemental doses of poliovirus vaccine for children aged 6‐9 months in Moradabad, India: a community‐based, randomised controlled trial. Lancet. Infectious Diseases2012;12(2):128‐35. [DOI: 10.1016/S1473‐3099(11)70190‐6; PUBMED: 22071249] '>Estívariz 2012</a>; <a href="./references#CD011780-bbs2-0005" title="ACTRN12616000124437p . Comparison of boosting of mucosal immunity after full and fractional dose of inactivated poliovirus vaccine, clinical trial in children in Sri Lanka, 2016 [Comparison of boosting of mucosal immunity after full and fractional dose of inactivated poliovirus vaccine, a randomized clinical trial in 300 children aged 10‐12 years of age living in Kalutara district of Sri Lanka, 2016]. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=369725 (first received 3 December 2015). GamageD , MachO , PalihawadanaP , ZhangY , WeldonWC , ObersteMS , et al. Boosting of mucosal immunity after fractional‐dose inactivated poliovirus vaccine. Journal of Infectious Diseases2018;218(12):1876‐82. [DOI: 10.1093/infdis/jiy389; PUBMED: 29982532] ">Gamage 2018</a>; <a href="./references#CD011780-bbs2-0006" title="MohammedAJ , AlAwaidyS , BawikarS , KurupPJ , ElamirE , ShabanMMA , et al. Fractional doses of inactivated poliovirus vaccine in Oman. New England Journal of Medicine2010;362(25):2351‐9. [DOI: 10.1056/NEJMoa0909383; PUBMED: 20573923] ">Mohammed 2010</a>; <a href="./references#CD011780-bbs2-0007" title="ResikS , TejedaA , LagoPM , DiazM , CarmenatesA , SarmientoL , et al. Randomized controlled clinical trial of fractional doses of inactivated poliovirus vaccine administered intradermally by needle‐free device in Cuba. Journal of Infectious Diseases2010;201(9):1344‐52. [DOI: 10.1086/651611; PUBMED: 20350164] ">Resik 2010</a>; <a href="./references#CD011780-bbs2-0008" title='ResikS , TejedaA , SutterRW , DiazM , SarmientoL , AlemañiN , et al. Priming after a fractional dose of inactivated poliovirus vaccine. New England Journal of Medicine2013;368(5):416‐24. [DOI: 10.1056/NEJMoa1202541; PUBMED: 23363495] SutterRW . Regarding your published paper about "Priming after a Fractional Dose of Inactivated Poliovirus Vaccine" published in NEJM 2013 [personal communication]. Email to: KK Thumburu 04 February 2016. '>Resik 2013</a>; <a href="./references#CD011780-bbs2-0009" title="ResikS , TejedaA , MachO , FonsecaM , DiazM , AlemanyN , et al. Immune responses after fractional doses of inactivated poliovirus vaccine using newly developed intradermal jet injectors: a randomized controlled trial in Cuba. Vaccine2015;33(2):307‐13. [DOI: 10.1016/j.vaccine.2014.11.025; PUBMED: 25448109] ">Resik 2015</a>; <a href="./references#CD011780-bbs2-0011" title="SoonawalaD , VerdijkP , Wijmenga‐MonsuurAJ , BoogCJ , KoedamP , VisserLG , et al. Intradermal fractional booster dose of inactivated poliomyelitis vaccine with a jet injector in healthy adults. Vaccine2013;31(36):3688‐94. [DOI: 10.1016/j.vaccine.2013.05.104; PUBMED: 23770332] ">Soonawala 2013</a>; <a href="./references#CD011780-bbs2-0012" title="Tejeda FuentesA , DeArmas LópezJ , Silva SosaM , Alemañy BuenoN , Carmenate GarcíaA , García GonzálezG , et al. Reactogenicity associated to the intradermally administered inactivated poliovirus vaccine with a needle‐free injector [Reactogenicidad asociada a la vacuna de poliovirus inactivada administrada por vía intradérmica con un inyector sin aguja]. Revista Cubana de Medicina Tropical2011;63(1):38‐43. [PUBMED: 23437535] ">Tejeda Fuentes 2011</a>). We judged two studies to be at unclear risk of performance bias as blinding of participants and personnel was not mentioned (<a href="./references#CD011780-bbs2-0010" title="ResikS , TejedaA , DiazM , OkayasuH , SeinC , MolodeckyNA , et al. Boosting immune responses following fractional‐dose inactivated poliovirus vaccine: a randomized, controlled trial. Journal of Infectious Diseases2017;215(2):175‐82. [DOI: 10.1093/infdis/jiw492; PUBMED: 28073858] ">Resik 2017</a>; <a href="./references#CD011780-bbs2-0013" title='TroyS . Regarding your paper "Comparison of the Immunogenicity of Various Booster Doses of Inactivated Polio Vaccine Delivered Intradermally Versus Intramuscularly to HIV‐Infected Adults" [personal communication]. Email to: A Agarwal 06 May 2016. TroySB , KouiavskaiaD , SiikJ , KochbaE , BeydounH , MirochnitchenkoO , et al. Comparison of the immunogenicity of various booster doses of inactivated polio vaccine delivered intradermally versus intramuscularly to HIV‐infected adults. Journal of Infectious Diseases2015;211(12):1969‐76. [DOI: 10.1093/infdis/jiu841; PMC4539908; PUBMED: 25567841] '>Troy 2015</a>). </p> </section> <section id="CD011780-sec-0079"> <h5 class="title">Blinding of outcome assessment (detection bias)</h5> <p>We rated five studies as at low risk of detection bias as they used laboratories or outcome assessors blinded to the intervention (<a href="./references#CD011780-bbs2-0003" title="ClarkeE , SaiduY , AdetifaJU , AdigwemeI , HydaraMB , BashorunAO , et al. Safety and immunogenicity of inactivated poliovirus vaccine when given with measles–rubella combined vaccine and yellow fever vaccine and when given via different administration routes: a phase 4, randomised, non‐inferiority trial in The Gambia. Lancet. Global Health2016;4(8):e534‐47. [DOI: 10.1016/S2214‐109X(16)30075‐4; PUBMED: 27364568] NCT01847872 . IPV clinical trial ‐ The Gambia (IPV) [A phase 4, randomized trial to assess the safety and immunogenicity of inactivated poliovirus vaccine when given concomitantly with measles and rubella combined vaccine and yellow fever vaccine at nine months and when administered via different vaccination routes]. clinicaltrials.gov/ct2/show/NCT01847872 (first received 19 April 2013). ">Clarke 2016</a>; <a href="./references#CD011780-bbs2-0006" title="MohammedAJ , AlAwaidyS , BawikarS , KurupPJ , ElamirE , ShabanMMA , et al. Fractional doses of inactivated poliovirus vaccine in Oman. New England Journal of Medicine2010;362(25):2351‐9. [DOI: 10.1056/NEJMoa0909383; PUBMED: 20573923] ">Mohammed 2010</a>; <a href="./references#CD011780-bbs2-0007" title="ResikS , TejedaA , LagoPM , DiazM , CarmenatesA , SarmientoL , et al. Randomized controlled clinical trial of fractional doses of inactivated poliovirus vaccine administered intradermally by needle‐free device in Cuba. Journal of Infectious Diseases2010;201(9):1344‐52. [DOI: 10.1086/651611; PUBMED: 20350164] ">Resik 2010</a>; <a href="./references#CD011780-bbs2-0008" title='ResikS , TejedaA , SutterRW , DiazM , SarmientoL , AlemañiN , et al. Priming after a fractional dose of inactivated poliovirus vaccine. New England Journal of Medicine2013;368(5):416‐24. [DOI: 10.1056/NEJMoa1202541; PUBMED: 23363495] SutterRW . Regarding your published paper about "Priming after a Fractional Dose of Inactivated Poliovirus Vaccine" published in NEJM 2013 [personal communication]. Email to: KK Thumburu 04 February 2016. '>Resik 2013</a>; <a href="./references#CD011780-bbs2-0012" title="Tejeda FuentesA , DeArmas LópezJ , Silva SosaM , Alemañy BuenoN , Carmenate GarcíaA , García GonzálezG , et al. Reactogenicity associated to the intradermally administered inactivated poliovirus vaccine with a needle‐free injector [Reactogenicidad asociada a la vacuna de poliovirus inactivada administrada por vía intradérmica con un inyector sin aguja]. Revista Cubana de Medicina Tropical2011;63(1):38‐43. [PUBMED: 23437535] ">Tejeda Fuentes 2011</a>). We rated six studies as at high risk of bias as they were open‐label or unblinded studies (<a href="./references#CD011780-bbs2-0001" title="AnandA . Regarding your published trial on IPV in the Vaccine journal [personal communication]. Email to: N Jaiswal 04 May 2016. AnandA , ZamanK , EstívarizCF , YunusM , GaryHE , WeldonWC , et al. Early priming with inactivated poliovirus vaccine (IPV) and intradermal fractional dose IPV administered by a microneedle device: a randomized controlled trial. Vaccine2015;33(48):6816‐22. [DOI: 10.1016/j.vaccine.2015.09.039; PUBMED: 26476367] ">Anand 2015</a>; <a href="./references#CD011780-bbs2-0002" title="Cadorna‐CarlosJ , VidorE , BonnetMC . Randomized controlled study of fractional doses of inactivated poliovirus vaccine administered intradermally with a needle in the Philippines. International Journal of Infectious Diseases2012;16(2):e110‐6. [DOI: 10.1016/j.ijid.2011.10.002; PUBMED: 22153001] ">Cadorna‐Carlos 2012</a>; <a href="./references#CD011780-bbs2-0004" title='EstívarezCF . Details regarding your published paper about "Immunogenicity of supplemental doses of poliovirus vaccine for children aged 6‐9 months in Moradabad, India: a community‐based, randomised controlled trial. Lancet 2012 [personal communication]. Email to: KK Thumburu 11 March 2016. EstívarizCF , JafariH , SutterRW , JohnTJ , JainV , AgarwalA , et al. Immunogenicity of supplemental doses of poliovirus vaccine for children aged 6‐9 months in Moradabad, India: a community‐based, randomised controlled trial. Lancet. Infectious Diseases2012;12(2):128‐35. [DOI: 10.1016/S1473‐3099(11)70190‐6; PUBMED: 22071249] '>Estívariz 2012</a>; <a href="./references#CD011780-bbs2-0005" title="ACTRN12616000124437p . Comparison of boosting of mucosal immunity after full and fractional dose of inactivated poliovirus vaccine, clinical trial in children in Sri Lanka, 2016 [Comparison of boosting of mucosal immunity after full and fractional dose of inactivated poliovirus vaccine, a randomized clinical trial in 300 children aged 10‐12 years of age living in Kalutara district of Sri Lanka, 2016]. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=369725 (first received 3 December 2015). GamageD , MachO , PalihawadanaP , ZhangY , WeldonWC , ObersteMS , et al. Boosting of mucosal immunity after fractional‐dose inactivated poliovirus vaccine. Journal of Infectious Diseases2018;218(12):1876‐82. [DOI: 10.1093/infdis/jiy389; PUBMED: 29982532] ">Gamage 2018</a>; <a href="./references#CD011780-bbs2-0009" title="ResikS , TejedaA , MachO , FonsecaM , DiazM , AlemanyN , et al. Immune responses after fractional doses of inactivated poliovirus vaccine using newly developed intradermal jet injectors: a randomized controlled trial in Cuba. Vaccine2015;33(2):307‐13. [DOI: 10.1016/j.vaccine.2014.11.025; PUBMED: 25448109] ">Resik 2015</a>; <a href="./references#CD011780-bbs2-0011" title="SoonawalaD , VerdijkP , Wijmenga‐MonsuurAJ , BoogCJ , KoedamP , VisserLG , et al. Intradermal fractional booster dose of inactivated poliomyelitis vaccine with a jet injector in healthy adults. Vaccine2013;31(36):3688‐94. [DOI: 10.1016/j.vaccine.2013.05.104; PUBMED: 23770332] ">Soonawala 2013</a>). We rated the two remaining studies as at unclear risk of detection bias as they did not mention blinding (<a href="./references#CD011780-bbs2-0010" title="ResikS , TejedaA , DiazM , OkayasuH , SeinC , MolodeckyNA , et al. Boosting immune responses following fractional‐dose inactivated poliovirus vaccine: a randomized, controlled trial. Journal of Infectious Diseases2017;215(2):175‐82. [DOI: 10.1093/infdis/jiw492; PUBMED: 28073858] ">Resik 2017</a>; <a href="./references#CD011780-bbs2-0013" title='TroyS . Regarding your paper "Comparison of the Immunogenicity of Various Booster Doses of Inactivated Polio Vaccine Delivered Intradermally Versus Intramuscularly to HIV‐Infected Adults" [personal communication]. Email to: A Agarwal 06 May 2016. TroySB , KouiavskaiaD , SiikJ , KochbaE , BeydounH , MirochnitchenkoO , et al. Comparison of the immunogenicity of various booster doses of inactivated polio vaccine delivered intradermally versus intramuscularly to HIV‐infected adults. Journal of Infectious Diseases2015;211(12):1969‐76. [DOI: 10.1093/infdis/jiu841; PMC4539908; PUBMED: 25567841] '>Troy 2015</a>). </p> </section> </section> <section id="CD011780-sec-0080"> <h4 class="title">Incomplete outcome data</h4> <p>We judged two studies with attrition of more than 15% to be at high risk of bias for this domain (<a href="./references#CD011780-bbs2-0007" title="ResikS , TejedaA , LagoPM , DiazM , CarmenatesA , SarmientoL , et al. Randomized controlled clinical trial of fractional doses of inactivated poliovirus vaccine administered intradermally by needle‐free device in Cuba. Journal of Infectious Diseases2010;201(9):1344‐52. [DOI: 10.1086/651611; PUBMED: 20350164] ">Resik 2010</a>; <a href="./references#CD011780-bbs2-0012" title="Tejeda FuentesA , DeArmas LópezJ , Silva SosaM , Alemañy BuenoN , Carmenate GarcíaA , García GonzálezG , et al. Reactogenicity associated to the intradermally administered inactivated poliovirus vaccine with a needle‐free injector [Reactogenicidad asociada a la vacuna de poliovirus inactivada administrada por vía intradérmica con un inyector sin aguja]. Revista Cubana de Medicina Tropical2011;63(1):38‐43. [PUBMED: 23437535] ">Tejeda Fuentes 2011</a>). We considered the 11 remaining studies to be at low risk of attrition bias as attrition was much lower (<a href="./references#CD011780-bbs2-0001" title="AnandA . Regarding your published trial on IPV in the Vaccine journal [personal communication]. Email to: N Jaiswal 04 May 2016. AnandA , ZamanK , EstívarizCF , YunusM , GaryHE , WeldonWC , et al. Early priming with inactivated poliovirus vaccine (IPV) and intradermal fractional dose IPV administered by a microneedle device: a randomized controlled trial. Vaccine2015;33(48):6816‐22. [DOI: 10.1016/j.vaccine.2015.09.039; PUBMED: 26476367] ">Anand 2015</a>; <a href="./references#CD011780-bbs2-0002" title="Cadorna‐CarlosJ , VidorE , BonnetMC . Randomized controlled study of fractional doses of inactivated poliovirus vaccine administered intradermally with a needle in the Philippines. International Journal of Infectious Diseases2012;16(2):e110‐6. [DOI: 10.1016/j.ijid.2011.10.002; PUBMED: 22153001] ">Cadorna‐Carlos 2012</a>; <a href="./references#CD011780-bbs2-0003" title="ClarkeE , SaiduY , AdetifaJU , AdigwemeI , HydaraMB , BashorunAO , et al. Safety and immunogenicity of inactivated poliovirus vaccine when given with measles–rubella combined vaccine and yellow fever vaccine and when given via different administration routes: a phase 4, randomised, non‐inferiority trial in The Gambia. Lancet. Global Health2016;4(8):e534‐47. [DOI: 10.1016/S2214‐109X(16)30075‐4; PUBMED: 27364568] NCT01847872 . IPV clinical trial ‐ The Gambia (IPV) [A phase 4, randomized trial to assess the safety and immunogenicity of inactivated poliovirus vaccine when given concomitantly with measles and rubella combined vaccine and yellow fever vaccine at nine months and when administered via different vaccination routes]. clinicaltrials.gov/ct2/show/NCT01847872 (first received 19 April 2013). ">Clarke 2016</a>; <a href="./references#CD011780-bbs2-0004" title='EstívarezCF . Details regarding your published paper about "Immunogenicity of supplemental doses of poliovirus vaccine for children aged 6‐9 months in Moradabad, India: a community‐based, randomised controlled trial. Lancet 2012 [personal communication]. Email to: KK Thumburu 11 March 2016. EstívarizCF , JafariH , SutterRW , JohnTJ , JainV , AgarwalA , et al. Immunogenicity of supplemental doses of poliovirus vaccine for children aged 6‐9 months in Moradabad, India: a community‐based, randomised controlled trial. Lancet. Infectious Diseases2012;12(2):128‐35. [DOI: 10.1016/S1473‐3099(11)70190‐6; PUBMED: 22071249] '>Estívariz 2012</a>; <a href="./references#CD011780-bbs2-0005" title="ACTRN12616000124437p . Comparison of boosting of mucosal immunity after full and fractional dose of inactivated poliovirus vaccine, clinical trial in children in Sri Lanka, 2016 [Comparison of boosting of mucosal immunity after full and fractional dose of inactivated poliovirus vaccine, a randomized clinical trial in 300 children aged 10‐12 years of age living in Kalutara district of Sri Lanka, 2016]. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=369725 (first received 3 December 2015). GamageD , MachO , PalihawadanaP , ZhangY , WeldonWC , ObersteMS , et al. Boosting of mucosal immunity after fractional‐dose inactivated poliovirus vaccine. Journal of Infectious Diseases2018;218(12):1876‐82. [DOI: 10.1093/infdis/jiy389; PUBMED: 29982532] ">Gamage 2018</a>; <a href="./references#CD011780-bbs2-0006" title="MohammedAJ , AlAwaidyS , BawikarS , KurupPJ , ElamirE , ShabanMMA , et al. Fractional doses of inactivated poliovirus vaccine in Oman. New England Journal of Medicine2010;362(25):2351‐9. [DOI: 10.1056/NEJMoa0909383; PUBMED: 20573923] ">Mohammed 2010</a>; <a href="./references#CD011780-bbs2-0008" title='ResikS , TejedaA , SutterRW , DiazM , SarmientoL , AlemañiN , et al. Priming after a fractional dose of inactivated poliovirus vaccine. New England Journal of Medicine2013;368(5):416‐24. [DOI: 10.1056/NEJMoa1202541; PUBMED: 23363495] SutterRW . Regarding your published paper about "Priming after a Fractional Dose of Inactivated Poliovirus Vaccine" published in NEJM 2013 [personal communication]. Email to: KK Thumburu 04 February 2016. '>Resik 2013</a>; <a href="./references#CD011780-bbs2-0009" title="ResikS , TejedaA , MachO , FonsecaM , DiazM , AlemanyN , et al. Immune responses after fractional doses of inactivated poliovirus vaccine using newly developed intradermal jet injectors: a randomized controlled trial in Cuba. Vaccine2015;33(2):307‐13. [DOI: 10.1016/j.vaccine.2014.11.025; PUBMED: 25448109] ">Resik 2015</a>; <a href="./references#CD011780-bbs2-0010" title="ResikS , TejedaA , DiazM , OkayasuH , SeinC , MolodeckyNA , et al. Boosting immune responses following fractional‐dose inactivated poliovirus vaccine: a randomized, controlled trial. Journal of Infectious Diseases2017;215(2):175‐82. [DOI: 10.1093/infdis/jiw492; PUBMED: 28073858] ">Resik 2017</a>; <a href="./references#CD011780-bbs2-0011" title="SoonawalaD , VerdijkP , Wijmenga‐MonsuurAJ , BoogCJ , KoedamP , VisserLG , et al. Intradermal fractional booster dose of inactivated poliomyelitis vaccine with a jet injector in healthy adults. Vaccine2013;31(36):3688‐94. [DOI: 10.1016/j.vaccine.2013.05.104; PUBMED: 23770332] ">Soonawala 2013</a>; <a href="./references#CD011780-bbs2-0013" title='TroyS . Regarding your paper "Comparison of the Immunogenicity of Various Booster Doses of Inactivated Polio Vaccine Delivered Intradermally Versus Intramuscularly to HIV‐Infected Adults" [personal communication]. Email to: A Agarwal 06 May 2016. TroySB , KouiavskaiaD , SiikJ , KochbaE , BeydounH , MirochnitchenkoO , et al. Comparison of the immunogenicity of various booster doses of inactivated polio vaccine delivered intradermally versus intramuscularly to HIV‐infected adults. Journal of Infectious Diseases2015;211(12):1969‐76. [DOI: 10.1093/infdis/jiu841; PMC4539908; PUBMED: 25567841] '>Troy 2015</a>). </p> </section> <section id="CD011780-sec-0081"> <h4 class="title">Selective reporting</h4> <p>We compared the protocols of 11 trials to the respective published reports to identify any unreported outcomes (<a href="./references#CD011780-bbs2-0001" title="AnandA . Regarding your published trial on IPV in the Vaccine journal [personal communication]. Email to: N Jaiswal 04 May 2016. AnandA , ZamanK , EstívarizCF , YunusM , GaryHE , WeldonWC , et al. Early priming with inactivated poliovirus vaccine (IPV) and intradermal fractional dose IPV administered by a microneedle device: a randomized controlled trial. Vaccine2015;33(48):6816‐22. [DOI: 10.1016/j.vaccine.2015.09.039; PUBMED: 26476367] ">Anand 2015</a>; <a href="./references#CD011780-bbs2-0002" title="Cadorna‐CarlosJ , VidorE , BonnetMC . Randomized controlled study of fractional doses of inactivated poliovirus vaccine administered intradermally with a needle in the Philippines. International Journal of Infectious Diseases2012;16(2):e110‐6. [DOI: 10.1016/j.ijid.2011.10.002; PUBMED: 22153001] ">Cadorna‐Carlos 2012</a>; <a href="./references#CD011780-bbs2-0003" title="ClarkeE , SaiduY , AdetifaJU , AdigwemeI , HydaraMB , BashorunAO , et al. Safety and immunogenicity of inactivated poliovirus vaccine when given with measles–rubella combined vaccine and yellow fever vaccine and when given via different administration routes: a phase 4, randomised, non‐inferiority trial in The Gambia. Lancet. Global Health2016;4(8):e534‐47. [DOI: 10.1016/S2214‐109X(16)30075‐4; PUBMED: 27364568] NCT01847872 . IPV clinical trial ‐ The Gambia (IPV) [A phase 4, randomized trial to assess the safety and immunogenicity of inactivated poliovirus vaccine when given concomitantly with measles and rubella combined vaccine and yellow fever vaccine at nine months and when administered via different vaccination routes]. clinicaltrials.gov/ct2/show/NCT01847872 (first received 19 April 2013). ">Clarke 2016</a>; <a href="./references#CD011780-bbs2-0004" title='EstívarezCF . Details regarding your published paper about "Immunogenicity of supplemental doses of poliovirus vaccine for children aged 6‐9 months in Moradabad, India: a community‐based, randomised controlled trial. Lancet 2012 [personal communication]. Email to: KK Thumburu 11 March 2016. EstívarizCF , JafariH , SutterRW , JohnTJ , JainV , AgarwalA , et al. Immunogenicity of supplemental doses of poliovirus vaccine for children aged 6‐9 months in Moradabad, India: a community‐based, randomised controlled trial. Lancet. Infectious Diseases2012;12(2):128‐35. [DOI: 10.1016/S1473‐3099(11)70190‐6; PUBMED: 22071249] '>Estívariz 2012</a>; <a href="./references#CD011780-bbs2-0005" title="ACTRN12616000124437p . Comparison of boosting of mucosal immunity after full and fractional dose of inactivated poliovirus vaccine, clinical trial in children in Sri Lanka, 2016 [Comparison of boosting of mucosal immunity after full and fractional dose of inactivated poliovirus vaccine, a randomized clinical trial in 300 children aged 10‐12 years of age living in Kalutara district of Sri Lanka, 2016]. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=369725 (first received 3 December 2015). GamageD , MachO , PalihawadanaP , ZhangY , WeldonWC , ObersteMS , et al. Boosting of mucosal immunity after fractional‐dose inactivated poliovirus vaccine. Journal of Infectious Diseases2018;218(12):1876‐82. [DOI: 10.1093/infdis/jiy389; PUBMED: 29982532] ">Gamage 2018</a>; <a href="./references#CD011780-bbs2-0006" title="MohammedAJ , AlAwaidyS , BawikarS , KurupPJ , ElamirE , ShabanMMA , et al. Fractional doses of inactivated poliovirus vaccine in Oman. New England Journal of Medicine2010;362(25):2351‐9. [DOI: 10.1056/NEJMoa0909383; PUBMED: 20573923] ">Mohammed 2010</a>; <a href="./references#CD011780-bbs2-0008" title='ResikS , TejedaA , SutterRW , DiazM , SarmientoL , AlemañiN , et al. Priming after a fractional dose of inactivated poliovirus vaccine. New England Journal of Medicine2013;368(5):416‐24. [DOI: 10.1056/NEJMoa1202541; PUBMED: 23363495] SutterRW . Regarding your published paper about "Priming after a Fractional Dose of Inactivated Poliovirus Vaccine" published in NEJM 2013 [personal communication]. Email to: KK Thumburu 04 February 2016. '>Resik 2013</a>; <a href="./references#CD011780-bbs2-0007" title="ResikS , TejedaA , LagoPM , DiazM , CarmenatesA , SarmientoL , et al. Randomized controlled clinical trial of fractional doses of inactivated poliovirus vaccine administered intradermally by needle‐free device in Cuba. Journal of Infectious Diseases2010;201(9):1344‐52. [DOI: 10.1086/651611; PUBMED: 20350164] ">Resik 2010</a>; <a href="./references#CD011780-bbs2-0009" title="ResikS , TejedaA , MachO , FonsecaM , DiazM , AlemanyN , et al. Immune responses after fractional doses of inactivated poliovirus vaccine using newly developed intradermal jet injectors: a randomized controlled trial in Cuba. Vaccine2015;33(2):307‐13. [DOI: 10.1016/j.vaccine.2014.11.025; PUBMED: 25448109] ">Resik 2015</a>; <a href="./references#CD011780-bbs2-0010" title="ResikS , TejedaA , DiazM , OkayasuH , SeinC , MolodeckyNA , et al. Boosting immune responses following fractional‐dose inactivated poliovirus vaccine: a randomized, controlled trial. Journal of Infectious Diseases2017;215(2):175‐82. [DOI: 10.1093/infdis/jiw492; PUBMED: 28073858] ">Resik 2017</a>; <a href="./references#CD011780-bbs2-0011" title="SoonawalaD , VerdijkP , Wijmenga‐MonsuurAJ , BoogCJ , KoedamP , VisserLG , et al. Intradermal fractional booster dose of inactivated poliomyelitis vaccine with a jet injector in healthy adults. Vaccine2013;31(36):3688‐94. [DOI: 10.1016/j.vaccine.2013.05.104; PUBMED: 23770332] ">Soonawala 2013</a>). One of these studies, <a href="./references#CD011780-bbs2-0008" title='ResikS , TejedaA , SutterRW , DiazM , SarmientoL , AlemañiN , et al. Priming after a fractional dose of inactivated poliovirus vaccine. New England Journal of Medicine2013;368(5):416‐24. [DOI: 10.1056/NEJMoa1202541; PUBMED: 23363495] SutterRW . Regarding your published paper about "Priming after a Fractional Dose of Inactivated Poliovirus Vaccine" published in NEJM 2013 [personal communication]. Email to: KK Thumburu 04 February 2016. '>Resik 2013</a>, did not report on all prespecified outcomes and was therefore rated as at high risk of bias. We rated another study, <a href="./references#CD011780-bbs2-0004" title='EstívarezCF . Details regarding your published paper about "Immunogenicity of supplemental doses of poliovirus vaccine for children aged 6‐9 months in Moradabad, India: a community‐based, randomised controlled trial. Lancet 2012 [personal communication]. Email to: KK Thumburu 11 March 2016. EstívarizCF , JafariH , SutterRW , JohnTJ , JainV , AgarwalA , et al. Immunogenicity of supplemental doses of poliovirus vaccine for children aged 6‐9 months in Moradabad, India: a community‐based, randomised controlled trial. Lancet. Infectious Diseases2012;12(2):128‐35. [DOI: 10.1016/S1473‐3099(11)70190‐6; PUBMED: 22071249] '>Estívariz 2012</a>, as at unclear risk of reporting bias as we could not distinguish clearly between the prespecified and reported outcomes. We considered the other nine studies to be at low risk of bias as all they reported on the prespecified outcomes (<a href="./references#CD011780-bbs2-0001" title="AnandA . Regarding your published trial on IPV in the Vaccine journal [personal communication]. Email to: N Jaiswal 04 May 2016. AnandA , ZamanK , EstívarizCF , YunusM , GaryHE , WeldonWC , et al. Early priming with inactivated poliovirus vaccine (IPV) and intradermal fractional dose IPV administered by a microneedle device: a randomized controlled trial. Vaccine2015;33(48):6816‐22. [DOI: 10.1016/j.vaccine.2015.09.039; PUBMED: 26476367] ">Anand 2015</a>; <a href="./references#CD011780-bbs2-0002" title="Cadorna‐CarlosJ , VidorE , BonnetMC . Randomized controlled study of fractional doses of inactivated poliovirus vaccine administered intradermally with a needle in the Philippines. International Journal of Infectious Diseases2012;16(2):e110‐6. [DOI: 10.1016/j.ijid.2011.10.002; PUBMED: 22153001] ">Cadorna‐Carlos 2012</a>; <a href="./references#CD011780-bbs2-0003" title="ClarkeE , SaiduY , AdetifaJU , AdigwemeI , HydaraMB , BashorunAO , et al. Safety and immunogenicity of inactivated poliovirus vaccine when given with measles–rubella combined vaccine and yellow fever vaccine and when given via different administration routes: a phase 4, randomised, non‐inferiority trial in The Gambia. Lancet. Global Health2016;4(8):e534‐47. [DOI: 10.1016/S2214‐109X(16)30075‐4; PUBMED: 27364568] NCT01847872 . IPV clinical trial ‐ The Gambia (IPV) [A phase 4, randomized trial to assess the safety and immunogenicity of inactivated poliovirus vaccine when given concomitantly with measles and rubella combined vaccine and yellow fever vaccine at nine months and when administered via different vaccination routes]. clinicaltrials.gov/ct2/show/NCT01847872 (first received 19 April 2013). ">Clarke 2016</a>; <a href="./references#CD011780-bbs2-0005" title="ACTRN12616000124437p . Comparison of boosting of mucosal immunity after full and fractional dose of inactivated poliovirus vaccine, clinical trial in children in Sri Lanka, 2016 [Comparison of boosting of mucosal immunity after full and fractional dose of inactivated poliovirus vaccine, a randomized clinical trial in 300 children aged 10‐12 years of age living in Kalutara district of Sri Lanka, 2016]. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=369725 (first received 3 December 2015). GamageD , MachO , PalihawadanaP , ZhangY , WeldonWC , ObersteMS , et al. Boosting of mucosal immunity after fractional‐dose inactivated poliovirus vaccine. Journal of Infectious Diseases2018;218(12):1876‐82. [DOI: 10.1093/infdis/jiy389; PUBMED: 29982532] ">Gamage 2018</a>; <a href="./references#CD011780-bbs2-0006" title="MohammedAJ , AlAwaidyS , BawikarS , KurupPJ , ElamirE , ShabanMMA , et al. Fractional doses of inactivated poliovirus vaccine in Oman. New England Journal of Medicine2010;362(25):2351‐9. [DOI: 10.1056/NEJMoa0909383; PUBMED: 20573923] ">Mohammed 2010</a>; <a href="./references#CD011780-bbs2-0007" title="ResikS , TejedaA , LagoPM , DiazM , CarmenatesA , SarmientoL , et al. Randomized controlled clinical trial of fractional doses of inactivated poliovirus vaccine administered intradermally by needle‐free device in Cuba. Journal of Infectious Diseases2010;201(9):1344‐52. [DOI: 10.1086/651611; PUBMED: 20350164] ">Resik 2010</a>; <a href="./references#CD011780-bbs2-0009" title="ResikS , TejedaA , MachO , FonsecaM , DiazM , AlemanyN , et al. Immune responses after fractional doses of inactivated poliovirus vaccine using newly developed intradermal jet injectors: a randomized controlled trial in Cuba. Vaccine2015;33(2):307‐13. [DOI: 10.1016/j.vaccine.2014.11.025; PUBMED: 25448109] ">Resik 2015</a>; <a href="./references#CD011780-bbs2-0010" title="ResikS , TejedaA , DiazM , OkayasuH , SeinC , MolodeckyNA , et al. Boosting immune responses following fractional‐dose inactivated poliovirus vaccine: a randomized, controlled trial. Journal of Infectious Diseases2017;215(2):175‐82. [DOI: 10.1093/infdis/jiw492; PUBMED: 28073858] ">Resik 2017</a>; <a href="./references#CD011780-bbs2-0011" title="SoonawalaD , VerdijkP , Wijmenga‐MonsuurAJ , BoogCJ , KoedamP , VisserLG , et al. Intradermal fractional booster dose of inactivated poliomyelitis vaccine with a jet injector in healthy adults. Vaccine2013;31(36):3688‐94. [DOI: 10.1016/j.vaccine.2013.05.104; PUBMED: 23770332] ">Soonawala 2013</a>). </p> <p>For the two remaining studies for which protocols were not available, we compared the outcomes in the Methods section with those reported in the Results section. We rated both studies as at low risk of reporting bias (<a href="./references#CD011780-bbs2-0012" title="Tejeda FuentesA , DeArmas LópezJ , Silva SosaM , Alemañy BuenoN , Carmenate GarcíaA , García GonzálezG , et al. Reactogenicity associated to the intradermally administered inactivated poliovirus vaccine with a needle‐free injector [Reactogenicidad asociada a la vacuna de poliovirus inactivada administrada por vía intradérmica con un inyector sin aguja]. Revista Cubana de Medicina Tropical2011;63(1):38‐43. [PUBMED: 23437535] ">Tejeda Fuentes 2011</a>; <a href="./references#CD011780-bbs2-0013" title='TroyS . Regarding your paper "Comparison of the Immunogenicity of Various Booster Doses of Inactivated Polio Vaccine Delivered Intradermally Versus Intramuscularly to HIV‐Infected Adults" [personal communication]. Email to: A Agarwal 06 May 2016. TroySB , KouiavskaiaD , SiikJ , KochbaE , BeydounH , MirochnitchenkoO , et al. Comparison of the immunogenicity of various booster doses of inactivated polio vaccine delivered intradermally versus intramuscularly to HIV‐infected adults. Journal of Infectious Diseases2015;211(12):1969‐76. [DOI: 10.1093/infdis/jiu841; PMC4539908; PUBMED: 25567841] '>Troy 2015</a>). </p> <p>We did not construct funnel plots for publication bias as there were fewer than 10 studies in each analysis. </p> </section> <section id="CD011780-sec-0082"> <h4 class="title">Other potential sources of bias</h4> <p>We rated three studies as at high risk of other bias as they were funded by drug companies (<a href="./references#CD011780-bbs2-0002" title="Cadorna‐CarlosJ , VidorE , BonnetMC . Randomized controlled study of fractional doses of inactivated poliovirus vaccine administered intradermally with a needle in the Philippines. International Journal of Infectious Diseases2012;16(2):e110‐6. [DOI: 10.1016/j.ijid.2011.10.002; PUBMED: 22153001] ">Cadorna‐Carlos 2012</a>; <a href="./references#CD011780-bbs2-0011" title="SoonawalaD , VerdijkP , Wijmenga‐MonsuurAJ , BoogCJ , KoedamP , VisserLG , et al. Intradermal fractional booster dose of inactivated poliomyelitis vaccine with a jet injector in healthy adults. Vaccine2013;31(36):3688‐94. [DOI: 10.1016/j.vaccine.2013.05.104; PUBMED: 23770332] ">Soonawala 2013</a>; <a href="./references#CD011780-bbs2-0013" title='TroyS . Regarding your paper "Comparison of the Immunogenicity of Various Booster Doses of Inactivated Polio Vaccine Delivered Intradermally Versus Intramuscularly to HIV‐Infected Adults" [personal communication]. Email to: A Agarwal 06 May 2016. TroySB , KouiavskaiaD , SiikJ , KochbaE , BeydounH , MirochnitchenkoO , et al. Comparison of the immunogenicity of various booster doses of inactivated polio vaccine delivered intradermally versus intramuscularly to HIV‐infected adults. Journal of Infectious Diseases2015;211(12):1969‐76. [DOI: 10.1093/infdis/jiu841; PMC4539908; PUBMED: 25567841] '>Troy 2015</a>). We rated one study as at unclear risk of other bias as one author was an employee from the vaccine company (<a href="./references#CD011780-bbs2-0004" title='EstívarezCF . Details regarding your published paper about "Immunogenicity of supplemental doses of poliovirus vaccine for children aged 6‐9 months in Moradabad, India: a community‐based, randomised controlled trial. Lancet 2012 [personal communication]. Email to: KK Thumburu 11 March 2016. EstívarizCF , JafariH , SutterRW , JohnTJ , JainV , AgarwalA , et al. Immunogenicity of supplemental doses of poliovirus vaccine for children aged 6‐9 months in Moradabad, India: a community‐based, randomised controlled trial. Lancet. Infectious Diseases2012;12(2):128‐35. [DOI: 10.1016/S1473‐3099(11)70190‐6; PUBMED: 22071249] '>Estívariz 2012</a>). We identified no other sources of bias in the nine remaining studies and so rated them as at low risk of other bias (<a href="./references#CD011780-bbs2-0001" title="AnandA . Regarding your published trial on IPV in the Vaccine journal [personal communication]. Email to: N Jaiswal 04 May 2016. AnandA , ZamanK , EstívarizCF , YunusM , GaryHE , WeldonWC , et al. Early priming with inactivated poliovirus vaccine (IPV) and intradermal fractional dose IPV administered by a microneedle device: a randomized controlled trial. Vaccine2015;33(48):6816‐22. [DOI: 10.1016/j.vaccine.2015.09.039; PUBMED: 26476367] ">Anand 2015</a>; <a href="./references#CD011780-bbs2-0003" title="ClarkeE , SaiduY , AdetifaJU , AdigwemeI , HydaraMB , BashorunAO , et al. Safety and immunogenicity of inactivated poliovirus vaccine when given with measles–rubella combined vaccine and yellow fever vaccine and when given via different administration routes: a phase 4, randomised, non‐inferiority trial in The Gambia. Lancet. Global Health2016;4(8):e534‐47. [DOI: 10.1016/S2214‐109X(16)30075‐4; PUBMED: 27364568] NCT01847872 . IPV clinical trial ‐ The Gambia (IPV) [A phase 4, randomized trial to assess the safety and immunogenicity of inactivated poliovirus vaccine when given concomitantly with measles and rubella combined vaccine and yellow fever vaccine at nine months and when administered via different vaccination routes]. clinicaltrials.gov/ct2/show/NCT01847872 (first received 19 April 2013). ">Clarke 2016</a>; <a href="./references#CD011780-bbs2-0005" title="ACTRN12616000124437p . Comparison of boosting of mucosal immunity after full and fractional dose of inactivated poliovirus vaccine, clinical trial in children in Sri Lanka, 2016 [Comparison of boosting of mucosal immunity after full and fractional dose of inactivated poliovirus vaccine, a randomized clinical trial in 300 children aged 10‐12 years of age living in Kalutara district of Sri Lanka, 2016]. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=369725 (first received 3 December 2015). GamageD , MachO , PalihawadanaP , ZhangY , WeldonWC , ObersteMS , et al. Boosting of mucosal immunity after fractional‐dose inactivated poliovirus vaccine. Journal of Infectious Diseases2018;218(12):1876‐82. [DOI: 10.1093/infdis/jiy389; PUBMED: 29982532] ">Gamage 2018</a>; <a href="./references#CD011780-bbs2-0006" title="MohammedAJ , AlAwaidyS , BawikarS , KurupPJ , ElamirE , ShabanMMA , et al. Fractional doses of inactivated poliovirus vaccine in Oman. New England Journal of Medicine2010;362(25):2351‐9. [DOI: 10.1056/NEJMoa0909383; PUBMED: 20573923] ">Mohammed 2010</a>; <a href="./references#CD011780-bbs2-0007" title="ResikS , TejedaA , LagoPM , DiazM , CarmenatesA , SarmientoL , et al. Randomized controlled clinical trial of fractional doses of inactivated poliovirus vaccine administered intradermally by needle‐free device in Cuba. Journal of Infectious Diseases2010;201(9):1344‐52. [DOI: 10.1086/651611; PUBMED: 20350164] ">Resik 2010</a>; <a href="./references#CD011780-bbs2-0008" title='ResikS , TejedaA , SutterRW , DiazM , SarmientoL , AlemañiN , et al. Priming after a fractional dose of inactivated poliovirus vaccine. New England Journal of Medicine2013;368(5):416‐24. [DOI: 10.1056/NEJMoa1202541; PUBMED: 23363495] SutterRW . Regarding your published paper about "Priming after a Fractional Dose of Inactivated Poliovirus Vaccine" published in NEJM 2013 [personal communication]. Email to: KK Thumburu 04 February 2016. '>Resik 2013</a>; <a href="./references#CD011780-bbs2-0009" title="ResikS , TejedaA , MachO , FonsecaM , DiazM , AlemanyN , et al. Immune responses after fractional doses of inactivated poliovirus vaccine using newly developed intradermal jet injectors: a randomized controlled trial in Cuba. Vaccine2015;33(2):307‐13. [DOI: 10.1016/j.vaccine.2014.11.025; PUBMED: 25448109] ">Resik 2015</a>; <a href="./references#CD011780-bbs2-0010" title="ResikS , TejedaA , DiazM , OkayasuH , SeinC , MolodeckyNA , et al. Boosting immune responses following fractional‐dose inactivated poliovirus vaccine: a randomized, controlled trial. Journal of Infectious Diseases2017;215(2):175‐82. [DOI: 10.1093/infdis/jiw492; PUBMED: 28073858] ">Resik 2017</a>; <a href="./references#CD011780-bbs2-0012" title="Tejeda FuentesA , DeArmas LópezJ , Silva SosaM , Alemañy BuenoN , Carmenate GarcíaA , García GonzálezG , et al. Reactogenicity associated to the intradermally administered inactivated poliovirus vaccine with a needle‐free injector [Reactogenicidad asociada a la vacuna de poliovirus inactivada administrada por vía intradérmica con un inyector sin aguja]. Revista Cubana de Medicina Tropical2011;63(1):38‐43. [PUBMED: 23437535] ">Tejeda Fuentes 2011</a>). </p> </section> </section> <section id="CD011780-sec-0083"> <h3 class="title" id="CD011780-sec-0083">Effects of interventions</h3> <p>See: <a href="./full#CD011780-tbl-0001"><b>Summary of findings for the main comparison</b> Equivalent schedules of intradermal fractional‐dose inactivated poliovirus vaccine compared to intramuscular inactivated poliovirus vaccine for the prevention of poliomyelitis in children</a> </p> <p>We have reported exact P values where possible, or as reported by the study authors. For P values less than 0.001, we express P &lt; 0.001. </p> <section id="CD011780-sec-0084"> <h4 class="title">Primary outcomes</h4> <section id="CD011780-sec-0085"> <h5 class="title">Paralytic poliomyelitis</h5> <p>None of the included studies reported data on the occurrence of paralytic poliomyelitis.</p> <p>One study from India, <a href="./references#CD011780-bbs2-0004" title='EstívarezCF . Details regarding your published paper about "Immunogenicity of supplemental doses of poliovirus vaccine for children aged 6‐9 months in Moradabad, India: a community‐based, randomised controlled trial. Lancet 2012 [personal communication]. Email to: KK Thumburu 11 March 2016. EstívarizCF , JafariH , SutterRW , JohnTJ , JainV , AgarwalA , et al. Immunogenicity of supplemental doses of poliovirus vaccine for children aged 6‐9 months in Moradabad, India: a community‐based, randomised controlled trial. Lancet. Infectious Diseases2012;12(2):128‐35. [DOI: 10.1016/S1473‐3099(11)70190‐6; PUBMED: 22071249] '>Estívariz 2012</a>, reported one participant with wild poliovirus type 3 infection who received a full dose of IPV delivered intramuscularly. </p> </section> <section id="CD011780-sec-0086"> <h5 class="title">Seroconversion rate</h5> <p>We conducted all analyses using a random‐effects model and performed subgroup analyses based on the World Bank classification of countries where possible. We also performed a sensitivity analysis using the fixed‐effect model. </p> <section id="CD011780-sec-0087"> <h6 class="title">Seroconversion rates in children</h6> <section id="CD011780-sec-0088"> <p><b>After a single primary dose</b></p> <p> <ul class="plain" id="CD011780-list-0008"> <li> <ol id="CD011780-list-0009"> <li> <p>Type 1 poliovirus: seroconversion rates were significantly higher in children who received intramuscular full‐dose IPV (odd ratio (OR) 0.30, 95% confidence interval (CI) 0.22 to 0.41, P &lt; 0.001; 6 studies, 2570 children; heterogeneity: Tau<sup>2</sup> = 0.00; Chi<sup>2</sup> = 3.93, df = 4 (P = 0.42); I<sup>2</sup> = 0%). Results of a subgroup analysis found no significant difference between the groups in low‐income countries (OR 0.51, 95% CI 0.15 to 1.70, P = 0.27; 1 study, 700 children), whereas there were significantly higher seroconversion rates in children given intramuscular full‐dose IPV from middle‐income countries (OR 0.25, 95% CI 0.17 to 0.37, P &lt; 0.001; 4 studies, 1502 children; heterogeneity: Tau<sup>2</sup> = 0.00; Chi<sup>2</sup> = 1.17, df = 2 (P = 0.56), I<sup>2</sup> = 0%) and high‐income countries (OR 0.41, 95% CI 0.23 to 0.75, P = 0.003; 1 study, 368 children). See <a href="./references#CD011780-fig-0004" title="">Analysis 1.1</a>. </p> </li> <li> <p>Type 2 poliovirus: seroconversion rates favoured children given intramuscular full‐dose IPV (OR 0.43, 95% CI 0.31 to 0.60, P &lt; 0.001; 6 studies, 2567 children; heterogeneity: Tau<sup>2</sup> = 0.05; Chi<sup>2</sup> = 7.43, df = 5 (P = 0.19); I<sup>2</sup> = 33%). A subgroup analysis showed no difference in seroconversion rates amongst children receiving intramuscular full‐dose IPV or intradermal fractional‐dose IPV in low‐income countries (OR 0.51, 95% CI 0.05 to 5.65, P = 0.58; 1 study, 700 children), but found a significant difference in favour of intramuscular full‐dose IPV in both middle‐income countries (OR 0.40, 95% CI 0.23 to 0.69, P = 0.001; 4 studies, 1502 children; heterogeneity: Tau<sup>2</sup> = 0.16; Chi<sup>2</sup> = 7.57, df = 3 (P = 0.06), I<sup>2</sup> = 60%) and high‐income countries (OR 0.43, 95% CI 0.26 to 0.71, P = 0.001; 1 study, 365 children). See <a href="./references#CD011780-fig-0005" title="">Analysis 1.2</a>. </p> </li> <li> <p>Type 3 poliovirus: seroconversion rates favoured children given intramuscular full‐dose IPV (OR 0.19, 95% CI 0.12 to 0.30, P &lt; 0.001; 6 studies, 2571 children; heterogeneity: Tau<sup>2</sup> = 0.23; Chi<sup>2</sup> = 15.19, df = 5 (P = 0.010), I<sup>2</sup> = 67%). A subgroup analysis also favoured children receiving intramuscular full‐dose IPV over those receiving intradermal fractional‐dose IPV in low‐income countries (OR 0.38, 95% CI 0.18 to 0.84, P = 0.02; 1 study, 700 children), middle‐income countries (OR 0.18, 95% CI 0.10 to 0.33, P &lt; 0.001; 4 studies, 1502 children; heterogeneity: Tau<sup>2</sup> = 0.27; Chi<sup>2</sup> = 10.01, df = 3 (P = 0.02), I<sup>2</sup> = 70%), and high‐income countries (OR 0.12, 95% CI 0.07 to 0.22, P &lt; 0.001; 1 study, 369 children). See <a href="./references#CD011780-fig-0006" title="">Analysis 1.3</a>. </p> </li> </ol> </li> </ul> </p> </section> <section id="CD011780-sec-0089"> <p><b>After two primary doses</b></p> <p> <ul class="plain" id="CD011780-list-0010"> <li> <ol id="CD011780-list-0011"> <li> <p>Type 1 poliovirus: seroconversion rates were significantly higher in children receiving intramuscular full‐dose IPV (OR 0.23, 95% CI 0.16 to 0.33, P &lt; 0.001; 3 studies, 981 children; heterogeneity: Tau<sup>2</sup> = 0.00; Chi<sup>2</sup> = 1.63, df = 2 (P = 0.44), I<sup>2</sup> = 0%). No studies from low‐income countries reported data on seroconversion rates after two doses of IPV. In studies conducted in middle‐income countries, the group given intramuscular full‐dose IPV had a significantly higher seroconversion rate (OR 0.19, 95% CI 0.07 to 0.47, P &lt; 0.001; 2 studies, 674 children; heterogeneity: Tau<sup>2</sup> = 0.20; Chi<sup>2</sup> = 1.18, df = 1 (P = 0.28), I<sup>2</sup> = 16%). The subgroup for high‐income countries also had seroconversion rates favouring the intramuscular full‐dose IPV group (OR 0.27, 95% CI 0.15 to 0.50, P &lt; 0.001; 1 study, 307 children). See <a href="./references#CD011780-fig-0007" title="">Analysis 1.4</a>. </p> </li> <li> <p>Type 2 poliovirus: seroconversion rates favoured children given intramuscular full‐dose IPV (OR 0.41, 95% CI 0.28 to 0.60, P &lt; 0.001; 3 studies, 853 children; heterogeneity: Tau<sup>2</sup> = 0.00; Chi<sup>2</sup> = 1.55, df = 2 (P = 0.46), I<sup>2</sup> = 0%). A subgroup analysis favoured intramuscular full‐dose IPV over intradermal fractional‐dose IPV in both middle‐income countries (OR 0.47, 95% CI 0.29 to 0.77, P = 0.003; 2 studies, 576 children; heterogeneity: Tau<sup>2</sup> = 0.00; Chi<sup>2</sup> = 0.64, df = 1 (P = 0.42), I<sup>2</sup> = 0%) and high‐income countries (OR 0.32, 95% CI 0.18 to 0.60, P &lt; 0.001; 1 study, 277 children). No studies from low‐income countries reported seroconversion rate after two doses of IPV. See <a href="./references#CD011780-fig-0008" title="">Analysis 1.5</a>. </p> </li> <li> <p>Type 3 poliovirus: seroconversion rates favoured children given intramuscular full‐dose IPV (OR 0.12, 95% CI 0.07 to 0.22, P &lt; 0.001; 3 studies, 855 children; heterogeneity: Tau<sup>2</sup> = 0.06; Chi<sup>2</sup> = 2.53, df = 2 (P = 0.28), I<sup>2</sup> = 21%). A subgroup analysis for both middle‐income countries (OR 0.08, 95% CI 0.04 to 0.16, P &lt; 0.001; 2 studies, 585 participants; heterogeneity: Tau<sup>2</sup> = 0.00; Chi<sup>2</sup> = 0.00, df = 1 (P = 0.97), I<sup>2</sup> = 0%) and high‐income countries (OR 0.19, 95% CI 0.09 to 0.43, P &lt; 0.001; 1 study, 270 children) favoured the intramuscular full‐dose IPV group. See <a href="./references#CD011780-fig-0009" title="">Analysis 1.6</a>. </p> </li> </ol> </li> </ul> </p> </section> <section id="CD011780-sec-0090"> <p><b>After three primary doses</b></p> <p> <ul class="plain" id="CD011780-list-0012"> <li> <ol id="CD011780-list-0013"> <li> <p>Type 1 poliovirus: seroconversion rates were not statistically significant in children receiving intramuscular full‐dose IPV (OR 0.45, 95% CI 0.07 to 3.15, P = 0.42; 3 studies, 973 children; heterogeneity: Tau<sup>2</sup> = 2.19; Chi<sup>2</sup> = 9.73, df = 2 (P = 0.008), I<sup>2</sup> = 79%). A subgroup analysis found that in studies conducted in middle‐income countries seroconversion rates amongst children were not significantly higher in children receiving full‐dose IPV (OR 0.75, 95% CI 0.06 to 9.59, P = 0.83; 2 studies, 600 children; heterogeneity: Tau<sup>2</sup> = 3.03; Chi<sup>2</sup> = 9.18, df = 1 (P = 0.002), I<sup>2</sup> = 89%), whereas the subgroup for high‐income countries showed no difference between the two groups (OR 0.09, 95% CI 0.00 to 1.62, P = 0.10; 1 study, 373 children). No studies from low‐income countries reported seroconversion rates after three doses of IPV. See <a href="./references#CD011780-fig-0010" title="">Analysis 1.7</a>. </p> </li> <li> <p>Type 2 poliovirus: seroconversion rates favoured children given intramuscular full‐dose IPV (OR 0.34, 95% CI 0.19 to 0.63, P &lt; 0.001; 3 studies, 973 children; heterogeneity: Tau<sup>2</sup> = 0.00; Chi<sup>2</sup> = 1.72, df = 2 (P = 0.42), I<sup>2</sup> = 0%). A subgroup analysis favoured intramuscular full‐dose IPV over intradermal fractional‐dose IPV in both middle‐income countries (OR 0.38, 95% CI 0.20 to 0.70, P = 0.002; 2 studies, 600 children; heterogeneity: Tau<sup>2</sup> = 0.00; Chi<sup>2</sup> = 0.02, df = 1 (P = 0.88), I<sup>2</sup> = 0%) and high‐income countries (OR 0.06, 95% CI 0.00 to 0.99, P = 0.05; 1 study, 373 children). No studies from low‐income countries reported on seroconversion rates after three doses of IPV. See <a href="./references#CD011780-fig-0011" title="">Analysis 1.8</a>. </p> </li> <li> <p>Type 3 poliovirus: seroconversion rates were not statistically significant (OR 0.18, 95% CI 0.01 to 2.58, P = 0.21; 3 studies, 973 children; heterogeneity: Tau<sup>2</sup> = 4.75; Chi<sup>2</sup> = 18.70, df = 2 (P &lt; 0.001), I<sup>2</sup> = 89%). A subgroup analysis for middle‐income (OR 0.21, 95% CI 0.01 to 7.07, P = 0.39; 2 studies, 600 children; heterogeneity: Tau<sup>2</sup> = 6.08; Chi<sup>2</sup> = 18.59, df = 1 (P &lt; 0.001), I<sup>2</sup> = 95%) and high‐income countries (OR 0.11, 95% CI 0.01 to 2.05, P = 0.14; 1 study, 373 participants) was also not statistically significant, although the effect estimate favoured full‐dose IPV. No studies from low‐income countries reported on seroconversion rates after three doses of IPV. See <a href="./references#CD011780-fig-0012" title="">Analysis 1.9</a>. </p> </li> </ol> </li> </ul> </p> </section> <section id="CD011780-sec-0091"> <p><b>Sensitivity analysis</b></p> <p>Sensitivity analyses showed that the fixed‐effect and random‐effects models produced similar findings for seroconversion rates for polio types 1, 2, and 3 in children after a single primary dose (see <a href="./references#CD011780-fig-0013" title="">Analysis 2.1</a>; <a href="./references#CD011780-fig-0014" title="">Analysis 2.2</a>; <a href="./references#CD011780-fig-0015" title="">Analysis 2.3</a>) and after two primary doses (see <a href="./references#CD011780-fig-0016" title="">Analysis 2.4</a>; <a href="./references#CD011780-fig-0017" title="">Analysis 2.5</a>; <a href="./references#CD011780-fig-0018" title="">Analysis 2.6</a>). After three primary doses, the sensitivity analyses showed similar seroconversion rate effects for the fixed‐effect and random‐effects models for type 1 (<a href="./references#CD011780-fig-0019" title="">Analysis 2.7</a>) and type 2 (<a href="./references#CD011780-fig-0020" title="">Analysis 2.8</a>) only. For type 3, the fixed‐effect analysis showed that seroconversion rates favoured the group given intramuscular full‐dose IPV (OR 0.22, 95% CI 0.10 to 0.48; 3 studies, 973 participants; <a href="./references#CD011780-fig-0021" title="">Analysis 2.9</a>), whereas the random‐effects model showed no clear difference between the two interventions (OR 0.18, 95% CI 0.01 to 2.58; 3 studies, 973 participants; <a href="./references#CD011780-fig-0012" title="">Analysis 1.9</a>). </p> </section> </section> <section id="CD011780-sec-0092"> <h6 class="title">Seroconversion rates in adults</h6> <p>Only two studies (565 participants) reported data on seroconversion rates in adults (<a href="./references#CD011780-bbs2-0010" title="ResikS , TejedaA , DiazM , OkayasuH , SeinC , MolodeckyNA , et al. Boosting immune responses following fractional‐dose inactivated poliovirus vaccine: a randomized, controlled trial. Journal of Infectious Diseases2017;215(2):175‐82. [DOI: 10.1093/infdis/jiw492; PUBMED: 28073858] ">Resik 2017</a>; <a href="./references#CD011780-bbs2-0013" title='TroyS . Regarding your paper "Comparison of the Immunogenicity of Various Booster Doses of Inactivated Polio Vaccine Delivered Intradermally Versus Intramuscularly to HIV‐Infected Adults" [personal communication]. Email to: A Agarwal 06 May 2016. TroySB , KouiavskaiaD , SiikJ , KochbaE , BeydounH , MirochnitchenkoO , et al. Comparison of the immunogenicity of various booster doses of inactivated polio vaccine delivered intradermally versus intramuscularly to HIV‐infected adults. Journal of Infectious Diseases2015;211(12):1969‐76. [DOI: 10.1093/infdis/jiu841; PMC4539908; PUBMED: 25567841] '>Troy 2015</a>). We were unable to pool these results in a meta‐analysis due to high levels of clinical heterogeneity. <a href="./references#CD011780-bbs2-0013" title='TroyS . Regarding your paper "Comparison of the Immunogenicity of Various Booster Doses of Inactivated Polio Vaccine Delivered Intradermally Versus Intramuscularly to HIV‐Infected Adults" [personal communication]. Email to: A Agarwal 06 May 2016. TroySB , KouiavskaiaD , SiikJ , KochbaE , BeydounH , MirochnitchenkoO , et al. Comparison of the immunogenicity of various booster doses of inactivated polio vaccine delivered intradermally versus intramuscularly to HIV‐infected adults. Journal of Infectious Diseases2015;211(12):1969‐76. [DOI: 10.1093/infdis/jiu841; PMC4539908; PUBMED: 25567841] '>Troy 2015</a> recruited adults who were HIV positive, whilst <a href="./references#CD011780-bbs2-0010" title="ResikS , TejedaA , DiazM , OkayasuH , SeinC , MolodeckyNA , et al. Boosting immune responses following fractional‐dose inactivated poliovirus vaccine: a randomized, controlled trial. Journal of Infectious Diseases2017;215(2):175‐82. [DOI: 10.1093/infdis/jiw492; PUBMED: 28073858] ">Resik 2017</a> recruited healthy adult males only. Both studies reported data on seroconversions post‐booster doses and showed no significant difference in seroconversion rates at one‐month postintervention (results not shown). </p> </section> </section> <section id="CD011780-sec-0093"> <h5 class="title">Geometric mean titres</h5> <p>Seven studies (4887 participants) measured geometric titres (<a href="./references#CD011780-bbs2-0002" title="Cadorna‐CarlosJ , VidorE , BonnetMC . Randomized controlled study of fractional doses of inactivated poliovirus vaccine administered intradermally with a needle in the Philippines. International Journal of Infectious Diseases2012;16(2):e110‐6. [DOI: 10.1016/j.ijid.2011.10.002; PUBMED: 22153001] ">Cadorna‐Carlos 2012</a>; <a href="./references#CD011780-bbs2-0003" title="ClarkeE , SaiduY , AdetifaJU , AdigwemeI , HydaraMB , BashorunAO , et al. Safety and immunogenicity of inactivated poliovirus vaccine when given with measles–rubella combined vaccine and yellow fever vaccine and when given via different administration routes: a phase 4, randomised, non‐inferiority trial in The Gambia. Lancet. Global Health2016;4(8):e534‐47. [DOI: 10.1016/S2214‐109X(16)30075‐4; PUBMED: 27364568] NCT01847872 . IPV clinical trial ‐ The Gambia (IPV) [A phase 4, randomized trial to assess the safety and immunogenicity of inactivated poliovirus vaccine when given concomitantly with measles and rubella combined vaccine and yellow fever vaccine at nine months and when administered via different vaccination routes]. clinicaltrials.gov/ct2/show/NCT01847872 (first received 19 April 2013). ">Clarke 2016</a>; <a href="./references#CD011780-bbs2-0004" title='EstívarezCF . Details regarding your published paper about "Immunogenicity of supplemental doses of poliovirus vaccine for children aged 6‐9 months in Moradabad, India: a community‐based, randomised controlled trial. Lancet 2012 [personal communication]. Email to: KK Thumburu 11 March 2016. EstívarizCF , JafariH , SutterRW , JohnTJ , JainV , AgarwalA , et al. Immunogenicity of supplemental doses of poliovirus vaccine for children aged 6‐9 months in Moradabad, India: a community‐based, randomised controlled trial. Lancet. Infectious Diseases2012;12(2):128‐35. [DOI: 10.1016/S1473‐3099(11)70190‐6; PUBMED: 22071249] '>Estívariz 2012</a>; <a href="./references#CD011780-bbs2-0006" title="MohammedAJ , AlAwaidyS , BawikarS , KurupPJ , ElamirE , ShabanMMA , et al. Fractional doses of inactivated poliovirus vaccine in Oman. New England Journal of Medicine2010;362(25):2351‐9. [DOI: 10.1056/NEJMoa0909383; PUBMED: 20573923] ">Mohammed 2010</a>; <a href="./references#CD011780-bbs2-0007" title="ResikS , TejedaA , LagoPM , DiazM , CarmenatesA , SarmientoL , et al. Randomized controlled clinical trial of fractional doses of inactivated poliovirus vaccine administered intradermally by needle‐free device in Cuba. Journal of Infectious Diseases2010;201(9):1344‐52. [DOI: 10.1086/651611; PUBMED: 20350164] ">Resik 2010</a>; <a href="./references#CD011780-bbs2-0008" title='ResikS , TejedaA , SutterRW , DiazM , SarmientoL , AlemañiN , et al. Priming after a fractional dose of inactivated poliovirus vaccine. New England Journal of Medicine2013;368(5):416‐24. [DOI: 10.1056/NEJMoa1202541; PUBMED: 23363495] SutterRW . Regarding your published paper about "Priming after a Fractional Dose of Inactivated Poliovirus Vaccine" published in NEJM 2013 [personal communication]. Email to: KK Thumburu 04 February 2016. '>Resik 2013</a>; <a href="./references#CD011780-bbs2-0009" title="ResikS , TejedaA , MachO , FonsecaM , DiazM , AlemanyN , et al. Immune responses after fractional doses of inactivated poliovirus vaccine using newly developed intradermal jet injectors: a randomized controlled trial in Cuba. Vaccine2015;33(2):307‐13. [DOI: 10.1016/j.vaccine.2014.11.025; PUBMED: 25448109] ">Resik 2015</a>). We were unable to pool these data in a meta‐analysis since all seven studies reported geometric titres as median, as opposed to mean titres. Consequently, we have presented a narrative summary of the results from each study in the section below. Detailed results are tabulated in <a href="#CD011780-tbl-0004">Table 3</a>. </p> <div class="table" id="CD011780-tbl-0004"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Geometric titres: children (median titres reported in included studies that could not be used in a meta‐analysis)</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study ID (location)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of doses given</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Type of antibody</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Median antibody titres: intradermal median (range)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Median antibody titres: intramuscular median (range)</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p><a href="./references#CD011780-bbs2-0002" title="Cadorna‐CarlosJ , VidorE , BonnetMC . Randomized controlled study of fractional doses of inactivated poliovirus vaccine administered intradermally with a needle in the Philippines. International Journal of Infectious Diseases2012;16(2):e110‐6. [DOI: 10.1016/j.ijid.2011.10.002; PUBMED: 22153001] ">Cadorna‐Carlos 2012</a> (the Philippines) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>3 primary doses given; end of primary series vaccination</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Antipolio antibody type 1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>221 (188 to 259)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>585 (482 to 710)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Antipolio antibody type 2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>234 (186 to 294)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>795 (638 to 992)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Antipolio antibody type 3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>194 (157 to 240)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>774 (622 to 963)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>1 booster dose given; booster series</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Antipolio antibody type 1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2833 (2392 to 3356)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6666 (5613 to 7916)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Antipolio antibody type 2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3210 (2672 to 3857)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6522 (5540 to 7678)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Antipolio antibody type 3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4498 (3608 to 5607)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11,952 (10,046 to 14,220)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD011780-bbs2-0003" title="ClarkeE , SaiduY , AdetifaJU , AdigwemeI , HydaraMB , BashorunAO , et al. Safety and immunogenicity of inactivated poliovirus vaccine when given with measles–rubella combined vaccine and yellow fever vaccine and when given via different administration routes: a phase 4, randomised, non‐inferiority trial in The Gambia. Lancet. Global Health2016;4(8):e534‐47. [DOI: 10.1016/S2214‐109X(16)30075‐4; PUBMED: 27364568] NCT01847872 . IPV clinical trial ‐ The Gambia (IPV) [A phase 4, randomized trial to assess the safety and immunogenicity of inactivated poliovirus vaccine when given concomitantly with measles and rubella combined vaccine and yellow fever vaccine at nine months and when administered via different vaccination routes]. clinicaltrials.gov/ct2/show/NCT01847872 (first received 19 April 2013). ">Clarke 2016</a> (The Gambia) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Single primary dose of intramuscular IPV or intradermal fractional‐dose IPV</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Antipoliovirus type 1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ol id="CD011780-list-0014"> <li> <p>Needle/syringe: 256 (256 to 256)</p> </li> <li> <p>Jet injection: 256 (128 to 256)</p> </li> </ol> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ol id="CD011780-list-0015"> <li> <p>Needle/syringe: 512 (256 to 512)</p> </li> <li> <p>Jet injection: 512 (256 to 512)</p> </li> </ol> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Antipoliovirus type 2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ol id="CD011780-list-0016"> <li> <p>Needle/syringe: 256 (256 to 512)</p> </li> <li> <p>Jet injection: 256 (128 to 256)</p> </li> </ol> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ol id="CD011780-list-0017"> <li> <p>Needle/syringe: 512 (512 to 512)</p> </li> <li> <p>Jet injection: 512 (256 to 512)</p> </li> </ol> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Antipoliovirus type 3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ol id="CD011780-list-0018"> <li> <p>Needle/syringe: 512 (512 to 512)</p> </li> <li> <p>Jet injection: 256 (256 to 512)</p> </li> </ol> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ol id="CD011780-list-0019"> <li> <p>Needle/syringe: 1024 (512 to 1024)</p> </li> <li> <p>Jet injection: 512 (512 to 1024)</p> </li> </ol> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD011780-bbs2-0004" title='EstívarezCF . Details regarding your published paper about "Immunogenicity of supplemental doses of poliovirus vaccine for children aged 6‐9 months in Moradabad, India: a community‐based, randomised controlled trial. Lancet 2012 [personal communication]. Email to: KK Thumburu 11 March 2016. EstívarizCF , JafariH , SutterRW , JohnTJ , JainV , AgarwalA , et al. Immunogenicity of supplemental doses of poliovirus vaccine for children aged 6‐9 months in Moradabad, India: a community‐based, randomised controlled trial. Lancet. Infectious Diseases2012;12(2):128‐35. [DOI: 10.1016/S1473‐3099(11)70190‐6; PUBMED: 22071249] '>Estívariz 2012</a> (India) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Single supplementary dose; 28 days after vaccination</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Antipolio antibody type 1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&gt; 1448 (&gt; 1448 to &gt; 1448)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ol id="CD011780-list-0020"> <li> <p>GSK: &gt; 1448 (&gt; 1448 to &gt; 1448)</p> </li> <li> <p>Panacea: &gt; 1448 (&gt; 1448 to &gt; 1448)</p> </li> </ol> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Antipolio antibody type 2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>724 (455 to 910)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ol id="CD011780-list-0021"> <li> <p>GSK: &gt; 1448 (1176 to &gt; 1448)</p> </li> <li> <p>Panacea: &gt; 1448 (1176 to &gt; 1448)</p> </li> </ol> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Antipolio antibody type 3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>202 (28 to 724)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ol id="CD011780-list-0022"> <li> <p>GSK: 455 (181 to 910)</p> </li> <li> <p>Panacea: 362 (288 to 724)</p> </li> </ol> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD011780-bbs2-0006" title="MohammedAJ , AlAwaidyS , BawikarS , KurupPJ , ElamirE , ShabanMMA , et al. Fractional doses of inactivated poliovirus vaccine in Oman. New England Journal of Medicine2010;362(25):2351‐9. [DOI: 10.1056/NEJMoa0909383; PUBMED: 20573923] ">Mohammed 2010</a> (Oman) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>3 primary doses given; end of primary vaccination series</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Antipolio antibody type 1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>228 (228 to 456)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>724 (575 to 912)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Antipolio antibody type 2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>287 (228 to 456)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1149 (912 to 1149)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Antipolio antibody type 3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>362 (287 to 456)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&gt; 1448 (&gt; 1448 to &gt; 1448)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD011780-bbs2-0007" title="ResikS , TejedaA , LagoPM , DiazM , CarmenatesA , SarmientoL , et al. Randomized controlled clinical trial of fractional doses of inactivated poliovirus vaccine administered intradermally by needle‐free device in Cuba. Journal of Infectious Diseases2010;201(9):1344‐52. [DOI: 10.1086/651611; PUBMED: 20350164] ">Resik 2010</a> (Cuba) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>3 primary doses at 6, 10, and 14 weeks; median titres reported at 18 weeks of age (4 weeks after the 3rd dose) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Antipolio antibody type 1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19 (19 to 22)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>85 (54 to 99)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Antipolio antibody type 2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>45 (45 to 54)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>214 (178 to 295)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Antipolio antibody type 3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32 (24 to 45)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>295 (214 to 355)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD011780-bbs2-0008" title='ResikS , TejedaA , SutterRW , DiazM , SarmientoL , AlemañiN , et al. Priming after a fractional dose of inactivated poliovirus vaccine. New England Journal of Medicine2013;368(5):416‐24. [DOI: 10.1056/NEJMoa1202541; PUBMED: 23363495] SutterRW . Regarding your published paper about "Priming after a Fractional Dose of Inactivated Poliovirus Vaccine" published in NEJM 2013 [personal communication]. Email to: KK Thumburu 04 February 2016. '>Resik 2013</a> (Cuba) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>2 doses of vaccine at 4 months and 8 months of age; titres after 30 days of 2nd dose</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Antipolio antibody type 1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>450 (357 to 566)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&gt; 1448 (&gt; 1448 to &gt; 1448)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Antipolio antibody type 2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>898 (713 to &gt; 1448)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&gt; 1448 (&gt; 1448 to &gt; 1448)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Antipolio antibody type 3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>71 (36 to 113)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>898 (566 to &gt; 1448)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD011780-bbs2-0009" title="ResikS , TejedaA , MachO , FonsecaM , DiazM , AlemanyN , et al. Immune responses after fractional doses of inactivated poliovirus vaccine using newly developed intradermal jet injectors: a randomized controlled trial in Cuba. Vaccine2015;33(2):307‐13. [DOI: 10.1016/j.vaccine.2014.11.025; PUBMED: 25448109] ">Resik 2015</a> (Cuba) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Single dose; 21 days after the dose</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Antipolio antibody type 1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ol id="CD011780-list-0023"> <li> <p>BCG syringe: 1423 (1130 to 1791)</p> </li> <li> <p>Injector X: 1423 (1423 to 1791)</p> </li> <li> <p>Injector Y: 898 (713 to 1130)</p> </li> <li> <p>Injector Z: 1423 (1130 to 1423)</p> </li> </ol> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4499 (3573 to 5664)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Antipolio antibody type 2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ol id="CD011780-list-0024"> <li> <p>BCG syringe: 1130 (898 to 1423)</p> </li> <li> <p>Injector X: 1130 (713 to 1423)</p> </li> <li> <p>Injector Y: 566 (450 to 713)</p> </li> <li> <p>Injector Z: 1130 (898 to 1130)</p> </li> </ol> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2839 (2255 to 3573)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Antipolio antibody type 3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ol id="CD011780-list-0025"> <li> <p>BCG syringe: 1130 (713 to 1423)</p> </li> <li> <p>Injector X: 1423 (1130 to 1791)</p> </li> <li> <p>Injector Y: 566 (357 to 713)</p> </li> <li> <p>Injector Z: 1423 (898 to 1791)</p> </li> </ol> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4499 (3573 to 4499)</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>BCG: bacille Calmette‐Guérin vaccine<br/> GSK: GlaxoSmithKline<br/> ID: identifier<br/> IPV: inactivated polio vaccine </p> </div> </div> <section id="CD011780-sec-0094"> <h6 class="title">Single‐study results</h6> <p> <ol id="CD011780-list-0026"> <li> <p><a href="./references#CD011780-bbs2-0002" title="Cadorna‐CarlosJ , VidorE , BonnetMC . Randomized controlled study of fractional doses of inactivated poliovirus vaccine administered intradermally with a needle in the Philippines. International Journal of Infectious Diseases2012;16(2):e110‐6. [DOI: 10.1016/j.ijid.2011.10.002; PUBMED: 22153001] ">Cadorna‐Carlos 2012</a> (461 participants) compared both primary and booster doses. Three primary doses were given. The median antibody titre against intradermal poliovirus type 1 was 221 (range = 188 to 259); type 2 was 234 (range = 186 to 294); and type 3 was 194 (range = 157 to 240), whilst the median antibody titre against intramuscular poliovirus type 1 was 585 (range = 482 to 710); type 2 was 795 (range = 638 to 992); and type 3 was 774 (range = 622 to 963). Only one booster dose was given. The median antibody titre against intradermal poliovirus type 1 was 2833 (range = 2392 to 3356); type 2 was 3210 (range = 2672 to 3857); and type 3 was 4498 (range = 3608 to 5607), whilst the median antibody titre against intramuscular poliovirus type 1 was 6666 (range = 5613 to 7916); type 2 was 6522 (range = 5540 to 7678); and type 3 was 11,952 (range = 10,046 to 14,220). </p> </li> <li> <p><a href="./references#CD011780-bbs2-0003" title="ClarkeE , SaiduY , AdetifaJU , AdigwemeI , HydaraMB , BashorunAO , et al. Safety and immunogenicity of inactivated poliovirus vaccine when given with measles–rubella combined vaccine and yellow fever vaccine and when given via different administration routes: a phase 4, randomised, non‐inferiority trial in The Gambia. Lancet. Global Health2016;4(8):e534‐47. [DOI: 10.1016/S2214‐109X(16)30075‐4; PUBMED: 27364568] NCT01847872 . IPV clinical trial ‐ The Gambia (IPV) [A phase 4, randomized trial to assess the safety and immunogenicity of inactivated poliovirus vaccine when given concomitantly with measles and rubella combined vaccine and yellow fever vaccine at nine months and when administered via different vaccination routes]. clinicaltrials.gov/ct2/show/NCT01847872 (first received 19 April 2013). ">Clarke 2016</a> (1504 participants) compared a single primary dose of intramuscular or intradermal injectable IPV and assessed antibody titres against three types of polioviruses (types 1, 2, and 3). The median antibody titre against intradermal poliovirus type 1 was 256 (range = 256 to 256) from needle/syringe and 256 (128 to 256) from jet injection; type 2 was 256 (range = 256 to 512) for needle/syringe and 256 (range = 128 to 256) for jet injection; and type 3 was 512 (range = 512 to 512) for needle/syringe and 256 (range = 256 to 512) for jet injection. The median antibody titre against intramuscular poliovirus type 1 was 512 (range = 256 to 512) from needle/syringe and 512 (range = 256 to 512) from jet injection; type 2 was 512 (range = 512 to 512) from needle/syringe and 512 (range = 256 to 512) from jet injection; and type 3 was 1024 (range = 512 to 1024) from needle/syringe and 512 (range = 512 to 1024) from jet injection. </p> </li> <li> <p><a href="./references#CD011780-bbs2-0004" title='EstívarezCF . Details regarding your published paper about "Immunogenicity of supplemental doses of poliovirus vaccine for children aged 6‐9 months in Moradabad, India: a community‐based, randomised controlled trial. Lancet 2012 [personal communication]. Email to: KK Thumburu 11 March 2016. EstívarizCF , JafariH , SutterRW , JohnTJ , JainV , AgarwalA , et al. Immunogenicity of supplemental doses of poliovirus vaccine for children aged 6‐9 months in Moradabad, India: a community‐based, randomised controlled trial. Lancet. Infectious Diseases2012;12(2):128‐35. [DOI: 10.1016/S1473‐3099(11)70190‐6; PUBMED: 22071249] '>Estívariz 2012</a> (1002 participants) used a single dose of either intramuscular or intradermal injectable IPV and recorded median titres after 28 days against all three types of poliovirus. The median antibody titre against intradermal poliovirus type 1 was &gt; 1448 (range = &gt; 1448 to &gt; 1448); type 2 was 724 (range = 455 to 910); and type 3 was 202 (range = 28 to 724). The median antibody titre against intramuscular poliovirus type 1 was &gt; 1448 (range = &gt; 1448 to &gt; 1448) for both GlaxoSmithKline (GSK) and Panacea Biotec groups; type 2 was &gt; 1448 (range = 1176 to &gt; 1448) for both GSK and Panacea Biotec groups; and type 3 was 455 (range = 181 to 910) for the GSK group and 362 (range = 288 to 724) for the Panacea Biotec group. </p> </li> <li> <p><a href="./references#CD011780-bbs2-0006" title="MohammedAJ , AlAwaidyS , BawikarS , KurupPJ , ElamirE , ShabanMMA , et al. Fractional doses of inactivated poliovirus vaccine in Oman. New England Journal of Medicine2010;362(25):2351‐9. [DOI: 10.1056/NEJMoa0909383; PUBMED: 20573923] ">Mohammed 2010</a> (400 participants) used three doses of the vaccine (i.e. either intramuscular full‐dose IPV or intradermal fractional‐dose IPV) as the primary series. The median antibody titre against intradermal poliovirus type 1 was 228 (range = 228 to 456); type 2 was 287 (range = 228 to 456); and type 3 was 362 (range = 287 to 456). The median antibody titre against intramuscular poliovirus type 1 was 724 (range = 575 to 912); type 2 was 1149 (range = 912 to 1149); and type 3 was &gt; 1448 (range = &gt; 1448 to &gt; 1448). </p> </li> <li> <p><a href="./references#CD011780-bbs2-0007" title="ResikS , TejedaA , LagoPM , DiazM , CarmenatesA , SarmientoL , et al. Randomized controlled clinical trial of fractional doses of inactivated poliovirus vaccine administered intradermally by needle‐free device in Cuba. Journal of Infectious Diseases2010;201(9):1344‐52. [DOI: 10.1086/651611; PUBMED: 20350164] ">Resik 2010</a> (471 participants) used three primary doses at 6, 10, and 14 weeks, and reported median titres at 18 weeks of age (i.e. four weeks after the third dose). The median antibody titre against intradermal poliovirus type 1 was 19 (range = 19 to 22); type 2 was 45 (range = 45 to 54); and type 3 was 32 (range = 24 to 45). The median antibody titre against intramuscular poliovirus type 1 was 85 (range = 54 to 99); type 2 was 214 (range = 178 to 295); and type 3 was 295 (range = 214 to 355). </p> </li> <li> <p><a href="./references#CD011780-bbs2-0008" title='ResikS , TejedaA , SutterRW , DiazM , SarmientoL , AlemañiN , et al. Priming after a fractional dose of inactivated poliovirus vaccine. New England Journal of Medicine2013;368(5):416‐24. [DOI: 10.1056/NEJMoa1202541; PUBMED: 23363495] SutterRW . Regarding your published paper about "Priming after a Fractional Dose of Inactivated Poliovirus Vaccine" published in NEJM 2013 [personal communication]. Email to: KK Thumburu 04 February 2016. '>Resik 2013</a> (320 participants) used two primary doses, given at four and eight months of age, and measured titres after 30 days of the second dose. The median antibody titre against intradermal poliovirus type 1 was 450 (range = 357 to 566); type 2 was 898 (range = 713 to &gt; 1448); and type 3 was 71 (range = 36 to 113). The median antibody titre against intramuscular poliovirus type 1 was &gt; 1448 (range = &gt; 1448 to &gt; 1448); type 2 was &gt; 1448 (range = &gt; 1448 to &gt; 1448); and type 3 was 898 (range = 566 to &gt; 1448). </p> </li> <li> <p><a href="./references#CD011780-bbs2-0009" title="ResikS , TejedaA , MachO , FonsecaM , DiazM , AlemanyN , et al. Immune responses after fractional doses of inactivated poliovirus vaccine using newly developed intradermal jet injectors: a randomized controlled trial in Cuba. Vaccine2015;33(2):307‐13. [DOI: 10.1016/j.vaccine.2014.11.025; PUBMED: 25448109] ">Resik 2015</a> (729 participants) used a single full dose of intramuscular or a fractional dose of intradermal injectable IPV and recorded the median antibody titre for all three types of poliovirus. The median antibody titre against intradermal fractional‐dose poliovirus type 1 was 1423 (range = 1130 to 1791) from BCG syringe, 1423 (range = 1423 to 1791) from injector X, 898 (range = 713 to 1130) from injector Y, and 1423 (range = 1130 to 1423) from injector Z; type 2 was 1130 (range = 898 to 1423) from BCG syringe, 1130 (range = 713 to 1423) from injector X, 566 (range = 450 to 713) from injector Y, and 1130 (range = 898 to 1130) from injector Z; and type 3 was 1130 (range = 713 to 1423) from BCG syringe, 1423 (range = 1130 to 1791) from injector X, 566 (range = 357 to 713) from injector Y, and 1423 (range = 898 to 1791) from injector Z. The median antibody titre against intramuscular poliovirus type 1 was 4499 (range = 3573 to 5664); type 2 was 2839 (range = 2255 to 3573); and type 3 was 4499 (range = 3573 to 4499). </p> </li> </ol> </p> </section> </section> <section id="CD011780-sec-0095"> <h5 class="title">Any vaccine‐related adverse event</h5> <p>The studies did not report on adverse events uniformly, therefore we were unable to conduct a meta‐analysis of the data. Instead, we have provided a summary of the individual results from the studies below; see results with children in <a href="./full#CD011780-tbl-0002">Table 1</a> and adults in <a href="#CD011780-tbl-0005">Table 4</a>. </p> <div class="table" id="CD011780-tbl-0005"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Adverse events: adults</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study ID (location)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Intradermal (number of individuals with events/total number of individuals)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Intramuscular (number of individuals with events/total number of individuals)</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011780-bbs2-0010" title="ResikS , TejedaA , DiazM , OkayasuH , SeinC , MolodeckyNA , et al. Boosting immune responses following fractional‐dose inactivated poliovirus vaccine: a randomized, controlled trial. Journal of Infectious Diseases2017;215(2):175‐82. [DOI: 10.1093/infdis/jiw492; PUBMED: 28073858] ">Resik 2017</a> (Cuba) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any adverse event</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28/268</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19/266</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="11" valign="top"> <p><a href="./references#CD011780-bbs2-0011" title="SoonawalaD , VerdijkP , Wijmenga‐MonsuurAJ , BoogCJ , KoedamP , VisserLG , et al. Intradermal fractional booster dose of inactivated poliomyelitis vaccine with a jet injector in healthy adults. Vaccine2013;31(36):3688‐94. [DOI: 10.1016/j.vaccine.2013.05.104; PUBMED: 23770332] ">Soonawala 2013</a> (the Netherlands) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Vaccine delivery (pain)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2/32</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19/62</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Erythema</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28/32</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34/62</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Swelling</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19/32</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12/62</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Induration</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11/32</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14/62</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Stiffness</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5/32</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22/62</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Soreness</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5/32</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33/62</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Systemic side effects</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Intradermal</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Intramuscular</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fever</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Myalgia</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3/32</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5/62</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fatigue</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10/32</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14/62</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Headache</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8/32</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12/62</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="7" valign="top"> <p><a href="./references#CD011780-bbs2-0013" title='TroyS . Regarding your paper "Comparison of the Immunogenicity of Various Booster Doses of Inactivated Polio Vaccine Delivered Intradermally Versus Intramuscularly to HIV‐Infected Adults" [personal communication]. Email to: A Agarwal 06 May 2016. TroySB , KouiavskaiaD , SiikJ , KochbaE , BeydounH , MirochnitchenkoO , et al. Comparison of the immunogenicity of various booster doses of inactivated polio vaccine delivered intradermally versus intramuscularly to HIV‐infected adults. Journal of Infectious Diseases2015;211(12):1969‐76. [DOI: 10.1093/infdis/jiu841; PMC4539908; PUBMED: 25567841] '>Troy 2015</a> (USA) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any adverse event</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29/63</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18/64</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fever</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2/63</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/64</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rash</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/63</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4/64</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Redness at injection site</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22/63</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4/64</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Swelling at injection site</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7/63</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3/64</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tenderness at injection site</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8/63</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11/64</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Itching at injection site</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4/63</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/64</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>ID: identifier</p> </div> </div> <section id="CD011780-sec-0096"> <h6 class="title">Single‐study results</h6> <p>The most commonly recorded adverse events were pain, redness, fever, and induration in eight studies with 4312 participants (<a href="./references#CD011780-bbs2-0002" title="Cadorna‐CarlosJ , VidorE , BonnetMC . Randomized controlled study of fractional doses of inactivated poliovirus vaccine administered intradermally with a needle in the Philippines. International Journal of Infectious Diseases2012;16(2):e110‐6. [DOI: 10.1016/j.ijid.2011.10.002; PUBMED: 22153001] ">Cadorna‐Carlos 2012</a>; <a href="./references#CD011780-bbs2-0003" title="ClarkeE , SaiduY , AdetifaJU , AdigwemeI , HydaraMB , BashorunAO , et al. Safety and immunogenicity of inactivated poliovirus vaccine when given with measles–rubella combined vaccine and yellow fever vaccine and when given via different administration routes: a phase 4, randomised, non‐inferiority trial in The Gambia. Lancet. Global Health2016;4(8):e534‐47. [DOI: 10.1016/S2214‐109X(16)30075‐4; PUBMED: 27364568] NCT01847872 . IPV clinical trial ‐ The Gambia (IPV) [A phase 4, randomized trial to assess the safety and immunogenicity of inactivated poliovirus vaccine when given concomitantly with measles and rubella combined vaccine and yellow fever vaccine at nine months and when administered via different vaccination routes]. clinicaltrials.gov/ct2/show/NCT01847872 (first received 19 April 2013). ">Clarke 2016</a>; <a href="./references#CD011780-bbs2-0007" title="ResikS , TejedaA , LagoPM , DiazM , CarmenatesA , SarmientoL , et al. Randomized controlled clinical trial of fractional doses of inactivated poliovirus vaccine administered intradermally by needle‐free device in Cuba. Journal of Infectious Diseases2010;201(9):1344‐52. [DOI: 10.1086/651611; PUBMED: 20350164] ">Resik 2010</a>; <a href="./references#CD011780-bbs2-0008" title='ResikS , TejedaA , SutterRW , DiazM , SarmientoL , AlemañiN , et al. Priming after a fractional dose of inactivated poliovirus vaccine. New England Journal of Medicine2013;368(5):416‐24. [DOI: 10.1056/NEJMoa1202541; PUBMED: 23363495] SutterRW . Regarding your published paper about "Priming after a Fractional Dose of Inactivated Poliovirus Vaccine" published in NEJM 2013 [personal communication]. Email to: KK Thumburu 04 February 2016. '>Resik 2013</a>; <a href="./references#CD011780-bbs2-0009" title="ResikS , TejedaA , MachO , FonsecaM , DiazM , AlemanyN , et al. Immune responses after fractional doses of inactivated poliovirus vaccine using newly developed intradermal jet injectors: a randomized controlled trial in Cuba. Vaccine2015;33(2):307‐13. [DOI: 10.1016/j.vaccine.2014.11.025; PUBMED: 25448109] ">Resik 2015</a>; <a href="./references#CD011780-bbs2-0011" title="SoonawalaD , VerdijkP , Wijmenga‐MonsuurAJ , BoogCJ , KoedamP , VisserLG , et al. Intradermal fractional booster dose of inactivated poliomyelitis vaccine with a jet injector in healthy adults. Vaccine2013;31(36):3688‐94. [DOI: 10.1016/j.vaccine.2013.05.104; PUBMED: 23770332] ">Soonawala 2013</a>; <a href="./references#CD011780-bbs2-0012" title="Tejeda FuentesA , DeArmas LópezJ , Silva SosaM , Alemañy BuenoN , Carmenate GarcíaA , García GonzálezG , et al. Reactogenicity associated to the intradermally administered inactivated poliovirus vaccine with a needle‐free injector [Reactogenicidad asociada a la vacuna de poliovirus inactivada administrada por vía intradérmica con un inyector sin aguja]. Revista Cubana de Medicina Tropical2011;63(1):38‐43. [PUBMED: 23437535] ">Tejeda Fuentes 2011</a>; <a href="./references#CD011780-bbs2-0013" title='TroyS . Regarding your paper "Comparison of the Immunogenicity of Various Booster Doses of Inactivated Polio Vaccine Delivered Intradermally Versus Intramuscularly to HIV‐Infected Adults" [personal communication]. Email to: A Agarwal 06 May 2016. TroySB , KouiavskaiaD , SiikJ , KochbaE , BeydounH , MirochnitchenkoO , et al. Comparison of the immunogenicity of various booster doses of inactivated polio vaccine delivered intradermally versus intramuscularly to HIV‐infected adults. Journal of Infectious Diseases2015;211(12):1969‐76. [DOI: 10.1093/infdis/jiu841; PMC4539908; PUBMED: 25567841] '>Troy 2015</a>). </p> <p>There were equal numbers of participants with local and systemic adverse events in both the intradermal and intramuscular groups in seven studies (3217 participants) in children, <a href="./references#CD011780-bbs2-0002" title="Cadorna‐CarlosJ , VidorE , BonnetMC . Randomized controlled study of fractional doses of inactivated poliovirus vaccine administered intradermally with a needle in the Philippines. International Journal of Infectious Diseases2012;16(2):e110‐6. [DOI: 10.1016/j.ijid.2011.10.002; PUBMED: 22153001] ">Cadorna‐Carlos 2012</a>; <a href="./references#CD011780-bbs2-0007" title="ResikS , TejedaA , LagoPM , DiazM , CarmenatesA , SarmientoL , et al. Randomized controlled clinical trial of fractional doses of inactivated poliovirus vaccine administered intradermally by needle‐free device in Cuba. Journal of Infectious Diseases2010;201(9):1344‐52. [DOI: 10.1086/651611; PUBMED: 20350164] ">Resik 2010</a>; <a href="./references#CD011780-bbs2-0008" title='ResikS , TejedaA , SutterRW , DiazM , SarmientoL , AlemañiN , et al. Priming after a fractional dose of inactivated poliovirus vaccine. New England Journal of Medicine2013;368(5):416‐24. [DOI: 10.1056/NEJMoa1202541; PUBMED: 23363495] SutterRW . Regarding your published paper about "Priming after a Fractional Dose of Inactivated Poliovirus Vaccine" published in NEJM 2013 [personal communication]. Email to: KK Thumburu 04 February 2016. '>Resik 2013</a>; <a href="./references#CD011780-bbs2-0009" title="ResikS , TejedaA , MachO , FonsecaM , DiazM , AlemanyN , et al. Immune responses after fractional doses of inactivated poliovirus vaccine using newly developed intradermal jet injectors: a randomized controlled trial in Cuba. Vaccine2015;33(2):307‐13. [DOI: 10.1016/j.vaccine.2014.11.025; PUBMED: 25448109] ">Resik 2015</a>; <a href="./references#CD011780-bbs2-0010" title="ResikS , TejedaA , DiazM , OkayasuH , SeinC , MolodeckyNA , et al. Boosting immune responses following fractional‐dose inactivated poliovirus vaccine: a randomized, controlled trial. Journal of Infectious Diseases2017;215(2):175‐82. [DOI: 10.1093/infdis/jiw492; PUBMED: 28073858] ">Resik 2017</a>; <a href="./references#CD011780-bbs2-0012" title="Tejeda FuentesA , DeArmas LópezJ , Silva SosaM , Alemañy BuenoN , Carmenate GarcíaA , García GonzálezG , et al. Reactogenicity associated to the intradermally administered inactivated poliovirus vaccine with a needle‐free injector [Reactogenicidad asociada a la vacuna de poliovirus inactivada administrada por vía intradérmica con un inyector sin aguja]. Revista Cubana de Medicina Tropical2011;63(1):38‐43. [PUBMED: 23437535] ">Tejeda Fuentes 2011</a>; <a href="./references#CD011780-bbs2-0013" title='TroyS . Regarding your paper "Comparison of the Immunogenicity of Various Booster Doses of Inactivated Polio Vaccine Delivered Intradermally Versus Intramuscularly to HIV‐Infected Adults" [personal communication]. Email to: A Agarwal 06 May 2016. TroySB , KouiavskaiaD , SiikJ , KochbaE , BeydounH , MirochnitchenkoO , et al. Comparison of the immunogenicity of various booster doses of inactivated polio vaccine delivered intradermally versus intramuscularly to HIV‐infected adults. Journal of Infectious Diseases2015;211(12):1969‐76. [DOI: 10.1093/infdis/jiu841; PMC4539908; PUBMED: 25567841] '>Troy 2015</a>, and three studies (659 participants) in adults, <a href="./references#CD011780-bbs2-0010" title="ResikS , TejedaA , DiazM , OkayasuH , SeinC , MolodeckyNA , et al. Boosting immune responses following fractional‐dose inactivated poliovirus vaccine: a randomized, controlled trial. Journal of Infectious Diseases2017;215(2):175‐82. [DOI: 10.1093/infdis/jiw492; PUBMED: 28073858] ">Resik 2017</a>; <a href="./references#CD011780-bbs2-0011" title="SoonawalaD , VerdijkP , Wijmenga‐MonsuurAJ , BoogCJ , KoedamP , VisserLG , et al. Intradermal fractional booster dose of inactivated poliomyelitis vaccine with a jet injector in healthy adults. Vaccine2013;31(36):3688‐94. [DOI: 10.1016/j.vaccine.2013.05.104; PUBMED: 23770332] ">Soonawala 2013</a>; <a href="./references#CD011780-bbs2-0013" title='TroyS . Regarding your paper "Comparison of the Immunogenicity of Various Booster Doses of Inactivated Polio Vaccine Delivered Intradermally Versus Intramuscularly to HIV‐Infected Adults" [personal communication]. Email to: A Agarwal 06 May 2016. TroySB , KouiavskaiaD , SiikJ , KochbaE , BeydounH , MirochnitchenkoO , et al. Comparison of the immunogenicity of various booster doses of inactivated polio vaccine delivered intradermally versus intramuscularly to HIV‐infected adults. Journal of Infectious Diseases2015;211(12):1969‐76. [DOI: 10.1093/infdis/jiu841; PMC4539908; PUBMED: 25567841] '>Troy 2015</a>. </p> <p>Two studies did not report adverse events (<a href="./references#CD011780-bbs2-0004" title='EstívarezCF . Details regarding your published paper about "Immunogenicity of supplemental doses of poliovirus vaccine for children aged 6‐9 months in Moradabad, India: a community‐based, randomised controlled trial. Lancet 2012 [personal communication]. Email to: KK Thumburu 11 March 2016. EstívarizCF , JafariH , SutterRW , JohnTJ , JainV , AgarwalA , et al. Immunogenicity of supplemental doses of poliovirus vaccine for children aged 6‐9 months in Moradabad, India: a community‐based, randomised controlled trial. Lancet. Infectious Diseases2012;12(2):128‐35. [DOI: 10.1016/S1473‐3099(11)70190‐6; PUBMED: 22071249] '>Estívariz 2012</a>; <a href="./references#CD011780-bbs2-0005" title="ACTRN12616000124437p . Comparison of boosting of mucosal immunity after full and fractional dose of inactivated poliovirus vaccine, clinical trial in children in Sri Lanka, 2016 [Comparison of boosting of mucosal immunity after full and fractional dose of inactivated poliovirus vaccine, a randomized clinical trial in 300 children aged 10‐12 years of age living in Kalutara district of Sri Lanka, 2016]. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=369725 (first received 3 December 2015). GamageD , MachO , PalihawadanaP , ZhangY , WeldonWC , ObersteMS , et al. Boosting of mucosal immunity after fractional‐dose inactivated poliovirus vaccine. Journal of Infectious Diseases2018;218(12):1876‐82. [DOI: 10.1093/infdis/jiy389; PUBMED: 29982532] ">Gamage 2018</a>). </p> </section> <section id="CD011780-sec-0097"> <h6 class="title">Adverse event: children</h6> <p>Five studies (1888 participants) reported adverse events at all doses in children (<a href="./references#CD011780-bbs2-0002" title="Cadorna‐CarlosJ , VidorE , BonnetMC . Randomized controlled study of fractional doses of inactivated poliovirus vaccine administered intradermally with a needle in the Philippines. International Journal of Infectious Diseases2012;16(2):e110‐6. [DOI: 10.1016/j.ijid.2011.10.002; PUBMED: 22153001] ">Cadorna‐Carlos 2012</a>; <a href="./references#CD011780-bbs2-0006" title="MohammedAJ , AlAwaidyS , BawikarS , KurupPJ , ElamirE , ShabanMMA , et al. Fractional doses of inactivated poliovirus vaccine in Oman. New England Journal of Medicine2010;362(25):2351‐9. [DOI: 10.1056/NEJMoa0909383; PUBMED: 20573923] ">Mohammed 2010</a>; <a href="./references#CD011780-bbs2-0007" title="ResikS , TejedaA , LagoPM , DiazM , CarmenatesA , SarmientoL , et al. Randomized controlled clinical trial of fractional doses of inactivated poliovirus vaccine administered intradermally by needle‐free device in Cuba. Journal of Infectious Diseases2010;201(9):1344‐52. [DOI: 10.1086/651611; PUBMED: 20350164] ">Resik 2010</a>; <a href="./references#CD011780-bbs2-0008" title='ResikS , TejedaA , SutterRW , DiazM , SarmientoL , AlemañiN , et al. Priming after a fractional dose of inactivated poliovirus vaccine. New England Journal of Medicine2013;368(5):416‐24. [DOI: 10.1056/NEJMoa1202541; PUBMED: 23363495] SutterRW . Regarding your published paper about "Priming after a Fractional Dose of Inactivated Poliovirus Vaccine" published in NEJM 2013 [personal communication]. Email to: KK Thumburu 04 February 2016. '>Resik 2013</a>; <a href="./references#CD011780-bbs2-0012" title="Tejeda FuentesA , DeArmas LópezJ , Silva SosaM , Alemañy BuenoN , Carmenate GarcíaA , García GonzálezG , et al. Reactogenicity associated to the intradermally administered inactivated poliovirus vaccine with a needle‐free injector [Reactogenicidad asociada a la vacuna de poliovirus inactivada administrada por vía intradérmica con un inyector sin aguja]. Revista Cubana de Medicina Tropical2011;63(1):38‐43. [PUBMED: 23437535] ">Tejeda Fuentes 2011</a>). Two studies (2233 participants) reported adverse events with a single primary dose (<a href="./references#CD011780-bbs2-0003" title="ClarkeE , SaiduY , AdetifaJU , AdigwemeI , HydaraMB , BashorunAO , et al. Safety and immunogenicity of inactivated poliovirus vaccine when given with measles–rubella combined vaccine and yellow fever vaccine and when given via different administration routes: a phase 4, randomised, non‐inferiority trial in The Gambia. Lancet. Global Health2016;4(8):e534‐47. [DOI: 10.1016/S2214‐109X(16)30075‐4; PUBMED: 27364568] NCT01847872 . IPV clinical trial ‐ The Gambia (IPV) [A phase 4, randomized trial to assess the safety and immunogenicity of inactivated poliovirus vaccine when given concomitantly with measles and rubella combined vaccine and yellow fever vaccine at nine months and when administered via different vaccination routes]. clinicaltrials.gov/ct2/show/NCT01847872 (first received 19 April 2013). ">Clarke 2016</a>; <a href="./references#CD011780-bbs2-0009" title="ResikS , TejedaA , MachO , FonsecaM , DiazM , AlemanyN , et al. Immune responses after fractional doses of inactivated poliovirus vaccine using newly developed intradermal jet injectors: a randomized controlled trial in Cuba. Vaccine2015;33(2):307‐13. [DOI: 10.1016/j.vaccine.2014.11.025; PUBMED: 25448109] ">Resik 2015</a>). The most commonly recorded adverse events were redness, tenderness, erythema, and fever. </p> <p>Five studies (2217 participants) reported more adverse events in the intradermal group than the intramuscular group (<a href="./references#CD011780-bbs2-0002" title="Cadorna‐CarlosJ , VidorE , BonnetMC . Randomized controlled study of fractional doses of inactivated poliovirus vaccine administered intradermally with a needle in the Philippines. International Journal of Infectious Diseases2012;16(2):e110‐6. [DOI: 10.1016/j.ijid.2011.10.002; PUBMED: 22153001] ">Cadorna‐Carlos 2012</a>; <a href="./references#CD011780-bbs2-0007" title="ResikS , TejedaA , LagoPM , DiazM , CarmenatesA , SarmientoL , et al. Randomized controlled clinical trial of fractional doses of inactivated poliovirus vaccine administered intradermally by needle‐free device in Cuba. Journal of Infectious Diseases2010;201(9):1344‐52. [DOI: 10.1086/651611; PUBMED: 20350164] ">Resik 2010</a>; <a href="./references#CD011780-bbs2-0008" title='ResikS , TejedaA , SutterRW , DiazM , SarmientoL , AlemañiN , et al. Priming after a fractional dose of inactivated poliovirus vaccine. New England Journal of Medicine2013;368(5):416‐24. [DOI: 10.1056/NEJMoa1202541; PUBMED: 23363495] SutterRW . Regarding your published paper about "Priming after a Fractional Dose of Inactivated Poliovirus Vaccine" published in NEJM 2013 [personal communication]. Email to: KK Thumburu 04 February 2016. '>Resik 2013</a>; <a href="./references#CD011780-bbs2-0009" title="ResikS , TejedaA , MachO , FonsecaM , DiazM , AlemanyN , et al. Immune responses after fractional doses of inactivated poliovirus vaccine using newly developed intradermal jet injectors: a randomized controlled trial in Cuba. Vaccine2015;33(2):307‐13. [DOI: 10.1016/j.vaccine.2014.11.025; PUBMED: 25448109] ">Resik 2015</a>; <a href="./references#CD011780-bbs2-0012" title="Tejeda FuentesA , DeArmas LópezJ , Silva SosaM , Alemañy BuenoN , Carmenate GarcíaA , García GonzálezG , et al. Reactogenicity associated to the intradermally administered inactivated poliovirus vaccine with a needle‐free injector [Reactogenicidad asociada a la vacuna de poliovirus inactivada administrada por vía intradérmica con un inyector sin aguja]. Revista Cubana de Medicina Tropical2011;63(1):38‐43. [PUBMED: 23437535] ">Tejeda Fuentes 2011</a>). In three of these studies, there were almost equal numbers of participants with local and systemic adverse events in both the intradermal and intramuscular groups (<a href="./references#CD011780-bbs2-0002" title="Cadorna‐CarlosJ , VidorE , BonnetMC . Randomized controlled study of fractional doses of inactivated poliovirus vaccine administered intradermally with a needle in the Philippines. International Journal of Infectious Diseases2012;16(2):e110‐6. [DOI: 10.1016/j.ijid.2011.10.002; PUBMED: 22153001] ">Cadorna‐Carlos 2012</a>; <a href="./references#CD011780-bbs2-0007" title="ResikS , TejedaA , LagoPM , DiazM , CarmenatesA , SarmientoL , et al. Randomized controlled clinical trial of fractional doses of inactivated poliovirus vaccine administered intradermally by needle‐free device in Cuba. Journal of Infectious Diseases2010;201(9):1344‐52. [DOI: 10.1086/651611; PUBMED: 20350164] ">Resik 2010</a>; <a href="./references#CD011780-bbs2-0008" title='ResikS , TejedaA , SutterRW , DiazM , SarmientoL , AlemañiN , et al. Priming after a fractional dose of inactivated poliovirus vaccine. New England Journal of Medicine2013;368(5):416‐24. [DOI: 10.1056/NEJMoa1202541; PUBMED: 23363495] SutterRW . Regarding your published paper about "Priming after a Fractional Dose of Inactivated Poliovirus Vaccine" published in NEJM 2013 [personal communication]. Email to: KK Thumburu 04 February 2016. '>Resik 2013</a>). One study, <a href="./references#CD011780-bbs2-0006" title="MohammedAJ , AlAwaidyS , BawikarS , KurupPJ , ElamirE , ShabanMMA , et al. Fractional doses of inactivated poliovirus vaccine in Oman. New England Journal of Medicine2010;362(25):2351‐9. [DOI: 10.1056/NEJMoa0909383; PUBMED: 20573923] ">Mohammed 2010</a>, reported 42 adverse events in total, 24 in the intramuscular group and 18 in the intradermal group. Another study, <a href="./references#CD011780-bbs2-0003" title="ClarkeE , SaiduY , AdetifaJU , AdigwemeI , HydaraMB , BashorunAO , et al. Safety and immunogenicity of inactivated poliovirus vaccine when given with measles–rubella combined vaccine and yellow fever vaccine and when given via different administration routes: a phase 4, randomised, non‐inferiority trial in The Gambia. Lancet. Global Health2016;4(8):e534‐47. [DOI: 10.1016/S2214‐109X(16)30075‐4; PUBMED: 27364568] NCT01847872 . IPV clinical trial ‐ The Gambia (IPV) [A phase 4, randomized trial to assess the safety and immunogenicity of inactivated poliovirus vaccine when given concomitantly with measles and rubella combined vaccine and yellow fever vaccine at nine months and when administered via different vaccination routes]. clinicaltrials.gov/ct2/show/NCT01847872 (first received 19 April 2013). ">Clarke 2016</a>, also reported more adverse events in the intramuscular group (n = 7) compared with the intradermal group (n = 5). </p> <p>See <a href="./full#CD011780-tbl-0002">Table 1</a>. </p> </section> <section id="CD011780-sec-0098"> <h6 class="title">Adverse event: adults</h6> <p>Three studies with 659 adult participants reported an approximately equal number of participants with adverse events in both the intradermal and intramuscular groups (<a href="./references#CD011780-bbs2-0010" title="ResikS , TejedaA , DiazM , OkayasuH , SeinC , MolodeckyNA , et al. Boosting immune responses following fractional‐dose inactivated poliovirus vaccine: a randomized, controlled trial. Journal of Infectious Diseases2017;215(2):175‐82. [DOI: 10.1093/infdis/jiw492; PUBMED: 28073858] ">Resik 2017</a>; <a href="./references#CD011780-bbs2-0011" title="SoonawalaD , VerdijkP , Wijmenga‐MonsuurAJ , BoogCJ , KoedamP , VisserLG , et al. Intradermal fractional booster dose of inactivated poliomyelitis vaccine with a jet injector in healthy adults. Vaccine2013;31(36):3688‐94. [DOI: 10.1016/j.vaccine.2013.05.104; PUBMED: 23770332] ">Soonawala 2013</a>; <a href="./references#CD011780-bbs2-0013" title='TroyS . Regarding your paper "Comparison of the Immunogenicity of Various Booster Doses of Inactivated Polio Vaccine Delivered Intradermally Versus Intramuscularly to HIV‐Infected Adults" [personal communication]. Email to: A Agarwal 06 May 2016. TroySB , KouiavskaiaD , SiikJ , KochbaE , BeydounH , MirochnitchenkoO , et al. Comparison of the immunogenicity of various booster doses of inactivated polio vaccine delivered intradermally versus intramuscularly to HIV‐infected adults. Journal of Infectious Diseases2015;211(12):1969‐76. [DOI: 10.1093/infdis/jiu841; PMC4539908; PUBMED: 25567841] '>Troy 2015</a>). In one study, rash and tenderness at the injection site were reported more frequently in the intradermal group (<a href="./references#CD011780-bbs2-0013" title='TroyS . Regarding your paper "Comparison of the Immunogenicity of Various Booster Doses of Inactivated Polio Vaccine Delivered Intradermally Versus Intramuscularly to HIV‐Infected Adults" [personal communication]. Email to: A Agarwal 06 May 2016. TroySB , KouiavskaiaD , SiikJ , KochbaE , BeydounH , MirochnitchenkoO , et al. Comparison of the immunogenicity of various booster doses of inactivated polio vaccine delivered intradermally versus intramuscularly to HIV‐infected adults. Journal of Infectious Diseases2015;211(12):1969‐76. [DOI: 10.1093/infdis/jiu841; PMC4539908; PUBMED: 25567841] '>Troy 2015</a>), whilst in another study, stiffness and soreness at the injection site were reported more frequently in the intradermal group (<a href="./references#CD011780-bbs2-0011" title="SoonawalaD , VerdijkP , Wijmenga‐MonsuurAJ , BoogCJ , KoedamP , VisserLG , et al. Intradermal fractional booster dose of inactivated poliomyelitis vaccine with a jet injector in healthy adults. Vaccine2013;31(36):3688‐94. [DOI: 10.1016/j.vaccine.2013.05.104; PUBMED: 23770332] ">Soonawala 2013</a>). </p> <p>See <a href="#CD011780-tbl-0005">Table 4</a>. </p> </section> </section> </section> <section id="CD011780-sec-0099"> <h4 class="title">Secondary outcomes</h4> <section id="CD011780-sec-0100"> <h5 class="title">Reciprocal antibody titres</h5> <p>Three studies in children reported data on reciprocal antibody titres as seroprevalence/seroprotection rates (<a href="./references#CD011780-bbs2-0002" title="Cadorna‐CarlosJ , VidorE , BonnetMC . Randomized controlled study of fractional doses of inactivated poliovirus vaccine administered intradermally with a needle in the Philippines. International Journal of Infectious Diseases2012;16(2):e110‐6. [DOI: 10.1016/j.ijid.2011.10.002; PUBMED: 22153001] ">Cadorna‐Carlos 2012</a>; <a href="./references#CD011780-bbs2-0003" title="ClarkeE , SaiduY , AdetifaJU , AdigwemeI , HydaraMB , BashorunAO , et al. Safety and immunogenicity of inactivated poliovirus vaccine when given with measles–rubella combined vaccine and yellow fever vaccine and when given via different administration routes: a phase 4, randomised, non‐inferiority trial in The Gambia. Lancet. Global Health2016;4(8):e534‐47. [DOI: 10.1016/S2214‐109X(16)30075‐4; PUBMED: 27364568] NCT01847872 . IPV clinical trial ‐ The Gambia (IPV) [A phase 4, randomized trial to assess the safety and immunogenicity of inactivated poliovirus vaccine when given concomitantly with measles and rubella combined vaccine and yellow fever vaccine at nine months and when administered via different vaccination routes]. clinicaltrials.gov/ct2/show/NCT01847872 (first received 19 April 2013). ">Clarke 2016</a>; <a href="./references#CD011780-bbs2-0009" title="ResikS , TejedaA , MachO , FonsecaM , DiazM , AlemanyN , et al. Immune responses after fractional doses of inactivated poliovirus vaccine using newly developed intradermal jet injectors: a randomized controlled trial in Cuba. Vaccine2015;33(2):307‐13. [DOI: 10.1016/j.vaccine.2014.11.025; PUBMED: 25448109] ">Resik 2015</a>). <a href="./references#CD011780-fig-0022" title="">Analysis 3.1</a>, <a href="./references#CD011780-fig-0023" title="">Analysis 3.2</a>, and <a href="./references#CD011780-fig-0024" title="">Analysis 3.3</a> show the seroprotection rates for antipoliovirus antibodies types 1, 2, and 3, respectively. There was no significant difference in seroprevalence/seroprotection rates amongst children given intramuscular full‐dose IPV compared to those given intradermal fractional‐dose IPV at postintervention for type 1 poliovirus (OR 1.42, 95% CI 0.59 to 3.39; 3 studies, 1661 participants; heterogeneity: I<sup>2</sup> = 0%) or type 2 poliovirus (OR 3.10, 95% CI 0.50 to 19.44; 3 studies, 1659 participants; heterogeneity: I<sup>2</sup> = 0%). However, for type 3 poliovirus, children receiving intramuscular full‐dose IPV had better seroprotection rates (OR 2.94, 95% CI 1.44 to 6.00; 3 studies, 1659 participants; heterogeneity: I<sup>2</sup> = 0%). </p> <p>None of the studies with adult participants reported data on reciprocal antibody titres.</p> <section id="CD011780-sec-0101"> <h6 class="title">Sensitivity analysis</h6> <p>A sensitivity analysis for 'reciprocal antibody titres: seroprevalence for antipoliovirus antibodies types 1, 2, and 3' using the fixed‐effect model showed similar results (<a href="./references#CD011780-fig-0025" title="">Analysis 4.1</a>; <a href="./references#CD011780-fig-0026" title="">Analysis 4.2</a>; <a href="./references#CD011780-fig-0027" title="">Analysis 4.3</a>) to the random‐effects model (<a href="./references#CD011780-fig-0022" title="">Analysis 3.1</a>; <a href="./references#CD011780-fig-0023" title="">Analysis 3.2</a>; <a href="./references#CD011780-fig-0024" title="">Analysis 3.3</a>). </p> </section> </section> <section id="CD011780-sec-0102"> <h5 class="title">Serum immunoglobulin (IgA) levels</h5> <p>None of the included studies reported data on serum IgA levels.</p> </section> <section id="CD011780-sec-0103"> <h5 class="title">Poliovirus shedding in stool</h5> <p>Faecal shedding after OPV is a proxy of mucosal immunity, and a more frequent excretion indicates lower mucosal immunity. Two studies reported poliovirus shedding after a challenge dose of OPV and found no difference between the two vaccines (intramuscular or intradermal) (<a href="./references#CD011780-bbs2-0005" title="ACTRN12616000124437p . Comparison of boosting of mucosal immunity after full and fractional dose of inactivated poliovirus vaccine, clinical trial in children in Sri Lanka, 2016 [Comparison of boosting of mucosal immunity after full and fractional dose of inactivated poliovirus vaccine, a randomized clinical trial in 300 children aged 10‐12 years of age living in Kalutara district of Sri Lanka, 2016]. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=369725 (first received 3 December 2015). GamageD , MachO , PalihawadanaP , ZhangY , WeldonWC , ObersteMS , et al. Boosting of mucosal immunity after fractional‐dose inactivated poliovirus vaccine. Journal of Infectious Diseases2018;218(12):1876‐82. [DOI: 10.1093/infdis/jiy389; PUBMED: 29982532] ">Gamage 2018</a>; <a href="./references#CD011780-bbs2-0006" title="MohammedAJ , AlAwaidyS , BawikarS , KurupPJ , ElamirE , ShabanMMA , et al. Fractional doses of inactivated poliovirus vaccine in Oman. New England Journal of Medicine2010;362(25):2351‐9. [DOI: 10.1056/NEJMoa0909383; PUBMED: 20573923] ">Mohammed 2010</a>). We were unable to pool the data from these studies due to differences in the frequency of doses of the two IPV vaccines (intramuscular and intradermal) used. </p> <section id="CD011780-sec-0104"> <h6 class="title">Single‐study results</h6> <p><a href="./references#CD011780-bbs2-0005" title="ACTRN12616000124437p . Comparison of boosting of mucosal immunity after full and fractional dose of inactivated poliovirus vaccine, clinical trial in children in Sri Lanka, 2016 [Comparison of boosting of mucosal immunity after full and fractional dose of inactivated poliovirus vaccine, a randomized clinical trial in 300 children aged 10‐12 years of age living in Kalutara district of Sri Lanka, 2016]. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=369725 (first received 3 December 2015). GamageD , MachO , PalihawadanaP , ZhangY , WeldonWC , ObersteMS , et al. Boosting of mucosal immunity after fractional‐dose inactivated poliovirus vaccine. Journal of Infectious Diseases2018;218(12):1876‐82. [DOI: 10.1093/infdis/jiy389; PUBMED: 29982532] ">Gamage 2018</a> found no difference in poliovirus shedding after the booster dose of either of the vaccines (intramuscular or intradermal) was given to children aged 10 to 12 years old. <a href="./references#CD011780-bbs2-0006" title="MohammedAJ , AlAwaidyS , BawikarS , KurupPJ , ElamirE , ShabanMMA , et al. Fractional doses of inactivated poliovirus vaccine in Oman. New England Journal of Medicine2010;362(25):2351‐9. [DOI: 10.1056/NEJMoa0909383; PUBMED: 20573923] ">Mohammed 2010</a> also did not find a clear difference in poliovirus shedding after the primary doses of the two vaccines (intramuscular or intradermal) were given to younger children. </p> </section> </section> <section id="CD011780-sec-0105"> <h5 class="title">Vaccine‐associated paralytic poliomyelitis (VAPP)</h5> <p>None of the included studies reported data on VAPP.</p> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD011780-sec-0106" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD011780-sec-0106"></div> <section id="CD011780-sec-0107"> <h3 class="title" id="CD011780-sec-0107">Summary of main results</h3> <p>This review included 13 RCTs with 7292 participants, from low‐, middle‐, and high‐income countries, comparing intradermal fractional‐dose (one‐fifth) IPV with intramuscular full‐dose IPV. The studies involved infants and children (n = 6402) and adults (n = 890). The studies ranged from 2 to 19 months in duration. </p> <p>The studies included in this review did not report on the occurrence of paralytic poliomyelitis but did report on seroconversion rates for all three types of poliovirus. We found that seroconversion was greater in participants given intramuscular full‐dose IPV than in participants given intradermal fractional‐dose IPV; however, we considered the certainty of the evidence to be low and very low due to limitations in design (risk of bias) and indirectness, meaning that we are not confident that the estimated effect reflects the true effect. The studies also reported data on geometric median titres, which were higher in the intramuscular full‐dose IPV group than in the intradermal fractional‐dose IPV group for an equal number of primary vaccine doses. </p> <p>Three studies reported data on reciprocal antibody titres as seroprotection/seroprevalence rates. We found a significant difference in seroprotection/prevalence rates between children given intramuscular full‐dose IPV and those given intradermal fractional‐dose IPV for type 3 poliovirus in favour of intramuscular IPV. Two studies reported data on poliovirus shedding after OPV challenge dose, finding no difference between groups. No studies reported data on serum IgA levels or VAPP. </p> </section> <section id="CD011780-sec-0108"> <h3 class="title" id="CD011780-sec-0108">Overall completeness and applicability of evidence</h3> <p>The studies included in this review represent the three economic divisions of the world (i.e. low‐income, middle‐income, and high‐income countries). Furthermore, study participants comprised all relevant age groups (i.e. children and adults). The body of evidence is thus representative of the population relevant to the review question. However, the interventions used in the studies differed in the number of doses and age of administration which introduced heterogeneity in the evidence base, thereby preventing generalisation. </p> <p>The included studies did not report data on all of our planned outcomes (<a href="./references#CD011780-bbs2-0065" title="JaiswalN , SinghM , ThumburuKK , AgarwalA , KaurH . Intradermal fractional dose vs intramuscular full dose of inactivated polio vaccine for prevention of poliomyelitis. Cochrane Database of Systematic Reviews2015, Issue 6. [DOI: 10.1002/14651858.CD011780] ">Jaiswal 2015</a>). No studies recorded the incidence of paralytic poliomyelitis. Furthermore, none of the included studies evaluated the impact of intradermal fractional‐dose IPV on mucosal immunity, which was projected to be one of the major advantages of intradermal administration of the vaccine. We found two ongoing studies (<a href="./references#CD011780-bbs2-0029" title="NCT02847026 . Fractional inactivated poliovirus vaccine booster and rotavirus study (fIPV) [Immunogenicity of a booster dose of fractional inactivated poliovirus vaccine (fIPV) delivered intradermally concomitantly with rotavirus vaccines]. clinicaltrials.gov/ct2/show/NCT02847026 (first received 25 July 2016). ">NCT02847026</a>; <a href="./references#CD011780-bbs2-0030" title="NCT03016949 . A study to evaluate immunogenicity of various schedules of inactivated polio vaccine [A phase 3, open‐label, randomized trial to evaluate humoral immunogenicity of various schedules of intramuscular full dose and intradermal fractional dose of inactivated polio vaccine in infants]. clinicaltrials.gov/ct2/show/NCT03016949 (first received 5 January 2017). ">NCT03016949</a>), of which only one is evaluating mucosal immunity (<a href="./references#CD011780-bbs2-0029" title="NCT02847026 . Fractional inactivated poliovirus vaccine booster and rotavirus study (fIPV) [Immunogenicity of a booster dose of fractional inactivated poliovirus vaccine (fIPV) delivered intradermally concomitantly with rotavirus vaccines]. clinicaltrials.gov/ct2/show/NCT02847026 (first received 25 July 2016). ">NCT02847026</a>). The results of these studies are much anticipated. </p> <p>The available evidence does not provide any information about the skill and accuracy of those involved in injecting vaccines, and no comparison of the costs involved in developing such skills is available. The lack of information about the costs involved could indirectly affect the applicability of the evidence. In the current review, the reported outcomes also differed across studies, hence a meta‐analysis was not always possible for all outcomes. A narrative synthesis of evidence also has applicability issues. </p> <p>We combined the data on seroconversion rates in meta‐analyses and found low‐ and very low‐certainty evidence of better performance of intramuscular full‐dose IPV compared to intradermal fractional‐dose IPV. During the course of this review, the WHO recommended two doses of fractional intradermal IPV over one full dose of intramuscular IPV (<a href="./references#CD011780-bbs2-0062" title="World Health Organization. Polio vaccines: WHO position paper ‐ March, 2016. Weekly Epidemiological Record2016;91(12):145‐68. [www.who.int/wer/2016/wer9112/en/] ">WHO 2016</a>). The current review was not designed for such analysis. However, this analysis can be incorporated in future updates, since more studies may follow the WHO recommendation. </p> </section> <section id="CD011780-sec-0109"> <h3 class="title" id="CD011780-sec-0109">Quality of the evidence</h3> <p>Using the GRADE approach (<a href="./references#CD011780-bbs2-0058" title="SchünemannHJ , OxmanAD , VistGE , HigginsJPT , DeeksJJ , GlasziouP , et al. on behalf of the Cochrane Applicability and Recommendations Methods Group. Chapter 12: Interpreting results and drawing conclusions. In: Higgins JPT, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Schünemann 2011</a>), we assessed the certainty of the evidence as low and very low for seroconversion rates, as shown in <a href="./full#CD011780-tbl-0001">summary of findings Table for the main comparison</a>. We downgraded the certainty of the evidence due to serious risk of bias and indirectness, which means that we are not confident that the estimated effect of a full dose of IPV given intramuscularly compared to the same frequency of a fractional dose of IPV given intradermally on seroconversion rates is the true effect. Although we were unable to pool the data on geometric mean antibody titres in a meta‐analysis, we have provided a narrative synthesis and rated the certainty of the evidence for this outcome as very low due to limitations in study design, indirectness in the evidence, and the heterogenous nature of the studies (<a href="./full#CD011780-tbl-0001">summary of findings Table for the main comparison</a>). We also rated the certainty of the body of evidence for vaccine‐related adverse events as very low due to indirectness, risk of bias, and heterogeneity (<a href="./full#CD011780-tbl-0001">summary of findings Table for the main comparison</a>). Although data on adverse events were not suitable for meta‐analysis, we conducted a narrative synthesis and applied the GRADE approach, which showed the evidence to be of very low certainty. None of the included studies reported data on paralytic poliomyelitis, hence we could not assess the certainty of the evidence for this outcome. </p> </section> <section id="CD011780-sec-0110"> <h3 class="title" id="CD011780-sec-0110">Potential biases in the review process</h3> <p>We were not able to assess publication bias due to the small number of included studies. In addition, we were unable to pool the data for most outcomes in a meta‐analysis and have therefore provided a narrative, and thus somewhat subjective, synthesis. </p> <p>It was challenging to extract the data from one study, <a href="./references#CD011780-bbs2-0012" title="Tejeda FuentesA , DeArmas LópezJ , Silva SosaM , Alemañy BuenoN , Carmenate GarcíaA , García GonzálezG , et al. Reactogenicity associated to the intradermally administered inactivated poliovirus vaccine with a needle‐free injector [Reactogenicidad asociada a la vacuna de poliovirus inactivada administrada por vía intradérmica con un inyector sin aguja]. Revista Cubana de Medicina Tropical2011;63(1):38‐43. [PUBMED: 23437535] ">Tejeda Fuentes 2011</a>, as it was written in Spanish. </p> </section> <section id="CD011780-sec-0111"> <h3 class="title" id="CD011780-sec-0111">Agreements and disagreements with other studies or reviews</h3> <p>This review compared intradermal and intramuscular routes of administration for IPV. A previous literature review, <a href="./references#CD011780-bbs2-0053" title="NelsonKS , JanssenJM , TroySB , MaldonadoY . Intradermal fractional dose inactivated polio vaccine: a review of the literature. Vaccine2012;30(2):121‐5. [DOI: 10.1016/j.vaccine.2011.11.018; PUBMED: 22100886] ">Nelson 2012</a>, also discussed intradermal IPV but did not compare it with the intramuscular route of administration. Another review, <a href="./references#CD011780-bbs2-0031" title="AnandA , MolodeckyNA , PallanschMA , SutterRW . Immunogenicity to poliovirus type 2 following two doses of fractional intradermal inactivated poliovirus vaccine: a novel dose sparing immunization schedule. Vaccine2017;35(22):2993‐8. [DOI: 10.1016/j.vaccine.2017.03.008; PUBMED: 28434691] ">Anand 2017</a>, compared two fractional doses with one full dose of IPV and found better immunogenicity with two doses of fractional IPV given intradermally. The current systematic review compared doses, in similar frequencies, of both fractional‐dose intradermal IPV and full‐dose intramuscular IPV, whereas the review by Anand and colleagues compared cumulative responses after two primary doses of fractional‐dose IPV with singular responses after the first primary dose of intramuscular IPV. <a href="./references#CD011780-bbs2-0031" title="AnandA , MolodeckyNA , PallanschMA , SutterRW . Immunogenicity to poliovirus type 2 following two doses of fractional intradermal inactivated poliovirus vaccine: a novel dose sparing immunization schedule. Vaccine2017;35(22):2993‐8. [DOI: 10.1016/j.vaccine.2017.03.008; PUBMED: 28434691] ">Anand 2017</a> had based the inferences on the post hoc analysis of four studies and found results favouring fractional‐dose IPV, whereas the current review, which was based on 13 studies, found better seroconversion rates in children receiving full‐dose intramuscular IPV compared to children receiving doses of intradermal IPV in equivalent schedules. WHO SAGE currently recommends two doses of fractional‐dose IPV intradermally over one full dose of intramuscular IPV (<a href="./references#CD011780-bbs2-0039" title="Global Polio EradicationInitiative . Use of fractional dose IPV in routine immunization programmes: considerations for decision‐making. www.who.int/immunization/diseases/poliomyelitis/endgame_objective2/inactivated_polio_vaccine/fIPV_considerations_for_decision‐making_April2017.pdf (assessed 10 October 2017). ">GPEI 2017</a>; <a href="./references#CD011780-bbs2-0062" title="World Health Organization. Polio vaccines: WHO position paper ‐ March, 2016. Weekly Epidemiological Record2016;91(12):145‐68. [www.who.int/wer/2016/wer9112/en/] ">WHO 2016</a>). We have not compared the effects of different dosing schedules in this review as the WHO recommendations were available only after the protocol for this review was published. However, this analysis can be incorporated in future updates of this review, since more studies may follow the WHO recommendation. </p> <p>The current review found no evidence comparing mucosal immunity between the two vaccines. However, another review comparing OPV and IPV found that OPV‐primed participants receiving IPV boosters had better mucosal immune responses (<a href="./references#CD011780-bbs2-0056" title="ParkerEP , MolodeckyNA , Pons‐SalortM , O'ReillyKM , GrasslyNC . Impact of inactivated poliovirus vaccine on mucosal immunity: implications for the polio eradication endgame. Expert Review of Vaccines2015;14(8):1113‐23. [DOI: 10.1586/14760584.2015.1052800; PMC4673562; PUBMED: 26159938] ">Parker 2015</a>). The authors of a narrative review, <a href="./references#CD011780-bbs2-0054" title="OkayasuH , SeinC , Chang BlancD , GonzalezAR , ZehrungD , JarrahianC , et al. Intradermal administration of fractional doses of inactivated poliovirus vaccine: a dose‐sparing option for polio immunization. Journal of Infectious Diseases2017;216(Suppl 1):S161‐7. [DOI: 10.1093/infdis/jix038; PMC5853966; PUBMED: 28838185] ">Okayasu 2017</a>, commented on the immune responses by the two routes and found that fractional‐dose IPV was not superior. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD011780-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011780.pub2/media/CDSR/CD011780/urn:x-wiley:14651858:media:CD011780:CD011780-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011780.pub2/media/CDSR/CD011780/image_t/tCD011780-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Study flow (PRISMA) diagram." data-id="CD011780-fig-0001" src="/cdsr/doi/10.1002/14651858.CD011780.pub2/media/CDSR/CD011780/image_n/nCD011780-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow (PRISMA) diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011780.pub2/full#CD011780-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011780.pub2/media/CDSR/CD011780/image_n/nCD011780-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011780-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011780.pub2/media/CDSR/CD011780/urn:x-wiley:14651858:media:CD011780:CD011780-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011780.pub2/media/CDSR/CD011780/image_t/tCD011780-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each 'Risk of bias' item for each included study." data-id="CD011780-fig-0002" src="/cdsr/doi/10.1002/14651858.CD011780.pub2/media/CDSR/CD011780/image_n/nCD011780-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each 'Risk of bias' item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011780.pub2/full#CD011780-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011780.pub2/media/CDSR/CD011780/image_n/nCD011780-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011780-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011780.pub2/media/CDSR/CD011780/urn:x-wiley:14651858:media:CD011780:CD011780-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011780.pub2/media/CDSR/CD011780/image_t/tCD011780-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph: review authors' judgements about each 'Risk of bias' item presented as percentages across all included studies." data-id="CD011780-fig-0003" src="/cdsr/doi/10.1002/14651858.CD011780.pub2/media/CDSR/CD011780/image_n/nCD011780-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each 'Risk of bias' item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011780.pub2/full#CD011780-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011780.pub2/media/CDSR/CD011780/image_n/nCD011780-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011780-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011780.pub2/media/CDSR/CD011780/urn:x-wiley:14651858:media:CD011780:CD011780-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011780.pub2/media/CDSR/CD011780/image_t/tCD011780-CMP-001-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Intradermal fractional‐dose IPV versus intramuscular IPV: children (random‐effects model) (primary outcome), Outcome 1 Seroconversion rate after a single primary dose: type 1 poliovirus." data-id="CD011780-fig-0004" src="/cdsr/doi/10.1002/14651858.CD011780.pub2/media/CDSR/CD011780/image_n/nCD011780-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 Intradermal fractional‐dose IPV versus intramuscular IPV: children (random‐effects model) (primary outcome), Outcome 1 Seroconversion rate after a single primary dose: type 1 poliovirus. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011780.pub2/references#CD011780-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011780.pub2/media/CDSR/CD011780/image_n/nCD011780-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011780-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011780.pub2/media/CDSR/CD011780/urn:x-wiley:14651858:media:CD011780:CD011780-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011780.pub2/media/CDSR/CD011780/image_t/tCD011780-CMP-001-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Intradermal fractional‐dose IPV versus intramuscular IPV: children (random‐effects model) (primary outcome), Outcome 2 Seroconversion rate after a single primary dose: type 2 poliovirus." data-id="CD011780-fig-0005" src="/cdsr/doi/10.1002/14651858.CD011780.pub2/media/CDSR/CD011780/image_n/nCD011780-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 Intradermal fractional‐dose IPV versus intramuscular IPV: children (random‐effects model) (primary outcome), Outcome 2 Seroconversion rate after a single primary dose: type 2 poliovirus. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011780.pub2/references#CD011780-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011780.pub2/media/CDSR/CD011780/image_n/nCD011780-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011780-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011780.pub2/media/CDSR/CD011780/urn:x-wiley:14651858:media:CD011780:CD011780-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011780.pub2/media/CDSR/CD011780/image_t/tCD011780-CMP-001-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Intradermal fractional‐dose IPV versus intramuscular IPV: children (random‐effects model) (primary outcome), Outcome 3 Seroconversion rate after a single primary dose: type 3 poliovirus." data-id="CD011780-fig-0006" src="/cdsr/doi/10.1002/14651858.CD011780.pub2/media/CDSR/CD011780/image_n/nCD011780-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 Intradermal fractional‐dose IPV versus intramuscular IPV: children (random‐effects model) (primary outcome), Outcome 3 Seroconversion rate after a single primary dose: type 3 poliovirus. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011780.pub2/references#CD011780-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011780.pub2/media/CDSR/CD011780/image_n/nCD011780-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011780-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011780.pub2/media/CDSR/CD011780/urn:x-wiley:14651858:media:CD011780:CD011780-CMP-001-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011780.pub2/media/CDSR/CD011780/image_t/tCD011780-CMP-001-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Intradermal fractional‐dose IPV versus intramuscular IPV: children (random‐effects model) (primary outcome), Outcome 4 Seroconversion rate after 2 primary doses: type 1 poliovirus." data-id="CD011780-fig-0007" src="/cdsr/doi/10.1002/14651858.CD011780.pub2/media/CDSR/CD011780/image_n/nCD011780-CMP-001-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 Intradermal fractional‐dose IPV versus intramuscular IPV: children (random‐effects model) (primary outcome), Outcome 4 Seroconversion rate after 2 primary doses: type 1 poliovirus. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011780.pub2/references#CD011780-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011780.pub2/media/CDSR/CD011780/image_n/nCD011780-CMP-001-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011780-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011780.pub2/media/CDSR/CD011780/urn:x-wiley:14651858:media:CD011780:CD011780-CMP-001-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011780.pub2/media/CDSR/CD011780/image_t/tCD011780-CMP-001-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Intradermal fractional‐dose IPV versus intramuscular IPV: children (random‐effects model) (primary outcome), Outcome 5 Seroconversion rate after 2 primary doses: type 2 poliovirus." data-id="CD011780-fig-0008" src="/cdsr/doi/10.1002/14651858.CD011780.pub2/media/CDSR/CD011780/image_n/nCD011780-CMP-001-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1 Intradermal fractional‐dose IPV versus intramuscular IPV: children (random‐effects model) (primary outcome), Outcome 5 Seroconversion rate after 2 primary doses: type 2 poliovirus. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011780.pub2/references#CD011780-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011780.pub2/media/CDSR/CD011780/image_n/nCD011780-CMP-001-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011780-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011780.pub2/media/CDSR/CD011780/urn:x-wiley:14651858:media:CD011780:CD011780-CMP-001-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011780.pub2/media/CDSR/CD011780/image_t/tCD011780-CMP-001-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Intradermal fractional‐dose IPV versus intramuscular IPV: children (random‐effects model) (primary outcome), Outcome 6 Seroconversion rate after 2 primary doses: type 3 poliovirus." data-id="CD011780-fig-0009" src="/cdsr/doi/10.1002/14651858.CD011780.pub2/media/CDSR/CD011780/image_n/nCD011780-CMP-001-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1 Intradermal fractional‐dose IPV versus intramuscular IPV: children (random‐effects model) (primary outcome), Outcome 6 Seroconversion rate after 2 primary doses: type 3 poliovirus. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011780.pub2/references#CD011780-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011780.pub2/media/CDSR/CD011780/image_n/nCD011780-CMP-001-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011780-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011780.pub2/media/CDSR/CD011780/urn:x-wiley:14651858:media:CD011780:CD011780-CMP-001-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011780.pub2/media/CDSR/CD011780/image_t/tCD011780-CMP-001-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Intradermal fractional‐dose IPV versus intramuscular IPV: children (random‐effects model) (primary outcome), Outcome 7 Seroconversion rate after 3 primary doses: type 1 poliovirus." data-id="CD011780-fig-0010" src="/cdsr/doi/10.1002/14651858.CD011780.pub2/media/CDSR/CD011780/image_n/nCD011780-CMP-001-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1 Intradermal fractional‐dose IPV versus intramuscular IPV: children (random‐effects model) (primary outcome), Outcome 7 Seroconversion rate after 3 primary doses: type 1 poliovirus. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011780.pub2/references#CD011780-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011780.pub2/media/CDSR/CD011780/image_n/nCD011780-CMP-001-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011780-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011780.pub2/media/CDSR/CD011780/urn:x-wiley:14651858:media:CD011780:CD011780-CMP-001-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011780.pub2/media/CDSR/CD011780/image_t/tCD011780-CMP-001-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Intradermal fractional‐dose IPV versus intramuscular IPV: children (random‐effects model) (primary outcome), Outcome 8 Seroconversion rate after 3 primary doses: type 2 poliovirus." data-id="CD011780-fig-0011" src="/cdsr/doi/10.1002/14651858.CD011780.pub2/media/CDSR/CD011780/image_n/nCD011780-CMP-001-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1 Intradermal fractional‐dose IPV versus intramuscular IPV: children (random‐effects model) (primary outcome), Outcome 8 Seroconversion rate after 3 primary doses: type 2 poliovirus. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011780.pub2/references#CD011780-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011780.pub2/media/CDSR/CD011780/image_n/nCD011780-CMP-001-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011780-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011780.pub2/media/CDSR/CD011780/urn:x-wiley:14651858:media:CD011780:CD011780-CMP-001-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011780.pub2/media/CDSR/CD011780/image_t/tCD011780-CMP-001-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Intradermal fractional‐dose IPV versus intramuscular IPV: children (random‐effects model) (primary outcome), Outcome 9 Seroconversion rate after 3 primary doses: type 3 poliovirus." data-id="CD011780-fig-0012" src="/cdsr/doi/10.1002/14651858.CD011780.pub2/media/CDSR/CD011780/image_n/nCD011780-CMP-001-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.9</div> <div class="figure-caption"> <p>Comparison 1 Intradermal fractional‐dose IPV versus intramuscular IPV: children (random‐effects model) (primary outcome), Outcome 9 Seroconversion rate after 3 primary doses: type 3 poliovirus. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011780.pub2/references#CD011780-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011780.pub2/media/CDSR/CD011780/image_n/nCD011780-CMP-001-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011780-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011780.pub2/media/CDSR/CD011780/urn:x-wiley:14651858:media:CD011780:CD011780-CMP-002-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011780.pub2/media/CDSR/CD011780/image_t/tCD011780-CMP-002-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Intradermal fractional‐dose IPV versus intramuscular IPV: children (fixed‐effect model) (primary outcome), Outcome 1 Seroconversion rate after a single primary dose: type 1 poliovirus." data-id="CD011780-fig-0013" src="/cdsr/doi/10.1002/14651858.CD011780.pub2/media/CDSR/CD011780/image_n/nCD011780-CMP-002-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2 Intradermal fractional‐dose IPV versus intramuscular IPV: children (fixed‐effect model) (primary outcome), Outcome 1 Seroconversion rate after a single primary dose: type 1 poliovirus. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011780.pub2/references#CD011780-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011780.pub2/media/CDSR/CD011780/image_n/nCD011780-CMP-002-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011780-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011780.pub2/media/CDSR/CD011780/urn:x-wiley:14651858:media:CD011780:CD011780-CMP-002-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011780.pub2/media/CDSR/CD011780/image_t/tCD011780-CMP-002-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Intradermal fractional‐dose IPV versus intramuscular IPV: children (fixed‐effect model) (primary outcome), Outcome 2 Seroconversion rate after a single primary dose: type 2 poliovirus." data-id="CD011780-fig-0014" src="/cdsr/doi/10.1002/14651858.CD011780.pub2/media/CDSR/CD011780/image_n/nCD011780-CMP-002-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2 Intradermal fractional‐dose IPV versus intramuscular IPV: children (fixed‐effect model) (primary outcome), Outcome 2 Seroconversion rate after a single primary dose: type 2 poliovirus. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011780.pub2/references#CD011780-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011780.pub2/media/CDSR/CD011780/image_n/nCD011780-CMP-002-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011780-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011780.pub2/media/CDSR/CD011780/urn:x-wiley:14651858:media:CD011780:CD011780-CMP-002-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011780.pub2/media/CDSR/CD011780/image_t/tCD011780-CMP-002-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Intradermal fractional‐dose IPV versus intramuscular IPV: children (fixed‐effect model) (primary outcome), Outcome 3 Seroconversion rate after a single primary dose: type 3 poliovirus." data-id="CD011780-fig-0015" src="/cdsr/doi/10.1002/14651858.CD011780.pub2/media/CDSR/CD011780/image_n/nCD011780-CMP-002-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2 Intradermal fractional‐dose IPV versus intramuscular IPV: children (fixed‐effect model) (primary outcome), Outcome 3 Seroconversion rate after a single primary dose: type 3 poliovirus. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011780.pub2/references#CD011780-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011780.pub2/media/CDSR/CD011780/image_n/nCD011780-CMP-002-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011780-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011780.pub2/media/CDSR/CD011780/urn:x-wiley:14651858:media:CD011780:CD011780-CMP-002-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011780.pub2/media/CDSR/CD011780/image_t/tCD011780-CMP-002-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Intradermal fractional‐dose IPV versus intramuscular IPV: children (fixed‐effect model) (primary outcome), Outcome 4 Seroconversion rate after 2 primary doses: type 1 poliovirus." data-id="CD011780-fig-0016" src="/cdsr/doi/10.1002/14651858.CD011780.pub2/media/CDSR/CD011780/image_n/nCD011780-CMP-002-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2 Intradermal fractional‐dose IPV versus intramuscular IPV: children (fixed‐effect model) (primary outcome), Outcome 4 Seroconversion rate after 2 primary doses: type 1 poliovirus. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011780.pub2/references#CD011780-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011780.pub2/media/CDSR/CD011780/image_n/nCD011780-CMP-002-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011780-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011780.pub2/media/CDSR/CD011780/urn:x-wiley:14651858:media:CD011780:CD011780-CMP-002-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011780.pub2/media/CDSR/CD011780/image_t/tCD011780-CMP-002-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Intradermal fractional‐dose IPV versus intramuscular IPV: children (fixed‐effect model) (primary outcome), Outcome 5 Seroconversion rate after 2 primary doses: type 2 poliovirus." data-id="CD011780-fig-0017" src="/cdsr/doi/10.1002/14651858.CD011780.pub2/media/CDSR/CD011780/image_n/nCD011780-CMP-002-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.5</div> <div class="figure-caption"> <p>Comparison 2 Intradermal fractional‐dose IPV versus intramuscular IPV: children (fixed‐effect model) (primary outcome), Outcome 5 Seroconversion rate after 2 primary doses: type 2 poliovirus. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011780.pub2/references#CD011780-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011780.pub2/media/CDSR/CD011780/image_n/nCD011780-CMP-002-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011780-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011780.pub2/media/CDSR/CD011780/urn:x-wiley:14651858:media:CD011780:CD011780-CMP-002-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011780.pub2/media/CDSR/CD011780/image_t/tCD011780-CMP-002-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Intradermal fractional‐dose IPV versus intramuscular IPV: children (fixed‐effect model) (primary outcome), Outcome 6 Seroconversion rate after 2 primary doses: type 3 poliovirus." data-id="CD011780-fig-0018" src="/cdsr/doi/10.1002/14651858.CD011780.pub2/media/CDSR/CD011780/image_n/nCD011780-CMP-002-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.6</div> <div class="figure-caption"> <p>Comparison 2 Intradermal fractional‐dose IPV versus intramuscular IPV: children (fixed‐effect model) (primary outcome), Outcome 6 Seroconversion rate after 2 primary doses: type 3 poliovirus. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011780.pub2/references#CD011780-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011780.pub2/media/CDSR/CD011780/image_n/nCD011780-CMP-002-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011780-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011780.pub2/media/CDSR/CD011780/urn:x-wiley:14651858:media:CD011780:CD011780-CMP-002-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011780.pub2/media/CDSR/CD011780/image_t/tCD011780-CMP-002-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Intradermal fractional‐dose IPV versus intramuscular IPV: children (fixed‐effect model) (primary outcome), Outcome 7 Seroconversion rate after 3 primary doses: type 1 poliovirus." data-id="CD011780-fig-0019" src="/cdsr/doi/10.1002/14651858.CD011780.pub2/media/CDSR/CD011780/image_n/nCD011780-CMP-002-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.7</div> <div class="figure-caption"> <p>Comparison 2 Intradermal fractional‐dose IPV versus intramuscular IPV: children (fixed‐effect model) (primary outcome), Outcome 7 Seroconversion rate after 3 primary doses: type 1 poliovirus. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011780.pub2/references#CD011780-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011780.pub2/media/CDSR/CD011780/image_n/nCD011780-CMP-002-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011780-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011780.pub2/media/CDSR/CD011780/urn:x-wiley:14651858:media:CD011780:CD011780-CMP-002-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011780.pub2/media/CDSR/CD011780/image_t/tCD011780-CMP-002-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Intradermal fractional‐dose IPV versus intramuscular IPV: children (fixed‐effect model) (primary outcome), Outcome 8 Seroconversion rate after 3 primary doses: type 2 poliovirus." data-id="CD011780-fig-0020" src="/cdsr/doi/10.1002/14651858.CD011780.pub2/media/CDSR/CD011780/image_n/nCD011780-CMP-002-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.8</div> <div class="figure-caption"> <p>Comparison 2 Intradermal fractional‐dose IPV versus intramuscular IPV: children (fixed‐effect model) (primary outcome), Outcome 8 Seroconversion rate after 3 primary doses: type 2 poliovirus. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011780.pub2/references#CD011780-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011780.pub2/media/CDSR/CD011780/image_n/nCD011780-CMP-002-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011780-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011780.pub2/media/CDSR/CD011780/urn:x-wiley:14651858:media:CD011780:CD011780-CMP-002-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011780.pub2/media/CDSR/CD011780/image_t/tCD011780-CMP-002-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Intradermal fractional‐dose IPV versus intramuscular IPV: children (fixed‐effect model) (primary outcome), Outcome 9 Seroconversion rate after 3 primary doses: type 3 poliovirus." data-id="CD011780-fig-0021" src="/cdsr/doi/10.1002/14651858.CD011780.pub2/media/CDSR/CD011780/image_n/nCD011780-CMP-002-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.9</div> <div class="figure-caption"> <p>Comparison 2 Intradermal fractional‐dose IPV versus intramuscular IPV: children (fixed‐effect model) (primary outcome), Outcome 9 Seroconversion rate after 3 primary doses: type 3 poliovirus. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011780.pub2/references#CD011780-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011780.pub2/media/CDSR/CD011780/image_n/nCD011780-CMP-002-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011780-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011780.pub2/media/CDSR/CD011780/urn:x-wiley:14651858:media:CD011780:CD011780-CMP-003-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011780.pub2/media/CDSR/CD011780/image_t/tCD011780-CMP-003-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Intradermal fractional‐dose IPV versus intramuscular IPV: children (random‐effects model) (secondary outcome), Outcome 1 Reciprocal antibody titres: seroprevalence for antipoliovirus antibodies type 1." data-id="CD011780-fig-0022" src="/cdsr/doi/10.1002/14651858.CD011780.pub2/media/CDSR/CD011780/image_n/nCD011780-CMP-003-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3 Intradermal fractional‐dose IPV versus intramuscular IPV: children (random‐effects model) (secondary outcome), Outcome 1 Reciprocal antibody titres: seroprevalence for antipoliovirus antibodies type 1. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011780.pub2/references#CD011780-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011780.pub2/media/CDSR/CD011780/image_n/nCD011780-CMP-003-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011780-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011780.pub2/media/CDSR/CD011780/urn:x-wiley:14651858:media:CD011780:CD011780-CMP-003-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011780.pub2/media/CDSR/CD011780/image_t/tCD011780-CMP-003-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Intradermal fractional‐dose IPV versus intramuscular IPV: children (random‐effects model) (secondary outcome), Outcome 2 Reciprocal antibody titres; seroprevalence for antipoliovirus antibodies type 2." data-id="CD011780-fig-0023" src="/cdsr/doi/10.1002/14651858.CD011780.pub2/media/CDSR/CD011780/image_n/nCD011780-CMP-003-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3 Intradermal fractional‐dose IPV versus intramuscular IPV: children (random‐effects model) (secondary outcome), Outcome 2 Reciprocal antibody titres; seroprevalence for antipoliovirus antibodies type 2. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011780.pub2/references#CD011780-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011780.pub2/media/CDSR/CD011780/image_n/nCD011780-CMP-003-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011780-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011780.pub2/media/CDSR/CD011780/urn:x-wiley:14651858:media:CD011780:CD011780-CMP-003-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011780.pub2/media/CDSR/CD011780/image_t/tCD011780-CMP-003-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Intradermal fractional‐dose IPV versus intramuscular IPV: children (random‐effects model) (secondary outcome), Outcome 3 Reciprocal antibody titres: seroprevalence for antipoliovirus antibodies type 3." data-id="CD011780-fig-0024" src="/cdsr/doi/10.1002/14651858.CD011780.pub2/media/CDSR/CD011780/image_n/nCD011780-CMP-003-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.3</div> <div class="figure-caption"> <p>Comparison 3 Intradermal fractional‐dose IPV versus intramuscular IPV: children (random‐effects model) (secondary outcome), Outcome 3 Reciprocal antibody titres: seroprevalence for antipoliovirus antibodies type 3. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011780.pub2/references#CD011780-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011780.pub2/media/CDSR/CD011780/image_n/nCD011780-CMP-003-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011780-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011780.pub2/media/CDSR/CD011780/urn:x-wiley:14651858:media:CD011780:CD011780-CMP-004-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011780.pub2/media/CDSR/CD011780/image_t/tCD011780-CMP-004-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Intradermal fractional‐dose IPV versus intramuscular IPV: children (fixed‐effect model) (secondary outcome), Outcome 1 Reciprocal antibody titres: seroprevalence for antipoliovirus antibodies type 1." data-id="CD011780-fig-0025" src="/cdsr/doi/10.1002/14651858.CD011780.pub2/media/CDSR/CD011780/image_n/nCD011780-CMP-004-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.1</div> <div class="figure-caption"> <p>Comparison 4 Intradermal fractional‐dose IPV versus intramuscular IPV: children (fixed‐effect model) (secondary outcome), Outcome 1 Reciprocal antibody titres: seroprevalence for antipoliovirus antibodies type 1. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011780.pub2/references#CD011780-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011780.pub2/media/CDSR/CD011780/image_n/nCD011780-CMP-004-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011780-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011780.pub2/media/CDSR/CD011780/urn:x-wiley:14651858:media:CD011780:CD011780-CMP-004-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011780.pub2/media/CDSR/CD011780/image_t/tCD011780-CMP-004-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Intradermal fractional‐dose IPV versus intramuscular IPV: children (fixed‐effect model) (secondary outcome), Outcome 2 Reciprocal antibody titres: seroprevalence for antipoliovirus antibodies type 2." data-id="CD011780-fig-0026" src="/cdsr/doi/10.1002/14651858.CD011780.pub2/media/CDSR/CD011780/image_n/nCD011780-CMP-004-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.2</div> <div class="figure-caption"> <p>Comparison 4 Intradermal fractional‐dose IPV versus intramuscular IPV: children (fixed‐effect model) (secondary outcome), Outcome 2 Reciprocal antibody titres: seroprevalence for antipoliovirus antibodies type 2. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011780.pub2/references#CD011780-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011780.pub2/media/CDSR/CD011780/image_n/nCD011780-CMP-004-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011780-fig-0027"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011780.pub2/media/CDSR/CD011780/urn:x-wiley:14651858:media:CD011780:CD011780-CMP-004-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011780.pub2/media/CDSR/CD011780/image_t/tCD011780-CMP-004-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Intradermal fractional‐dose IPV versus intramuscular IPV: children (fixed‐effect model) (secondary outcome), Outcome 3 Reciprocal antibody titres: seroprevalence for antipoliovirus antibodies type 3." data-id="CD011780-fig-0027" src="/cdsr/doi/10.1002/14651858.CD011780.pub2/media/CDSR/CD011780/image_n/nCD011780-CMP-004-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.3</div> <div class="figure-caption"> <p>Comparison 4 Intradermal fractional‐dose IPV versus intramuscular IPV: children (fixed‐effect model) (secondary outcome), Outcome 3 Reciprocal antibody titres: seroprevalence for antipoliovirus antibodies type 3. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011780.pub2/references#CD011780-fig-0027">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011780.pub2/media/CDSR/CD011780/image_n/nCD011780-CMP-004-03.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD011780-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Equivalent schedules of intradermal fractional‐dose inactivated poliovirus vaccine compared to intramuscular inactivated poliovirus vaccine for the prevention of poliomyelitis in children</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Equivalent schedules of intradermal fractional‐dose inactivated poliovirus vaccine compared to intramuscular inactivated poliovirus vaccine for the prevention of poliomyelitis in children</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> children<br/> <b>Setting:</b> community<br/> <b>Intervention:</b> intradermal fractional‐dose inactivated poliovirus vaccine<br/> <b>Comparison:</b> intramuscular inactivated poliovirus vaccine </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments </b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with intramuscular IPV</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with intradermal fractional‐dose IPV</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Paralytic poliomyelitis</b> (not measured) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>This outcome was not reported by any of the included studies.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p><b>Seroconversion rate</b> (after a single primary dose) </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Type 1 poliovirus</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>OR 0.30</b> <br/> <b>(0.22 to 0.41)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2570</p> <p>(6 RCTs)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low<sup>a,b</sup> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>721 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>437 per 1000</b><br/> (363 to 515) </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Type 2 poliovirus</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>OR 0.43</b> <br/> <b>(0.31 to 0.60)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2567</p> <p>(6 RCTs)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low<sup>b,d</sup> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>773 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>595 per 1000</b><br/> (514 to 672) </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Type 3 poliovirus</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>OR 0.19</b> <br/> <b>(0.12 to 0.30)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2571</p> <p>(6 RCTs)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low<sup>a,b,d</sup> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>753 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>366 per 1000</b><br/> (268 to 477) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p><b>Seroconversion rate</b> (after 2 primary doses) </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Type 1 poliovirus</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>OR 0.23</b> <br/> <b>(0.16 to 0.33)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>981</p> <p>(3 RCTs)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low<sup>b,e</sup> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>826 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>522 per 1000</b><br/> (432 to 611) </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Type 2 poliovirus</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>OR 0.41</b> <br/> <b>(0.28 to 0.60)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>853</p> <p>(3 RCTs)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low<sup>b,f</sup> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>846 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>693 per 1000</b><br/> (606 to 767) </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Type 3 poliovirus</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>OR 0.12</b> <br/> <b>(0.07 to 0.22)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>855</p> <p>(3 RCTs)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low<sup>b,e</sup> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>941 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>657 per 1000</b><br/> (528 to 778) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p><b>Seroconversion rate</b> (after 3 primary doses) </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Type 1 poliovirus</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>OR 0.45</b> <br/> <b>(0.07 to 3.15)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>973</p> <p>(3 RCTs)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low<sup>b,d,e</sup> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>913 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>825 per 1000</b><br/> (423 to 970) </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Type 2 poliovirus</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>OR 0.34</b> <br/> <b>(0.19 to 0.63)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>973</p> <p>(3 RCTs)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low<sup>a,b</sup> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>969 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>914 per 1000</b><br/> (855 to 951) </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Type 3 poliovirus</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>OR 0.18</b> <br/> <b>(0.01 to 2.58)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>973</p> <p>(3 RCTs)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low<sup>b,c,d,f</sup> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>979 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>894 per 1000</b><br/> (320 to 991) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Geometric mean titres</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>7 studies reported median titres rather than mean titres. In all 7 studies, antibody titres showed better protective effects with intradermal fractional‐dose (1/5) IPV, albeit in fewer numbers of participants. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4887</p> <p>(7 RCTs)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low<sup>b,d,e</sup> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Vaccine‐related adverse events</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>5 studies reported more adverse events in the intradermal group, whilst 2 studies reported more adverse events in the intramuscular group. The most common adverse events were redness, tenderness, erythema, and fever. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4121</p> <p>(7 RCTs)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low<sup>b,c,d</sup> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See <a href="./full#CD011780-tbl-0002">Table 1</a> for full results. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> confidence interval; <b>IPV:</b> inactivated poliovirus vaccine; <b>OR:</b> odds ratio; <b>RCT:</b> randomised controlled trial </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate certainty:</b> We are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low certainty:</b> Our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/> <b>Very low certainty:</b> We have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded one level for risk of bias: one study had high attrition; one study did not report all of the prespecified outcomes; and all studies included in this analysis were open‐label.<br/> <sup>b</sup>Downgraded one level due to indirectness: there were different schedules of the intervention and comparisons.<br/> <sup>c</sup>Downgraded one level due to limitations in the design: there was the potential for high risk of bias due to high attrition in one study and unclear methods of randomisation, and all of the studies included in this analysis were open‐label.<br/> <sup>d</sup>Downgraded one level due to heterogeneity: there was significant heterogeneity in the studies included in this analysis.<br/> <sup>e</sup>Downgraded one level due to limitations in the design: there was the potential for bias due to attrition and selective reporting, and the studies included in this analysis were not blinded.<br/> <sup>f</sup>Downgraded one level due to imprecision: the effect estimate had wide CI. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Equivalent schedules of intradermal fractional‐dose inactivated poliovirus vaccine compared to intramuscular inactivated poliovirus vaccine for the prevention of poliomyelitis in children</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011780.pub2/full#CD011780-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD011780-tbl-0002"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Adverse events: children</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study ID (location)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Doses</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Intradermal (number of individuals with events/total number of individuals)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Intramuscular (number of individuals with events/total number of individuals)</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="11" valign="top"> <p><a href="./references#CD011780-bbs2-0002" title="Cadorna‐CarlosJ , VidorE , BonnetMC . Randomized controlled study of fractional doses of inactivated poliovirus vaccine administered intradermally with a needle in the Philippines. International Journal of Infectious Diseases2012;16(2):e110‐6. [DOI: 10.1016/j.ijid.2011.10.002; PUBMED: 22153001] ">Cadorna‐Carlos 2012</a> (the Philippines) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="11" valign="top"> <p>3 primary doses of intramuscular IPV or fractional dose of intradermal IPV</p> </td> <td align="left" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>Solicited injection site reactions</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tenderness</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>71/109</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>59/114</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Erythema</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>82/109</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34/114</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Swelling</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25/109</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11/114</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>Solicited systemic reactions</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fever</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7/109</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12/114</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Vomiting</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18/109</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25/114</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Crying abnormal</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40/109</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>36/114</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Drowsiness</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>44/109</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>41/114</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Appetite lost</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19/109</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23/114</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Irritability</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>58/109</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>51/114</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011780-bbs2-0003" title="ClarkeE , SaiduY , AdetifaJU , AdigwemeI , HydaraMB , BashorunAO , et al. Safety and immunogenicity of inactivated poliovirus vaccine when given with measles–rubella combined vaccine and yellow fever vaccine and when given via different administration routes: a phase 4, randomised, non‐inferiority trial in The Gambia. Lancet. Global Health2016;4(8):e534‐47. [DOI: 10.1016/S2214‐109X(16)30075‐4; PUBMED: 27364568] NCT01847872 . IPV clinical trial ‐ The Gambia (IPV) [A phase 4, randomized trial to assess the safety and immunogenicity of inactivated poliovirus vaccine when given concomitantly with measles and rubella combined vaccine and yellow fever vaccine at nine months and when administered via different vaccination routes]. clinicaltrials.gov/ct2/show/NCT01847872 (first received 19 April 2013). ">Clarke 2016</a> (The Gambia) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Single primary dose of intramuscular IPV or fractional dose of intradermal IPV</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Redness and swelling on tenderness</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 (needle syringe)</p> <p>2 (jet injector)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 (needle syringe)</p> <p>5 (jet injector)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011780-bbs2-0006" title="MohammedAJ , AlAwaidyS , BawikarS , KurupPJ , ElamirE , ShabanMMA , et al. Fractional doses of inactivated poliovirus vaccine in Oman. New England Journal of Medicine2010;362(25):2351‐9. [DOI: 10.1056/NEJMoa0909383; PUBMED: 20573923] ">Mohammed 2010</a> (Oman) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 primary doses of intramuscular IPV or fractional dose of intradermal IPV</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>42 serious events (39 = infectious disease, 2 = anaemia, 1 = fall)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18 events</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24 events</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="15" valign="top"> <p><a href="./references#CD011780-bbs2-0007" title="ResikS , TejedaA , LagoPM , DiazM , CarmenatesA , SarmientoL , et al. Randomized controlled clinical trial of fractional doses of inactivated poliovirus vaccine administered intradermally by needle‐free device in Cuba. Journal of Infectious Diseases2010;201(9):1344‐52. [DOI: 10.1086/651611; PUBMED: 20350164] ">Resik 2010</a> (Cuba) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="5" valign="top"> <p>Dose 1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Temperature</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>39/187</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34/177</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Redness</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25/187</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8/177</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Induration</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4/187</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2/177</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pain</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/187</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/177</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Combination</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26/187</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9/177</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="5" valign="top"> <p>Dose 2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Temperature</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21/187</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>41/177</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Redness</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8/187</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3/177</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Induration</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3/187</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/177</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pain</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/187</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/177</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Combination</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/187</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/177</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="5" valign="top"> <p>Dose 3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Temperature</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11/187</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28/177</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Redness</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19/187</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/177</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Induration</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5/187</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/177</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pain</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/187</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/177</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Combination</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/187</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/177</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="8" valign="top"> <p><a href="./references#CD011780-bbs2-0008" title='ResikS , TejedaA , SutterRW , DiazM , SarmientoL , AlemañiN , et al. Priming after a fractional dose of inactivated poliovirus vaccine. New England Journal of Medicine2013;368(5):416‐24. [DOI: 10.1056/NEJMoa1202541; PUBMED: 23363495] SutterRW . Regarding your published paper about "Priming after a Fractional Dose of Inactivated Poliovirus Vaccine" published in NEJM 2013 [personal communication]. Email to: KK Thumburu 04 February 2016. '>Resik 2013</a> (Cuba) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Dose 1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Temp ≥ 38 °C</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/157</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2/153</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Redness</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>47/157</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3/153</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Induration</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11/157</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2/153</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Other</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/157</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/153</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Dose 2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Temp ≥ 38 °C</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2/157</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/153</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Redness</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>37/157</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2/153</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Induration</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14/157</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/153</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Other</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/157</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/153</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><a href="./references#CD011780-bbs2-0009" title="ResikS , TejedaA , MachO , FonsecaM , DiazM , AlemanyN , et al. Immune responses after fractional doses of inactivated poliovirus vaccine using newly developed intradermal jet injectors: a randomized controlled trial in Cuba. Vaccine2015;33(2):307‐13. [DOI: 10.1016/j.vaccine.2014.11.025; PUBMED: 25448109] ">Resik 2015</a> (Cuba) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Single primary dose of intramuscular IPV or fractional dose of intradermal IPV</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fever</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13/583</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8/146</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Redness</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9/583</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2/146</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Induration</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15/583</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/146</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Infiltration</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14/583</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/146</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="21" valign="top"> <p><a href="./references#CD011780-bbs2-0012" title="Tejeda FuentesA , DeArmas LópezJ , Silva SosaM , Alemañy BuenoN , Carmenate GarcíaA , García GonzálezG , et al. Reactogenicity associated to the intradermally administered inactivated poliovirus vaccine with a needle‐free injector [Reactogenicidad asociada a la vacuna de poliovirus inactivada administrada por vía intradérmica con un inyector sin aguja]. Revista Cubana de Medicina Tropical2011;63(1):38‐43. [PUBMED: 23437535] ">Tejeda Fuentes 2011</a> (Cuba) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="7" valign="top"> <p>Dose 1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>General adverse events (temperature 37 to 37.9 °C)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>38</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>General adverse events (temperature above 37.9 °C)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>General adverse events (crying &lt; 1 hour)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Local adverse events (redness)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Local adverse events (induration)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Local adverse events (pain)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Combination of all local adverse events</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="7" valign="top"> <p>Dose 2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>General adverse events (temperature 37 to 37.9 °C)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>41</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>General adverse events (temperature above 37.9 °C)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>General adverse events (crying &lt; 1 hour)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Local adverse events (redness)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Local adverse events (induration)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Local adverse events (pain)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Combination of all local adverse events</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="7" valign="top"> <p>Dose 3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>General adverse events (temperature 37 to 37.9 °C)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>General adverse events (temperature above 37.9 °C)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>General adverse events (crying &lt; 1 hour)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Local adverse events (redness)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Local adverse events (induration)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Local adverse events (pain)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Combination of all local adverse events</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="5"> <div class="table-footnote"> <p>ID: identifier<br/> IPV: inactivated poliovirus vaccine </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Adverse events: children</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011780.pub2/full#CD011780-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD011780-tbl-0003"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Criteria for assigning 'Risk of bias' judgements</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Domain</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Rating</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Criteria</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b>Random sequence generation</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low risk of bias</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Study used a random method, such as a computer‐generated system or random number table, to generate the allocation sequence and described the approach in sufficient detail. Drawing of lots, tossing of coin, shuffling of cards, or throwing dice was considered adequate if a person who was not otherwise involved in the recruitment of participants performed the procedure. </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear risk of bias</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Method used to generate the allocation sequence was not described.</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High risk of bias</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Study used a non‐random method, such as dates, names, or admittance numbers, to generate the allocation sequence of participants. </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b>Allocation concealment</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low risk of bias</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Allocation of participants to study groups was concealed from participants and investigators using a central independent unit, on‐site locked computer, identical syringes or schedules (used by an independent pharmacist or investigator), or opaque, sealed envelopes. </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear risk of bias</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Method for allocation concealment was not described or was not described in sufficient detail to permit a judgement of low or high risk of bias. </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High risk of bias</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Allocations were not concealed and were known to both participants and investigators.</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b>Blinding of participants and personnel</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low risk of bias</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Parents/guardians or recipients (in cases of older children/adults) were blinded; blinding was described in sufficient detail; and it was unlikely that the blinding could have been broken. </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear risk of bias</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Blinding was not described or was not described in sufficient detail to permit a judgement of low or high risk of bias. </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High risk of bias</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Parents or recipients were not blinded; blinding was broken; or it was likely that the outcome could have been affected by the lack of blinding. </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b>Blinding of outcome assessment</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low risk of bias</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Outcome assessment was blinded; details of blinding were described in sufficient detail; and it was unlikely that the blinding could have been broken, or there was no blinding but the outcome assessment was unlikely to have been affected by the lack of blinding. </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear risk of bias</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Blinding was not described or was not described in sufficient detail to permit a judgement of low or high risk of bias. </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High risk of bias</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Outcome assessment was not blinded; blinding was broken; or it was likely that the outcome assessment could have been influenced by the lack of blinding. </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b>Incomplete outcome data</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low risk of bias</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No missing data; the reasons for the missing data were unrelated to the true outcome; or the study used appropriate methods to impute the data </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear risk of bias</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient information to permit a judgement of low or high risk of bias</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High risk of bias</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Reasons for missing data were related to the true outcome, or the study used inappropriate methods to impute the data. </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b>Selective outcome reporting</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low risk of bias</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Study protocol was available, and all prespecified outcomes were reported and in the manner specified; or study protocol was not available, but it was clear that all prespecified outcomes had been reported. </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear risk of bias</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient information to permit a judgement of low or high risk of bias</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High risk of bias</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Study protocol was available, but not all of the study’s prespecified outcomes were reported, or not all were reported in prespecified way, or one or more were reported incorrectly; or outcomes were reported that were not prespecified; or study did not have a protocol, and not all expected outcomes were reported. </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b>Other bias</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low risk of bias</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No other sources of bias</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear risk of bias</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient information to judge that an important risk of bias exists</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High risk of bias</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Other important potential sources of bias (e.g. studies were privately funded) exist.</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Criteria for assigning 'Risk of bias' judgements</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011780.pub2/full#CD011780-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD011780-tbl-0004"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Geometric titres: children (median titres reported in included studies that could not be used in a meta‐analysis)</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study ID (location)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of doses given</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Type of antibody</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Median antibody titres: intradermal median (range)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Median antibody titres: intramuscular median (range)</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p><a href="./references#CD011780-bbs2-0002" title="Cadorna‐CarlosJ , VidorE , BonnetMC . Randomized controlled study of fractional doses of inactivated poliovirus vaccine administered intradermally with a needle in the Philippines. International Journal of Infectious Diseases2012;16(2):e110‐6. [DOI: 10.1016/j.ijid.2011.10.002; PUBMED: 22153001] ">Cadorna‐Carlos 2012</a> (the Philippines) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>3 primary doses given; end of primary series vaccination</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Antipolio antibody type 1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>221 (188 to 259)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>585 (482 to 710)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Antipolio antibody type 2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>234 (186 to 294)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>795 (638 to 992)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Antipolio antibody type 3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>194 (157 to 240)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>774 (622 to 963)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>1 booster dose given; booster series</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Antipolio antibody type 1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2833 (2392 to 3356)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6666 (5613 to 7916)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Antipolio antibody type 2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3210 (2672 to 3857)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6522 (5540 to 7678)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Antipolio antibody type 3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4498 (3608 to 5607)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11,952 (10,046 to 14,220)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD011780-bbs2-0003" title="ClarkeE , SaiduY , AdetifaJU , AdigwemeI , HydaraMB , BashorunAO , et al. Safety and immunogenicity of inactivated poliovirus vaccine when given with measles–rubella combined vaccine and yellow fever vaccine and when given via different administration routes: a phase 4, randomised, non‐inferiority trial in The Gambia. Lancet. Global Health2016;4(8):e534‐47. [DOI: 10.1016/S2214‐109X(16)30075‐4; PUBMED: 27364568] NCT01847872 . IPV clinical trial ‐ The Gambia (IPV) [A phase 4, randomized trial to assess the safety and immunogenicity of inactivated poliovirus vaccine when given concomitantly with measles and rubella combined vaccine and yellow fever vaccine at nine months and when administered via different vaccination routes]. clinicaltrials.gov/ct2/show/NCT01847872 (first received 19 April 2013). ">Clarke 2016</a> (The Gambia) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Single primary dose of intramuscular IPV or intradermal fractional‐dose IPV</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Antipoliovirus type 1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ol id="CD011780-list-0014"> <li> <p>Needle/syringe: 256 (256 to 256)</p> </li> <li> <p>Jet injection: 256 (128 to 256)</p> </li> </ol> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ol id="CD011780-list-0015"> <li> <p>Needle/syringe: 512 (256 to 512)</p> </li> <li> <p>Jet injection: 512 (256 to 512)</p> </li> </ol> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Antipoliovirus type 2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ol id="CD011780-list-0016"> <li> <p>Needle/syringe: 256 (256 to 512)</p> </li> <li> <p>Jet injection: 256 (128 to 256)</p> </li> </ol> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ol id="CD011780-list-0017"> <li> <p>Needle/syringe: 512 (512 to 512)</p> </li> <li> <p>Jet injection: 512 (256 to 512)</p> </li> </ol> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Antipoliovirus type 3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ol id="CD011780-list-0018"> <li> <p>Needle/syringe: 512 (512 to 512)</p> </li> <li> <p>Jet injection: 256 (256 to 512)</p> </li> </ol> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ol id="CD011780-list-0019"> <li> <p>Needle/syringe: 1024 (512 to 1024)</p> </li> <li> <p>Jet injection: 512 (512 to 1024)</p> </li> </ol> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD011780-bbs2-0004" title='EstívarezCF . Details regarding your published paper about "Immunogenicity of supplemental doses of poliovirus vaccine for children aged 6‐9 months in Moradabad, India: a community‐based, randomised controlled trial. Lancet 2012 [personal communication]. Email to: KK Thumburu 11 March 2016. EstívarizCF , JafariH , SutterRW , JohnTJ , JainV , AgarwalA , et al. Immunogenicity of supplemental doses of poliovirus vaccine for children aged 6‐9 months in Moradabad, India: a community‐based, randomised controlled trial. Lancet. Infectious Diseases2012;12(2):128‐35. [DOI: 10.1016/S1473‐3099(11)70190‐6; PUBMED: 22071249] '>Estívariz 2012</a> (India) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Single supplementary dose; 28 days after vaccination</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Antipolio antibody type 1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&gt; 1448 (&gt; 1448 to &gt; 1448)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ol id="CD011780-list-0020"> <li> <p>GSK: &gt; 1448 (&gt; 1448 to &gt; 1448)</p> </li> <li> <p>Panacea: &gt; 1448 (&gt; 1448 to &gt; 1448)</p> </li> </ol> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Antipolio antibody type 2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>724 (455 to 910)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ol id="CD011780-list-0021"> <li> <p>GSK: &gt; 1448 (1176 to &gt; 1448)</p> </li> <li> <p>Panacea: &gt; 1448 (1176 to &gt; 1448)</p> </li> </ol> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Antipolio antibody type 3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>202 (28 to 724)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ol id="CD011780-list-0022"> <li> <p>GSK: 455 (181 to 910)</p> </li> <li> <p>Panacea: 362 (288 to 724)</p> </li> </ol> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD011780-bbs2-0006" title="MohammedAJ , AlAwaidyS , BawikarS , KurupPJ , ElamirE , ShabanMMA , et al. Fractional doses of inactivated poliovirus vaccine in Oman. New England Journal of Medicine2010;362(25):2351‐9. [DOI: 10.1056/NEJMoa0909383; PUBMED: 20573923] ">Mohammed 2010</a> (Oman) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>3 primary doses given; end of primary vaccination series</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Antipolio antibody type 1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>228 (228 to 456)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>724 (575 to 912)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Antipolio antibody type 2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>287 (228 to 456)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1149 (912 to 1149)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Antipolio antibody type 3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>362 (287 to 456)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&gt; 1448 (&gt; 1448 to &gt; 1448)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD011780-bbs2-0007" title="ResikS , TejedaA , LagoPM , DiazM , CarmenatesA , SarmientoL , et al. Randomized controlled clinical trial of fractional doses of inactivated poliovirus vaccine administered intradermally by needle‐free device in Cuba. Journal of Infectious Diseases2010;201(9):1344‐52. [DOI: 10.1086/651611; PUBMED: 20350164] ">Resik 2010</a> (Cuba) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>3 primary doses at 6, 10, and 14 weeks; median titres reported at 18 weeks of age (4 weeks after the 3rd dose) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Antipolio antibody type 1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19 (19 to 22)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>85 (54 to 99)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Antipolio antibody type 2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>45 (45 to 54)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>214 (178 to 295)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Antipolio antibody type 3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32 (24 to 45)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>295 (214 to 355)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD011780-bbs2-0008" title='ResikS , TejedaA , SutterRW , DiazM , SarmientoL , AlemañiN , et al. Priming after a fractional dose of inactivated poliovirus vaccine. New England Journal of Medicine2013;368(5):416‐24. [DOI: 10.1056/NEJMoa1202541; PUBMED: 23363495] SutterRW . Regarding your published paper about "Priming after a Fractional Dose of Inactivated Poliovirus Vaccine" published in NEJM 2013 [personal communication]. Email to: KK Thumburu 04 February 2016. '>Resik 2013</a> (Cuba) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>2 doses of vaccine at 4 months and 8 months of age; titres after 30 days of 2nd dose</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Antipolio antibody type 1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>450 (357 to 566)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&gt; 1448 (&gt; 1448 to &gt; 1448)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Antipolio antibody type 2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>898 (713 to &gt; 1448)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&gt; 1448 (&gt; 1448 to &gt; 1448)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Antipolio antibody type 3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>71 (36 to 113)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>898 (566 to &gt; 1448)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD011780-bbs2-0009" title="ResikS , TejedaA , MachO , FonsecaM , DiazM , AlemanyN , et al. Immune responses after fractional doses of inactivated poliovirus vaccine using newly developed intradermal jet injectors: a randomized controlled trial in Cuba. Vaccine2015;33(2):307‐13. [DOI: 10.1016/j.vaccine.2014.11.025; PUBMED: 25448109] ">Resik 2015</a> (Cuba) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Single dose; 21 days after the dose</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Antipolio antibody type 1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ol id="CD011780-list-0023"> <li> <p>BCG syringe: 1423 (1130 to 1791)</p> </li> <li> <p>Injector X: 1423 (1423 to 1791)</p> </li> <li> <p>Injector Y: 898 (713 to 1130)</p> </li> <li> <p>Injector Z: 1423 (1130 to 1423)</p> </li> </ol> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4499 (3573 to 5664)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Antipolio antibody type 2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ol id="CD011780-list-0024"> <li> <p>BCG syringe: 1130 (898 to 1423)</p> </li> <li> <p>Injector X: 1130 (713 to 1423)</p> </li> <li> <p>Injector Y: 566 (450 to 713)</p> </li> <li> <p>Injector Z: 1130 (898 to 1130)</p> </li> </ol> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2839 (2255 to 3573)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Antipolio antibody type 3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ol id="CD011780-list-0025"> <li> <p>BCG syringe: 1130 (713 to 1423)</p> </li> <li> <p>Injector X: 1423 (1130 to 1791)</p> </li> <li> <p>Injector Y: 566 (357 to 713)</p> </li> <li> <p>Injector Z: 1423 (898 to 1791)</p> </li> </ol> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4499 (3573 to 4499)</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="5"> <div class="table-footnote"> <p>BCG: bacille Calmette‐Guérin vaccine<br/> GSK: GlaxoSmithKline<br/> ID: identifier<br/> IPV: inactivated polio vaccine </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Geometric titres: children (median titres reported in included studies that could not be used in a meta‐analysis)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011780.pub2/full#CD011780-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD011780-tbl-0005"> <div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Adverse events: adults</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study ID (location)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Intradermal (number of individuals with events/total number of individuals)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Intramuscular (number of individuals with events/total number of individuals)</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011780-bbs2-0010" title="ResikS , TejedaA , DiazM , OkayasuH , SeinC , MolodeckyNA , et al. Boosting immune responses following fractional‐dose inactivated poliovirus vaccine: a randomized, controlled trial. Journal of Infectious Diseases2017;215(2):175‐82. [DOI: 10.1093/infdis/jiw492; PUBMED: 28073858] ">Resik 2017</a> (Cuba) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any adverse event</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28/268</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19/266</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="11" valign="top"> <p><a href="./references#CD011780-bbs2-0011" title="SoonawalaD , VerdijkP , Wijmenga‐MonsuurAJ , BoogCJ , KoedamP , VisserLG , et al. Intradermal fractional booster dose of inactivated poliomyelitis vaccine with a jet injector in healthy adults. Vaccine2013;31(36):3688‐94. [DOI: 10.1016/j.vaccine.2013.05.104; PUBMED: 23770332] ">Soonawala 2013</a> (the Netherlands) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Vaccine delivery (pain)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2/32</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19/62</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Erythema</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28/32</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34/62</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Swelling</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19/32</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12/62</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Induration</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11/32</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14/62</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Stiffness</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5/32</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22/62</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Soreness</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5/32</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33/62</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Systemic side effects</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Intradermal</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Intramuscular</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fever</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Myalgia</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3/32</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5/62</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fatigue</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10/32</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14/62</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Headache</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8/32</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12/62</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="7" valign="top"> <p><a href="./references#CD011780-bbs2-0013" title='TroyS . Regarding your paper "Comparison of the Immunogenicity of Various Booster Doses of Inactivated Polio Vaccine Delivered Intradermally Versus Intramuscularly to HIV‐Infected Adults" [personal communication]. Email to: A Agarwal 06 May 2016. TroySB , KouiavskaiaD , SiikJ , KochbaE , BeydounH , MirochnitchenkoO , et al. Comparison of the immunogenicity of various booster doses of inactivated polio vaccine delivered intradermally versus intramuscularly to HIV‐infected adults. Journal of Infectious Diseases2015;211(12):1969‐76. [DOI: 10.1093/infdis/jiu841; PMC4539908; PUBMED: 25567841] '>Troy 2015</a> (USA) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any adverse event</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29/63</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18/64</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fever</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2/63</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/64</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rash</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/63</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4/64</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Redness at injection site</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22/63</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4/64</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Swelling at injection site</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7/63</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3/64</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tenderness at injection site</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8/63</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11/64</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Itching at injection site</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4/63</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/64</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="4"> <div class="table-footnote"> <p>ID: identifier</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Adverse events: adults</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011780.pub2/full#CD011780-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011780-tbl-0006"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Intradermal fractional‐dose IPV versus intramuscular IPV: children (random‐effects model) (primary outcome)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Seroconversion rate after a single primary dose: type 1 poliovirus <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2570</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.30 [0.22, 0.41]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Low‐income country</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>700</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.51 [0.15, 1.70]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Middle‐income country</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1502</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.25 [0.17, 0.37]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3 High‐income country</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>368</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.41 [0.23, 0.75]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Seroconversion rate after a single primary dose: type 2 poliovirus <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2567</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.43 [0.31, 0.60]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Low‐income country</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>700</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.51 [0.05, 5.65]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Middle‐income country</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1502</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.40 [0.23, 0.69]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3 High‐income country</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>365</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.43 [0.26, 0.71]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Seroconversion rate after a single primary dose: type 3 poliovirus <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2571</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.19 [0.12, 0.30]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Low‐income country</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>700</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.38 [0.18, 0.84]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 Middle‐income country</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1502</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.18 [0.10, 0.33]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3 High‐income country</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>369</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.12 [0.07, 0.22]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Seroconversion rate after 2 primary doses: type 1 poliovirus <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>981</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.23 [0.16, 0.33]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Low‐income country</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 Middle‐income country</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>674</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.19 [0.07, 0.47]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.3 High‐income country</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>307</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.27 [0.15, 0.50]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Seroconversion rate after 2 primary doses: type 2 poliovirus <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>853</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.41 [0.28, 0.60]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 Low‐income country</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 Middle‐income country</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>576</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.47 [0.29, 0.77]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.3 High‐income country</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>277</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.32 [0.18, 0.60]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Seroconversion rate after 2 primary doses: type 3 poliovirus <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>855</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.12 [0.07, 0.22]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 Low‐income country</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2 Middle‐income country</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>585</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.08 [0.04, 0.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.3 High‐income country</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>270</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.19 [0.09, 0.43]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Seroconversion rate after 3 primary doses: type 1 poliovirus <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>973</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.45 [0.07, 3.15]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 Low‐income country</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2 Middle‐income country</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>600</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.75 [0.06, 9.59]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.3 High‐income country</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>373</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.09 [0.00, 1.62]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Seroconversion rate after 3 primary doses: type 2 poliovirus <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>973</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.34 [0.19, 0.63]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1 Low‐income country</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.2 Middle‐income country</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>600</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.38 [0.20, 0.70]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.3 High‐income country</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>373</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.06 [0.00, 0.99]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Seroconversion rate after 3 primary doses: type 3 poliovirus <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>973</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.18 [0.01, 2.58]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.1 Low‐income country</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.2 Middle‐income country</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>600</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.21 [0.01, 7.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.3 High‐income country</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>373</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.11 [0.01, 2.05]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Intradermal fractional‐dose IPV versus intramuscular IPV: children (random‐effects model) (primary outcome)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011780.pub2/references#CD011780-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011780-tbl-0007"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Intradermal fractional‐dose IPV versus intramuscular IPV: children (fixed‐effect model) (primary outcome)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Seroconversion rate after a single primary dose: type 1 poliovirus <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2570</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.30 [0.22, 0.41]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Low‐income country</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>700</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.51 [0.15, 1.70]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Middle‐income country</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1502</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.25 [0.17, 0.37]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3 High‐income country</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>368</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.41 [0.23, 0.75]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Seroconversion rate after a single primary dose: type 2 poliovirus <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2567</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.44 [0.34, 0.57]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Low‐income country</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>700</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.51 [0.05, 5.65]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Middle‐income country</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1502</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.44 [0.33, 0.60]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3 High‐income country</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>365</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.43 [0.26, 0.71]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Seroconversion rate after a single primary dose: type 3 poliovirus <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2571</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.18 [0.14, 0.24]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Low‐income country</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>700</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.38 [0.18, 0.84]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 Middle‐income country</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1502</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.18 [0.13, 0.25]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3 High‐income country</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>369</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.12 [0.07, 0.22]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Seroconversion rate after 2 primary doses: type 1 poliovirus <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>981</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.23 [0.16, 0.33]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Low‐income country</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 Middle‐income country</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>674</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.21 [0.14, 0.33]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.3 High‐income country</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>307</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.27 [0.15, 0.50]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Seroconversion rate after 2 primary doses: type 2 poliovirus <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>853</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.41 [0.28, 0.60]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 Low‐income country</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 Middle‐income country</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>576</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.47 [0.29, 0.77]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.3 High‐income country</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>277</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.32 [0.18, 0.60]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Seroconversion rate after 2 primary doses: type 3 poliovirus <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>855</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.12 [0.07, 0.19]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 Low‐income country</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2 Middle‐income country</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>585</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.08 [0.04, 0.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.3 High‐income country</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>270</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.19 [0.09, 0.43]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Seroconversion rate after 3 primary doses: type 1 poliovirus <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>973</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.27 [0.18, 0.43]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 Low‐income country</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2 Middle‐income country</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>600</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.28 [0.18, 0.44]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.3 High‐income country</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>373</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.09 [0.00, 1.62]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Seroconversion rate after 3 primary doses: type 2 poliovirus <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>973</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.34 [0.19, 0.63]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1 Low‐income country</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.2 Middle‐income country</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>600</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.38 [0.20, 0.70]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.3 High‐income country</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>373</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.06 [0.00, 0.99]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Seroconversion rate after 3 primary doses: type 3 poliovirus <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>973</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.22 [0.10, 0.48]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.1 Low‐income country</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.2 Middle‐income country</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>600</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.23 [0.10, 0.52]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.3 High‐income country</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>373</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.11 [0.01, 2.05]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Intradermal fractional‐dose IPV versus intramuscular IPV: children (fixed‐effect model) (primary outcome)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011780.pub2/references#CD011780-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011780-tbl-0008"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Intradermal fractional‐dose IPV versus intramuscular IPV: children (random‐effects model) (secondary outcome)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Reciprocal antibody titres: seroprevalence for antipoliovirus antibodies type 1 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1661</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.42 [0.59, 3.39]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Reciprocal antibody titres; seroprevalence for antipoliovirus antibodies type 2 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1659</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.10 [0.50, 19.44]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Reciprocal antibody titres: seroprevalence for antipoliovirus antibodies type 3 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1659</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.94 [1.44, 6.00]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Intradermal fractional‐dose IPV versus intramuscular IPV: children (random‐effects model) (secondary outcome)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011780.pub2/references#CD011780-tbl-0008">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011780-tbl-0009"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Intradermal fractional‐dose IPV versus intramuscular IPV: children (fixed‐effect model) (secondary outcome)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Reciprocal antibody titres: seroprevalence for antipoliovirus antibodies type 1 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1661</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.42 [0.59, 3.39]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Reciprocal antibody titres: seroprevalence for antipoliovirus antibodies type 2 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1659</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.10 [0.50, 19.44]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Reciprocal antibody titres: seroprevalence for antipoliovirus antibodies type 3 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1659</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.94 [1.44, 6.00]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Intradermal fractional‐dose IPV versus intramuscular IPV: children (fixed‐effect model) (secondary outcome)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011780.pub2/references#CD011780-tbl-0009">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD011780.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD011780-note-0003">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD011780-note-0001">فارسی</a> </li> <li class="section-language"> <a class="" href="ms#CD011780-note-0013">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="pl#CD011780-note-0002">Polski</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD011780-note-0012">简体中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738735355000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738735355000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011780\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011780\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011780\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD011780\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011780\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011780\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011780\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011780\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011780\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD011780\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011780\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011780\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011780\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD011780\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011780\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011780\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011780\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD011780\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=zCmos3jT&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD011780.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD011780.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD011780.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD011780.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD011780.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740725486807"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD011780.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740725486810"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD011780.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918e7c6d6b47f4b8',t:'MTc0MDcyNTQ4Ny4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 